

Review

Not peer-reviewed version

A Direct Relationship Between ‘Blood Stasis’ and Fibrinoid Microclots in Chronic, Inflammatory and Vascular Diseases, and Some Traditional Natural Products Approaches to Treatment

[Douglas Kell](#)^{*}, [Etheresia Pretorius](#)^{*}, Huihui Zhao^{*}

Posted Date: 20 February 2025

doi: 10.20944/preprints202502.1537.v1

Keywords: blood stasis; clotting; amyloid; fibrinoid; proteomics; natural products; bioactive molecules; Chinese Herbal Medicine; inflammation



Preprints.org is a free multidisciplinary platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Review

A Direct Relationship Between 'Blood Stasis' and Fibrinoid Microclots in Chronic, Inflammatory and Vascular Diseases, and Some Traditional Natural Products Approaches to Treatment

Douglas B Kell ^{1,2,3*}, Etheresia Pretorius ^{1,2*} and Huihui Zhao ^{4,5}

¹ Department of Biochemistry, Cell and Systems Biology, Institute of Systems, Molecular and Integrative Biology, Faculty of Health and Life Sciences, University of Liverpool, Crown St, Liverpool L69 7ZB, UK.

² The Novo Nordisk Foundation Centre for Biosustainability, Building 220, Søtofts Plads 200, Technical University of Denmark, 2800 Kongens Lyngby, Denmark.

³ Department of Physiological Sciences, Faculty of Science, Stellenbosch University, Stellenbosch Private Bag X1 Matieland, 7602, South Africa.

⁴ School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 10026, China

⁵ Institute of Ethnic Medicine and Pharmacy, Beijing University of Chinese Medicine, Beijing 10026, China

* Correspondence: dbk@liv.ac.uk; resiap@sun.ac.za; hh686@126.com

Abstract: 'Blood stasis' (syndrome) (BSS) is a fundamental concept in Traditional Chinese Medicine (TCM), where it is known as Xue Yu (血瘀). Similar concepts exist in Traditional Korean Medicine ('Eohyul') and in Japanese Kampo medicine (Oketsu). Blood stasis is considered to underpin a large variety of inflammatory diseases, though an exact equivalent in western systems medicine is yet to be described. Some time ago we discovered that blood can clot into an anomalous amyloid form, creating what we have referred to as fibrinoid microclots. These microclots occur in a great many chronic, inflammatory diseases, are comparatively resistant to fibrinolysis, and thus have the ability to block microcapillaries and hence lower oxygen transfer to tissues, with multiple pathological consequences. We here develop the idea that it is precisely the fibrinoid microclots that relate to, and are largely mechanistically responsible for, the traditional concept of blood stasis (a term also used by Virchow). First, the diseases known to be associated with microclots are all associated with blood stasis. Secondly, fibrinoid microclots provide a simple mechanistic explanation for the physical slowing down ('stasis') of blood flow. Thirdly, Chinese herbal medicine formulae proposed to treat these diseases, especially Xue Fu Zhu Yu and its derivatives, are known mechanistically to be anticoagulatory and anti-inflammatory, consistent with the idea that they are actually helping to lower the levels of fibrinoid microclots, plausibly in part by blocking the catalysis of the polymerisation of fibrinogen into an amyloid form. We rehearse some of the known actions of its constituent herbs and specific bioactive molecules that they contain. Consequently, such herbal formulations (and some of their components), that are comparatively little known to Western science and medicine, would seem to offer the opportunity to provide novel, safe and useful treatments for chronic inflammatory diseases that display fibrinoid microclots, including Myalgic Encephalopathy/ Chronic Fatigue Syndrome and Long COVID.

Keywords: blood stasis; clotting; amyloid; fibrinoid; proteomics; natural products; bioactive molecules; Chinese Herbal Medicine; inflammation

Table of contents

A direct relationship between 'blood stasis' and fibrinoid microclots in chronic, inflammatory and vascular diseases, and some traditional natural products approaches to treatment.....	1
Table of contents.....	2
Abstract.....	1
Introduction.....	3
Preamble, audience, and scope.....	3
A note on systems and personalised medicine.....	3
Blood stasis.....	4
Fibrinoid microclots.....	4
Diseases involving blood stasis in which raised levels of fibrinoid microclots have been detected.....	6
Diseases involving blood stasis where fibrinoid microclots are yet to be measured directly.....	7
Cancer and classical amyloidoses.....	13
Amyloid nature of the blood clots in blood stasis.....	14
A focus on Xue Fu Zhu Yu.....	14
Bioactive molecules in Xue Fu Zhu Yu.....	16
Mechanism(s) of action of Xuefu Zhuyu decoction.....	26
Summarising and concluding remarks.....	26
Acknowledgments.....	27
Author Contributions.....	27
Funding.....	27
Conflicts of Interest.....	27
References.....	27

Introduction

Preamble, Audience, and Scope

This review integrates concepts of systems medicine from both Eastern and Western systems medicine. It is intended to be read (and readable) by scientists, clinicians and patients from very different intellectual and cultural backgrounds, and will necessarily include subsections that are completely familiar to some but entirely arcane to others. We hope that at the end readers will recognise that the discovery of fibrinoid microclots provides a ready general explanation for the traditional, if molecularly ill-defined concept of 'Blood Stasis'. Equivalently, the concepts (and extensive traditional knowledge) of blood stasis may provide extremely useful insights into the biology of fibrinoid microclots and the means of treating them and the diseases with which they are associated. Our focus is on Chinese Herbal Medicine, and we acknowledge (but for reasons of scope we mainly do not rehearse) the underlying principles of Traditional Chinese Medicine (TCM) such as 5-element theory, and the analysis of pulses, meridians and Qi¹, nor do we directly consider other adjunctive treatment elements of TCM such as acupuncture, moxibustion, cupping, massage, and so on, since the focus is the mode of action of relevant Chinese herbal formulae as they relate to blood stasis. We then focus on a particular herbal formulation used to treat blood stasis, and the nature and mechanisms of the bioactive chemicals that it contains.

A Note on Systems and Personalised Medicine

Modern western medicine, especially that based on pharmaceuticals, has tended to assume (incorrectly) that a particular drug will be efficacious in all patients. Given the existence of some 25,000 genes, each with many alleles, leave aside phenotypic variations such as those based on lifestyle effects, it has always been obvious that this could not be the case (e.g.²). As phrased by the 18th century physician Caleb Parry (quoted in³), "It is much more important to know what kind of patient has a disease than to know what kind of disease a patient has". This principle of personalised medicine (e.g.^{4,5}) lies at the heart of TCM, and is intimately linked with equivalent western concepts such as systems biology⁶⁻¹², systems medicine^{13, 14}, polypharmacology¹⁵⁻²⁶, and network pharmacology²⁷⁻³⁰. A subset of systems biology known as metabolic control analysis (e.g.³¹⁻³⁸) describes explicitly how and why individual reactions contribute only weakly to the control of metabolic fluxes, and why, to have big effects, one must modulate multiple reactions simultaneously. Natural evolution selects for robustness to individual insults³⁹, and the kinetic and architectural⁴⁰ properties of such networks tend to provide it; indeed, the interlinked kinetics of reaction networks mean that it is easy to find circumstances in which two inhibitors individually have negligible effects on a metabolic flux whereas together their effect can be massive^{41,42}.

As a systems approach, Chinese herbal medicine adheres to the **Jun-Chen-Zuo-Shi principle**⁴³⁻⁴⁷ (Westerners will find some minor variations of the Chinese characters). As phrased by⁴⁴ "The Jun (emperor) component is the principal phytochemical targeting the major symptom of the disease. There are only a few varieties of Jun medicinals that are administered as a single formula, usually in large doses. The Chen (minister) herbs synergize with Jun to strengthen its therapeutic effects, and may also treat secondary symptoms. The Zuo (assistant) medicinal reduces or eliminates possible adverse or toxic effects of the Jun and/or Chen components, while also enhancing their effects and sometimes treating secondary symptoms. Finally, the Shi (courier) herbs facilitate delivery of the principal components to the lesion sites, or facilitate the overall action of the other components". It is particularly interesting that the last component effectively relates to the significance of pharmaceutical drug transporter proteins, something finally being recognised more widely (e.g.⁴⁸⁻⁵²) and that in fact had evolved precisely to transport natural products⁵³.

While recognising that TCM practitioners will vary treatments precisely to suit the individual, we do not normally have access to such information for our scientific purposes. Equally, we rarely know the multiple targets of even single pharmaceutical drugs (in 2008 the average number of known targets per drug molecule was six⁵⁴). Consequently, this review will seek to paint a big

picture, recognising in particular that it is combinations of herbs affecting multiple processes that have the greatest chance of having useful effects ^{30, 55-59}, while seeking to bring together the biochemistry of microclots (see below) with what is known of blood stasis.

Blood Stasis

“Blood stasis” (or blood stasis syndrome, BSS) is a fundamental concept in Traditional Chinese Medicine (TCM), where it is known as Xue Yu (血瘀)⁶⁰. BSS refers to conditions in which the circulation of blood is not smooth or is slowed down in some way (e.g. ^{61, 62}, and see later). It has been known (using other terms) at least from the time of *The Yellow Emperor’s Inner Classic* (Huang Di Nei Jing) ^{60, 63}. The same concept exists in many other traditional medicines, including Traditional Korean Medicine (where blood stasis is known as 'Eohyul' or 'Ouhyul') ^{12, 64}, and in Japanese Kampo medicine (where it is termed Oketsu). Even within TCM there are similar variants (e.g. ⁶⁵). Blood stasis can be caused by vascular obstruction, abnormal flow of blood, blood congestion in a viscous, and contaminated blood, has at least four subtypes ⁶⁶, and is regarded as the cause or the result of a great many chronic, inflammatory diseases ⁶⁷⁻⁶⁹, that we summarise later.

Many general reviews of blood stasis exist, e.g. ^{61, 67, 70-75}.

Traditionally, BSS is measured somewhat subjectively by a practitioner’s observation of symptoms or manifestations such as tongue colour and the results of palpations. More recently attempts have been made to objectify or quantify the extent of BSS using various kinds of scores (e.g. ^{63, 76-87}). Blood stasis is fundamentally related to haemorheology measurements (i.e. viscosity) ^{80, 88, 89}. We rehearse explicitly this point about scoring BSS, as such quantitative measurements (as used e.g. for scoring fatigue in long COVID ⁹⁰) will be highly desirable for future studies that seek to relate microclot burden to BSS. However, such data presently do not exist.

It is also worth rehearsing here that the 19th-century physiologist Virchow recognised three factors (known as Virchow’s Triad ⁹¹⁻⁹⁵) that contribute to the development of venous thrombosis, and these are stasis of blood flow, hypercoagulability, and endothelial injury. The significance of the terminology of the first one is not lost on us.

Fibrinoid Microclots

Fibrinogen, one of the most abundant plasma proteins (2-4 g.L⁻¹), has dimensions of some 5x45 nm giving a length:diameter ratio of ~9. As is well known, a key part of blood clotting involves the removal from fibrinogen by the protease thrombin of two fibrinopeptides (FpA and FpB), leading to a remarkable self-organisation in which fibrinogen molecules accrete to form far larger fibrils and protofibrils via a ‘knobs and stalks’ mechanism (Figure 1A-C). In normal clotting, the fibrinogen molecules are essentially oriented in the direction of the growing chain, that looks somewhat like cooked spaghetti in the electron microscope (EM) (Figure 1B). Other things such as erythrocytes and platelets may also be trapped, along with non-fibrin proteins whose concentrations in the clot roughly correlate with those in normal soluble plasma ^{96, 97}.

Over a decade ago, it was discovered that certain small molecules such as specific oestrogens ^{98, 99} or unliganded iron ¹⁰⁰⁻¹⁰⁵ could cause fibrinogen to form highly anomalous clots that in the EM appeared like claggy aggregations of partly boiled spaghetti, and that were referred to at the time as ‘dense matted deposits’ ^{102, 103, 106-108} (Figure 1C).





Figure 1. Structure and dimensions of fibrinogen and its folding into healthy and pathological amyloid fibrin(ogen). **A)** Fluorescence microscopy of healthy plasma (with and without spike protein), with thioflavin T (to show amyloid areas in fibrin(ogen)) and added thrombin. **B)** Scanning electron microscopy of fibrin(ogen) with and without lipopolysaccharide (LPS) and thrombin **C).** Scanning electron microscopy of human plasma with FeCl_3 and thrombin. (Adapted from ^{103, 109}. Generated with Biorender.com.)

Subsequent studies, using the well-established ¹¹⁰⁻¹¹² amyloid stain thioflavin T (Figure 2), as well as the commercial oligothiophene 'Amytracker™' stains ^{113, 114}, showed that this anomalous clotting (i) was actually due to the conversion of the fibrin(ogen) into amyloid forms, that are characterised by crossed- β motifs that bind these stains and effect their observable fluorescence, (ii) could be induced by minuscule amounts of bacterial cell wall components (e.g. one molecule of bacterial lipopolysaccharide per 100 million fibrinogen molecules ¹¹³), and (iii) could be observed in a large variety of chronic, inflammatory diseases (e.g. ¹¹⁵ and Table 1). Much as with prion and other amyloid proteins ^{116, 117}, there is no thermodynamic problem; the clotting will happen anyway and these molecules simply catalyse a different route of self-organisation that maintains the necessary close packing in the relevant macrostates. **Figure 2.** Representative confocal images of human plasma with three amyloid markers (cyan: Amytracker™ 480; red: Amytracker™ 680; green: ThT). (A to C) Naïve human plasma; (D to F) Plasma exposed to Lipopolysaccharide (LPS); (G to I) Plasma exposed to iron; (J to L) Plasma exposed to lipoteichoic acid-1; (M to O) Plasma exposed to lipoteichoic acid-1. (Taken from a CC-BY Open Access publication ¹¹⁸.)



Clearly such insoluble microclots (like other microparticulates ^{119, 120}) can straightforwardly interfere with the flow of blood through microcapillaries, leading to a loss of O₂ transfer, hypoxia, and other pathological consequences ¹²¹.

Diseases Involving Blood Stasis in Which Raised Levels of Fibrinoid Microclots Have Been Detected

Over the years, we and others have assessed the raised presence of fibrinoid microclots in a series of chronic, inflammatory diseases, each of which, it transpires, is considered to involve blood stasis. Table 1 provides a summary. Note of course that many of these syndromes, especially those (as here) involving vascular issues, exhibit comorbidities because they have common causes. Diabetes and Alzheimer's disease provide one such example ^{115, 122-136} of many. TCM of course recognises this explicitly, where it is known as "Treating Different Diseases with the Same Treatment" ^{75, 137-139}.

Table 1. Some diseases or syndromes in which fibrinoid microclots have been observed, and which are considered to involve blood stasis.

Disease or Syndrome	Selected References Showing Microclot Formation	Selected References Relating the Disease to Blood Stasis
Alzheimer's disease	140-143	71, 144-146

(Acute) COVID-19 infection	147-151	152-159
Diabetes type 2	141, 151, 160-162	68, 71, 74, 163-166
Long COVID	117, 121, 167-173	155, 174, 175
Migraines	176	71 177
Myalgic Encephalopathy/ Chronic Fatigue Syndrome	178, 179	175, 180-183 (see also ¹⁸⁴)
Parkinson's disease	141, 185-187	61, 188-190
Rheumatoid arthritis	167, 191, 192	71, 166, 193, 194
Sepsis	195	196, 197, 198-216, 217, 218-222
Septic shock	195	223-235
Stroke	236	75, 79, 237-257

Diseases Involving Blood Stasis Where Fibrinoid Microclots Are Yet to Be Measured Directly

In a similar vein, effectively the converse of the above, there are many diseases involving blood stasis in which microclots have yet to be assessed, but which would make obvious objects of study from this point of view. The basic reasoning is as per the paired papers ^{258, 259} on amyloid clot proteomics. In the first ²⁵⁸, we showed that known amyloid microclots had proteomes that differed markedly from those of known ('normal') clots. Besides fibrin they contained various proteins that were in low concentration in soluble plasma yet lacked many that were in high concentration there. Indeed, normal clots had a proteome that roughly mirrored the soluble plasma proteome, implying a relatively weak binding or sequestration (see Figure 3). The proteins 'enriched' in the microclots were highly amyloidogenic, suggesting that they were actually incorporated into the fibrils via the cross-b motifs common to all amyloids. The second paper ²⁵⁹ asked the 'inverse' question, i.e. if we know the composition of the clot proteome in various thrombotic diseases can we predict whether or not the clot is amyloidogenic? In all cases the answer was that these clots should indeed be amyloid, which can thus be tested (and in the case of ischaemic stroke had been ²³⁶).




Figure 3. Weak binding or sequestration. Different classes or types of protein co-aggregation: Titration; Sequestration; Axial and lateral. (Figure adapted from Open Access papers ^{258, 259}, which was based on ²⁶⁰.) Generated with Biorender.com.

Table 2 gives a listing of various vascular and thrombotic diseases that are known from TCM to be associated with blood stasis but are not in Table 1, along with some mechanistic comments that suggest that such studies to assess whether or not the microclots were both present and amyloid in character in these diseases would likely be attended with success.

Table 2. Diseases involving blood stasis where fibrinaloid microclots are yet to be measured directly. These diseases are mostly vascular or thrombotic. We here ignore classical amyloidoses and cancer.

Disease or Syndrome	Selected References Relating the Disease to Blood Stasis	Comments
Angina pectoris	71, 261-277	A very obvious example, as vasodilators are the main treatment. The tightening of the chest and shortness of breath are easily explained by microclots blocking capillaries.

Atherosclerosis	278-283	Another very obvious example of fibrinoid microclots resisting fibrinolysis contributing to atherosclerotic plaques (and later to stroke ²³⁶). The pairing Danshen-Chuanxiong is often used ^{284 281} .
Atrial Fibrillation (AF)	12	At one level, atrial blood stasis is seen as synonymous as an effect of AF ^{285, 286} . Evidence that fibrinoid microclots are more a cause than an effect of AF was summarised in ²⁸⁷
Attention deficit hyperactivity disorder (ADHD)	288-291	Plausibly due to decreased blood flow caused by microclots.
Chronic kidney disease	70, 292, 293	Less likelihood of kidneys excreting microclots if diseased.
Chronic obstructive pulmonary disease (COPD)	294-298	Strong hint in the term 'obstructive'
Coronary heart disease	83, 84, 271, 274, 299-307 308-310	Xue Fu Zhu Yu (a formula to overcome blood stasis) helps ^{301, 303, 311-313} .
Deep vein thrombosis (DVT)	314-316	TCM classifies DVT as blood stasis in the category of "pulse closed" and "femoral swelling". Xue Fu Zhu Yu helps, and there is evidence ²⁵⁹ that the thromboses are likely to be amyloid in nature.
Dysmenorrhoea	317-322	Note that 17- β -oestradiol was one of the first small molecules discovered to induce anomalous clotting ⁹⁸

Fibromyalgia syndrome (FMS)	180, 323	We consider it likely that FMS (and fibrosis ²⁹⁶) is caused by the deposition of fibrin caused by fibrinoid microclots ¹⁰⁹ . There is little actual work on BSS here.
Heart failure and Ischaemic heart disease	324-327	Various formulas used for this kind of blood stasis
Metabolic syndrome (MS)	71, 80, 328, 329	MS covers a variety of different syndromes; at this stage we do not seek to deconvolve it.
Non-alcoholic fatty liver disease (NAFLD) (since mid-2023 it is called metabolic dysfunction-associated steatotic liver disease (MASLD) ³³⁰)	166, 331, 332	
Postural Orthostatic Tachycardia Syndrome (POTS)	333	Capillary blocking by fibrinoid microclots provides a ready explanation for POTS ³³⁴ (see also ³³⁵)
Pre-eclampsia (PE)	336-339	PE has a microbial origin ^{340, 341} and is significantly prothrombotic ³⁴²
Pulmonary embolism	91, 343	
Sub-arachnoid haemorrhage	344, 345	The only predictor of a later stroke ³⁴⁶ was ESR, a measure of blood stasis
Thrombotic diseases generally	347-349	High likelihood of the clots involved being amyloid in nature ²⁵⁹

Tinnitus	74, 350	A common accompaniment to diseases (such as Long COVID) where microclots are involved and where both can be induced by spike protein (cf. ¹⁴⁷ and ³⁵¹⁻³⁵³).
Transient ischaemic attack (TIA)	248, 354, 355	TIA is of course a common precursor to ischaemic stroke ³⁵⁶ , where amyloid clotting has been demonstrated ²³⁶
Traumatic brain injury (TBI)	357-363	Blood stasis is seen as a core component of (the sequelae of) TBI, that include coagulopathy ³⁶⁴ . Most significantly, Xue Fu Zhu Yu ameliorated neurological deficiencies without impairing blood coagulation in a rat model ³⁶¹ .
Traumatic injury generally	365 65	

These all tend to be systems diseases, and so the different components of herbal preparations will tend to interrogate different elements of what has been disrupted. An example from traumatic brain injury ³⁶³ is given in Figure 4, and one from Long COVID, showing the multiplicity of symptoms, in Figure 5.




Figure 4. Multipotential drug treatment strategies for Traumatic Brain Injury. Redrawn from ³⁶³. Generated with Biorender.com.




Figure 5. Long COVID symptoms (taken from ¹⁷¹). Generated with Biorender.com.

Cancer and Classical Amyloidoses

We did not include the classical amyloidoses in the above Table (though Alzheimer's and Parkinson's, listed in Table 1, would certainly fall into those categories), not least because there are a great variety of them ^{366, 367}, cross-seeding is commonplace (e.g. ^{258, 368}), and they deserve a separate treatment in their own right. Similarly, cancer is a topic that is so broad and massive that it too deserves (and will receive) a separate treatment. Consequently, we here note only three things:

- (i) Cancer, particularly pancreatic cancer (PDAC), is strongly linked to thromboembolic states ³⁶⁹⁻³⁸⁶, with thrombotic events often leading to a worse outcome.

- (ii) Cancer is strongly associated (as is Long COVID) with fatigue ³⁸⁷⁻³⁹⁴
- (iii) Unsurprisingly, therefore, cancers are strongly associated with blood stasis ^{62, 65, 71, 300, 395-402}

Amyloid Nature of the Blood Clots in Blood Stasis

While we are not aware of any measurement of the amyloid nature (or otherwise) of microclots in samples characterised by CHM practitioners as involving blood stasis, proteomics can on its own predict whether a clot is likely to be normal or amyloid in character ^{258, 403}, and all the recent assessments of the microclots occurring in these various diseases shows that they are amyloid in character. Such proteins (that include prions and prionoids) are well known, because of the cross- β sheet motifs, to be rather resistant to most proteases ⁴⁰⁴⁻⁴¹⁰. This, together with the presence of various anti-fibrinolytics trapped in such clots ^{168, 169}, provides a ready explanation for the failure to remove them, such that they can contribute strongly to the phenomena of blood stasis.

A focus on Xue Fu Zhu Yu

Having established the consonance between cases (accompanied by inflammation and coagulopathies) where fibrinoid microclots have been measured, and the co-existence of blood stasis as defined within TCM, it is of interest to begin to understand what these various herbs may be doing. As mentioned, even single pharmaceutical drugs have multiple known targets ⁵⁴; in some cases (such as statins, reviewed in ⁴¹¹) the so-called 'off-target' effects are actually largely responsible for the efficacy of the drug in terms of increasing longevity. Consequently, deconvolving accurately what everything is doing within a Chinese herbal medicine cocktail is going to be very difficult. However, this does not mean that some progress cannot be made in terms of establishing components that e.g. are anti-inflammatory or anti-oxidant, and ²⁹⁶ provides a nice example for pulmonary fibrosis. To rehearse again, it is by hitting these multiple targets simultaneously that one can expect and find that the formulae are efficacious.

Xue-Fu-Zhu-Yu (sometimes XueFu ZhuYu, Zuefuzhuyu) is a herb combination designed to boost Qi and remove blood stasis ⁴¹²⁻⁴¹⁷. Xuefu Zhuyu Decoction (Xuefu zhuyu tang, XFZYD) is used explicitly for a variety of **coronary diseases** ^{263, 268, 270, 271, 301, 303, 312, 418-434} (notably a decreased mortality from ischaemic heart disease more than 4-fold ⁴³⁵), as well as **traumatic brain injury** ^{45, 361, 436-447}, **NAFLD** ^{331, 448}, **deep vein thrombosis** ³¹⁶, **fibrosis** ⁴⁴⁹, **ischaemic stroke** ^{431, 450, 451}, **COPD** ²⁹⁵, **sepsis** ¹⁹⁶ (including a five-herb injectable variant known as Xuebijing (XBJ, see below) ^{197, 198-205, 206, 207-216, 217, 218-222}), **amyloidogenesis** ¹⁴⁴, **myocardial fibrosis** ⁴²¹, **dysmenorrhea** ^{317, 319, 320}, **hypertension** ⁴⁵², and **tumours** ⁴⁵³.

For illustrative purposes, we are therefore going to concentrate on Xue Fu Zhu Yu (血府逐瘀); 'Blood stasis-expelling decoction' or Stasis in the mansion of blood'), since – while others such as Danshen-Chuanxiong) are certainly in use against some diseases of blood stasis (e.g. ⁴⁵⁴⁻⁴⁵⁶) this formula <https://sys02.lib.hkbu.edu.hk/cmfid/details.asp?lang=eng&id=F00115> (accessed 6/2/2025) is among those most commonly used to treat blood stasis ^{414, 457, 458}.




Figure 6. Blood stasis-expelling decoction' or Stasis in the mansion of blood', based on the material at <https://sys02.lib.hkbu.edu.hk/cmfid/details.asp?lang=eng&id=F00115>.

The aim is to indicate the kind of knowledge we presently have of the most significant chemical components in each herb, while recognising that some modest variations would likely be prescribed for individuals who are physically seen by a Chinese Medical Herbalist.

Xue Fu Zhu Yu, also known as Xuefu Zhuyu, has 11 herbal components⁴⁵⁹⁻⁴⁶¹. Proportions vary, but we give the percentages in a particular preparation of which we are aware. The ingredients are *Semen persicae* aka *Prunus persica* = peach seed (Tao Ren) 16%, *Radix rehmanniae* from *Rehmannia glutinosa* Libosch (Di Huang or Sheng Di depending on whether dried or fresh) 12%, *Radix Achyranthis Bidentata* or *Cyathulae Radix* (Niu Xi) 12%, *Radix Angelicae sinensis* (Chinese angelica)(Dang Gui) 12%, *Flos carthami* aka safflower (Hong Hua) 12%, *Fructus aurantia* (Zhi Qiao) 8%, *Radix paeoniae rubra* Chi Shao) 8%, *Radix platycodonis* (Jie Geng) 6%, *Rhizoma chuanxiong* (= *Ligusticum chuanxiong*) or Szechuan lovage roots 6%, *Radix glycyrrhizae* (Chinese licorice)(Gan Cao) 4%, *Radix Bupleuri* (Chinese Thorawax Root)(Chai Hu) 4%. We note also that *Angelica sinensis* also houses endophytic fungi that can have great effects on the metabolome⁴⁶². (Xuebijing is an injectable subset of Xue Fu Xhu Yu plus Danshen (*Salviae Miltiorrhizae Radix et Rhizoma*), composed of five Chinese herbs, which are Honghua (*Carthami Flos*), Chishao (*Paeoniae Radix Rubra*), Chuanxiong (*Chuanxiong Rhizoma*), Danggui (*Angelicae Sinensis Radix*) and Danshen (*Salviae Miltiorrhizae Radix et Rhizoma*), particularly used against sepsis^{207, 216}. A recent study²¹⁹ selected hydroxysaffron yellow A (HSYA), vanillin, ligustilide, paeoniflorin and other substances as the main active ingredients of XueBijing through a comprehensive analysis of metabolomics and network pharmacology. Among them, HSYA showed outstanding performance in promoting endothelial cell proliferation²¹⁹.

According to <https://sys02.lib.hkbu.edu.hk/cmfid/details.asp?lang=eng&id=F00115> (and using slightly different names), within the Jun-Chen-Zuo-Shi (Emperor-Minister-Assistant-Courier) principle mentioned above, the components are considered to be: Tao Ren and Hong Hua as Emperor; Chi Shao, ChuanXiong and Niu Xi as Minister; Sheng Di, Danggui, Jie Geng, Zhi Qiao and Chai Hu as Assistant; and Gan Cao as Courier.

Bioactive molecules in Xue Fu Zhu Yu

We now look at some of the molecules that are considered to be active within the different herbs (Table 3). While this is likely to be far from complete, it shows clearly the known and multiple effects of some of the major bioactive components in the herbs comprising Xue Fu Zhu Yu.

Table 3. Constituent herbs of Xue Fu Zhu Yu, some known bioactives it contains, and some known activities.

Herb	Some Known Bioactive Molecules Therein	Some Known Targets or General Properties
Tao Ren; <i>Semen persicae</i> ; peach kernel (Emperor)	Amygdalin ^{463, 464}	Follistatin induction ⁴⁶³ ; ERK1/2 activation ⁴⁶⁴
Hong Hua; <i>Flos carthami</i> ; <i>Carthamus tinctorius</i> L.; safflower (Emperor)	(Hydroxy)safflor yellow A ⁴⁶⁵⁻⁴⁷⁰ Kaempferol, quercetin	Antithrombotic, angiogenic, anticoagulant, antiplatelet. Reviews: ⁴⁷¹⁻⁴⁷⁶ Antioxidants/ anti-inflammatory ⁴⁶⁵
	Endothelial cell protection	Enhances HIF1-a ⁴⁶⁵
Chi Shao; <i>Radix paeoniae rubra</i> ; <i>Paeonia lactiflora</i> Pall; red peony root (Minister)	Oxypaeoniflorin Paeoniflorin ⁴⁷⁷	Anti-thrombin ³⁴⁸ Anti-inflammatory ^{478, 479} and antioxidant ⁴⁸⁰ ; blocks TGF1b signalling, ERK1/2, JNK1/2, NF-kB, etc ^{477, 481, 482} ; deactivation of STAT3 ⁴⁸³ ; Akt/Nrf2/GPX4 ¹⁹⁰
	Paeonol	Anti-inflammatory, antioxidant, protects endothelium ⁴⁸⁴ ; endothelium-protecting and antiplatelet ⁴⁸⁵ ; antioxidant and anti-inflammatory ⁴⁸⁶
<i>Rhizoma chuanxiong</i> (= <i>Ligusticum chuanxiong</i>); Szechuan lovage roots (Minister)	Reviews ⁴⁸⁷⁻⁴⁹⁰	
	Ligustrazine	Anti-inflammatory ^{491, 492} ; dilates

		blood vessels, inhibits platelet aggregation and prevents thrombopoiesis ⁴⁹² . Anti-anginal ⁴⁹³ . Multiple roles ⁴⁹⁴ .
	Ligustilide (also in Dang Gui and Niu Xi)	Anti-inflammatory and antioxidant ⁴⁹⁵ . Improves lipid metabolism, antioxidant and anti-inflammatory, protects vascular endothelium, inhibits vascular endothelial fibrosis ⁴⁹⁶ . Cannabinoid receptor 2 activation
	Sekyunolide I (SEI)	Reviews on antioxidant and anti-inflammatory properties ⁴⁹⁷⁻⁴⁹⁹ . Other targets of SEI include Nrf2 ⁵⁰⁰ , activity vs NAFLD ⁵⁰¹ , UVB damage ⁵⁰² , NET formation ⁵⁰³ , ischaemia-reperfusion injury ⁵⁰⁴⁻⁵⁰⁷ . It occurs in appreciable concentrations in both ChuanXiong ⁵⁰⁸ , ⁵⁰⁹ . and <i>Angelica sinensis</i> (Danggui) ⁵¹⁰ .
	Ferulic acid	Anti-thrombin activity ⁵¹¹
<i>Radix Achyranthis Bidentata</i> (Niu Xi), also <i>Cyathulae Radix</i> (Minister ; may also be a Courier ⁵¹²)	Achyranthine, but no real stand-outs	Seemingly not well understood ^{513, 514}
<i>Radix rehmanniae</i> (Di Huang or Sheng Di) (Assistant)	Reviews: ⁵¹⁵⁻⁵¹⁷	Multiple effects, including anti-inflammation, antioxidation, anti-tumor, immunomodulation, cardiovascular and cerebrovascular regulation ⁵¹⁷ . Hypoglycaemic ⁵¹⁸
	iridoid glycosides (such as catalpol and aucuboside),	Catalpol blocks AMPK signalling ⁵¹⁹ and promotes angiogenesis ⁵²⁰ and cell migration ⁵²¹ . Antioxidant via


		Nrf2/HO-1 ⁵²² and NF-kB ⁵²³ , Many other references, reviewed in ⁵²⁴⁻⁵²⁶ . Aucuboside is an immunomodulator ⁵²⁷ .
	phenylpropanoid glycosides (such as acteoside),	Acteoside e.g. stimulates amyloid degradation ⁵²⁸ and ameliorates ischaemia- reperfusion injury ⁵²⁹ , and has many other effects ⁵³⁰ including anticancer ⁵³¹ .
<hr/>		
<i>Radix Angelicae sinensis</i> (Chinese angelica) (Dang Gui) (Assistant)		
Z-lingustilide (see above)		
	Ferulic acid	Antioxidant and anti- inflammatory ⁵³² . Nephroprotective ⁵³³ . Ameliorates lipid metabolism via AMPK/ACC and PI3K/AKT pathways ⁵³⁴ .
<hr/>		
Sekyunolide I (see above)		
<hr/>		
<i>Radix platycodonis</i> (Balloonflower root) (Jie Geng) (Assistant; may also be a Courier⁵¹²)	Platycodins ^{535 536} (triterpenoid saponins)	Many activities ^{537, 538} including anti-inflammatory and antioxidant ^{535, 539, 540} , vasodilatory ⁵⁴¹ , antiviral ⁵⁴² ,
<hr/>		
<i>Fructus aurantia (Citrus aurantium L.) Bitter orange</i> (Zhi Qiao) (Assistant)	Flavones and flavonoids, including sinensetin, tangeretin, demethylnobiletin and chrysin.	Antioxidant, anti- inflammatory ⁵⁴³ and other activities via JAK-STAT3n and PI3K-AKT signalling ⁵⁴⁴
<hr/>		
<i>Radix Bupleuri</i> (Chinese Thorawax Root) (Chai Hu) (Assistant)	Quercetin ²⁷¹ Saikosaponins (triterpenoid saponins)	Antioxidant and other properties (some not at all newly discovered ^{545, 546}) Many activities including antioxidant and anti- inflammatory ⁵⁴⁷⁻⁵⁵⁰
<hr/>		

<i>Radix glycyrrhizae</i> (<i>Glycyrrhiza uralensis</i> Fisch; licorice) (Gan Cao) (Courier)	Flavanones Liquiritigenin and Isoliquiritigenin	Anti-oxidant ⁵⁵¹ , also anti-amyloid ⁵⁵² and transporter inducers. Reviews ^{553, 554} .
	Triterpene saponins including glycyrrhizin	Antiviral and other ^{555-561 562-565}


What is also clear is that there is a wealth of literature in some cases and a dearth in others, and comparing subsets of the mixtures leads to an infeasible combinatorial explosion ⁵⁶⁶. There are also some consonances, with molecules or classes being common to more than one of the herbs (Table 3), and of course it is well known that natural products can make for successful drugs, even in western medicine (e.g. ⁵⁶⁷⁻⁵⁷¹). It is also of interest that the triterpenoid saponins (platycodins, saikosaponins and glycyrrhizin), molecules of increasing importance in natural products drug discovery ⁵⁷²⁻⁵⁷⁵, can also contain most or all of a steroid nucleus ⁵⁷⁶⁻⁵⁸⁰, and have good bioavailability ⁵⁸¹(probably through their chemical relatedness to steroids and bile acids ^{582, 583 584}). Importantly, such triterpenoids may inhibit toxic amyloidogenesis (e.g. ⁵⁸⁵⁻⁶¹⁶), and indeed appear in other herbal formulae for stimulating blood circulation in blood stasis syndrome (e.g. ⁶¹⁷⁻⁶²¹).

To avoid cluttering up Table 3, chemical structures of some of the main components of the herbs in Xue Fu Zhu Yu are given in Table 4.


Table 4. Chemical structures of some of the constituents in Xue Fu Zhu Yu as mentioned in Table 3.

Molecule	Structure
Acteoside	


Amygdalin




Aucuboside




Catalpol




Glycyrrhizin




Hydroxysafflor yellow A




Isoliquiritigenin
(2',4,4'-Trihydroxychalcone)




(Z-)Ligustilide




Ligustrazine (2,3,5,6-tetramethylpyrazine)




Liquiritigenin 4', 7- dihydroxyflavanone




Oxypaeoniflorin




Paeniflorin




Paeonol




Platycodins: variants of structure at right.
One example is below, in which R1 is
glucose and R2 is arabinose-rhamnose-
xylose-apifuranosyl




Platycodin D




Quercetin



Safflor yellow A




Saikosaponin nucleus



Saikosaponin A

As above, R₁ = *b*-OH, R₂ = CH₂OH

Sekyunolide I



What is also clear from Table 4 is the large number of different chemical structures of even the main, known bioactives in Xue Fu Zhu Yu, as well as their multiple targets (Table 3). Natural products tend to be larger than purely chemical drugs⁶²²⁻⁶³¹, which may imply that they have even more targets than the average of six mentioned above for pharmaceutical drugs⁵⁴. While little is known of the transporters responsible for their uptake into cells, it is known that pharmaceutical drugs that are taken up do mimic natural products⁵³.

Mechanism(s) of Action of Xuefu Zhuyu Decoction

For illustrative purposes, these include at least the following:

1. Neuroprotective effects: XFZYD may exert neuroprotective effects by regulating miRNA expression and promoting synaptic remodelling. A study found that XFZYD could reverse the reduction of BDNF and TrkB in the hippocampus caused by Traumatic Brain Injury, and increase the number of synaptic connections, as well as the expression of synaptic-related protein PSD95, axon-related protein GAP43, and neuron-specific protein TUBB3⁴⁴⁶.

2. Anti-inflammatory effects: Multiple studies have shown that XFZYD has anti-inflammatory effects. In an alopecia model, XFZYD can significantly inhibit the levels of IL-6, IL-1 β , and TNF- α in serum and skin tissue⁶³².

3. Promoting angiogenesis: A study evaluated the angiogenic effect of XFZYD using a PTK787-induced segmental vascular injury zebrafish model. Through various analytical methods, seven active components promoting angiogenesis were identified, including ferulic acid, paeoniflorin, and hesperidin⁶³³.

Summarising and Concluding Remarks

The concept of blood stasis is exceptionally important in traditional Asian medicines, and we have here argued that it reflects the fibrinoid microclots that two of us had discovered. The recognition that herbal formulae such as Xue Fu Zhu Yu are well known (by relevant practitioners) to be of value in treating blood stasis, as well as some of the bioactive molecules that it contains, thus opens up the area of microclots to focused pharmacological analyses. It also offers the hope of effective treatments.

Author Contributions: All authors contributed to the conceptualisation, analyses, funding acquisition, drafting, and final editing. All authors have read and agreed to the published version of the manuscript.

Funding: D.B.K. thanks the Balvi Foundation (grant 18) and the Novo Nordisk Foundation for funding (grant NNF20CC0035580). E.P.: Funding was provided by NRF of South Africa (grant number 142142) and SA MRC (self-initiated research (SIR) grant), and Balvi Foundation. The content and findings reported and illustrated are the sole deduction, view and responsibility of the researchers and do not reflect the official position and sentiments of the funders.

Acknowledgments: DBK thanks a great many people for useful discussions, including Yisheng Chen, Amanda Crist, Meng Li, Linghui Lu, Michael Moran and Louanne Richards.

Conflicts of Interest: E.P. is a named inventor on a patent application covering the use of fluorescence methods for microclot detection in Long COVID. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

1. K. M. Ko and H. Y. Leung, The Essential Role of Zheng Qi in Promoting Health: From the Perspective of Chinese Medicine and Modern Medicine, *Chinese Med*, 2024, **15**, 27-33.
2. R. J. Williams, *Biochemical Individuality*, John Wiley, New York, 1956.
3. A. M. Henney, The promise and challenge of personalized medicine: aging populations, complex diseases, and unmet medical need, *Croat Med J*, 2012, **53**, 207-210.
4. A. Mastrangelo, E. G. Armitage, A. Garcia and C. Barbas, Metabolomics as a tool for drug discovery and personalised medicine. A review, *Curr Top Med Chem*, 2015, **14**, 2627-2636.
5. C. Superchi, F. Brion Bouvier, C. Gerardi, M. Carmona, L. San Miguel, L. M. Sanchez-Gomez, I. Imaz-Iglesia, P. Garcia, J. Demotes, R. Banzi, R. Porcher and PERMIT Group, Study designs for clinical trials applied to personalised medicine: a scoping review, *BMJ Open*, 2022, **12**, e052926.
6. H. Kitano, Systems biology: a brief overview, *Science*, 2002, **295**, 1662-1664.
7. L. Hood, Systems biology: integrating technology, biology, and computation, *Mech Ageing Dev*, 2003, **124**, 9-16.
8. E. Klipp, R. Herwig, A. Kowald, C. Wierling and H. Lehrach, *Systems biology in practice: concepts, implementation and clinical application*, Wiley/VCH, Berlin, 2005.
9. U. Alon, *An introduction to systems biology: design principles of biological circuits*, Chapman and Hall/CRC, London, 2006.
10. D. Noble, *The music of life: biology beyond genes*, Oxford University Press, Oxford, 2006.
11. B. Ø. Palsson, *Systems biology: properties of reconstructed networks*, Cambridge University Press, Cambridge, 2006.
12. M. S. Park, J. Kim, K. H. Kim, H. R. Yoo, I. Chae, J. Lee, I. H. Joo and D. H. Kim, Modern concepts and biomarkers of blood stasis in cardio- and cerebrovascular diseases from the perspectives of Eastern and Western medicine: a scoping review protocol, *JBI Evid Synth*, 2023, **21**, 214-222.
13. C. Auffray, Z. Chen and L. Hood, Systems medicine: the future of medical genomics and healthcare, *Genome med*, 2009, **1**, 2.
14. L. Hood and M. Flores, A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory, *New Biotechnology*, 2012, **29**, 613-624.
15. J. Achenbach, P. Tiikkainen, L. Franke and E. Proschak, Computational tools for polypharmacology and repurposing, *Future Med Chem*, 2011, **3**, 961-968.
16. A. Anighoro, J. Bajorath and G. Rastelli, Polypharmacology: Challenges and Opportunities in Drug Discovery, *J Med Chem*, 2014, **57**, 7874-7887.
17. A. D. W. Boran and R. Iyengar, Systems approaches to polypharmacology and drug discovery, *Curr Opin Drug Discov Devel*, 2010, **13**, 297-309.

18. A. Lavecchia and C. Cerchia, *In silico* methods to address polypharmacology: current status, applications and future perspectives, *Drug Discov Today*, 2016, **21**, 288-298.
19. J. U. Peters, Polypharmacology - Foe or Friend?, *J Med Chem*, 2013, **56**, 8955-8971.
20. C. Plake and M. Schroeder, Computational polypharmacology with text mining and ontologies, *Curr Pharm Biotechnol*, 2011, **12**, 449-457.
21. A. S. Reddy and S. Zhang, Polypharmacology: drug discovery for the future, *Expert Rev Clin Pharmacol*, 2013, **6**, 41-47.
22. S. Salentin, V. J. Haupt, S. Daminelli and M. Schroeder, Polypharmacology rescored: Protein-ligand interaction profiles for remote binding site similarity assessment, *Prog Biophys Mol Biol*, 2014, **116**, 174-186.
23. L. Xie, L. Xie, S. L. Kinnings and P. E. Bourne, Novel computational approaches to polypharmacology as a means to define responses to individual drugs, *Annu Rev Pharmacol Toxicol*, 2012, **52**, 361-379.
24. J. Chand, S. R. Panda, S. Jain, U. S. N. Murty, A. M. Das, G. J. Kumar and V. G. M. Naidu, Phytochemistry and polypharmacology of cleome species: A comprehensive Ethnopharmacological review of the medicinal plants, *J Ethnopharmacol*, 2022, **282**, 114600.
25. S. M. Stefan and M. Rafehi, Medicinal polypharmacology-a scientific glossary of terminology and concepts, *Front Pharmacol*, 2024, **15**, 1419110.
26. O. J. Manzoni, A. Manduca and V. Trezza, Therapeutic potential of cannabidiol polypharmacology in neuropsychiatric disorders, *Trends Pharmacol Sci*, 2025, **46**, 145-162.
27. A. L. Hopkins, Network pharmacology: the next paradigm in drug discovery, *Nat Chem Biol*, 2008, **4**, 682-690.
28. M. Kibble, N. Saarinen, J. Tang, K. Wennerberg, S. Mäkelä and T. Aittokallio, Network pharmacology applications to map the unexplored target space and therapeutic potential of natural products, *Nat Prod Rep*, 2015, **32**, 1249-1266.
29. N. Dagar, A. Kale, H. R. Jadhav and A. B. Gaikwad, Nutraceuticals and network pharmacology approach for acute kidney injury: A review from the drug discovery aspect, *Fitoterapia*, 2023, **168**, 105563.
30. X. Duan, N. Wang and D. Peng, Application of network pharmacology in synergistic action of Chinese herbal compounds, *Theory Biosci*, 2024, **143**, 195-203.
31. H. Kacser and J. A. Burns, The control of flux, in *Rate Control of Biological Processes. Symposium of the Society for Experimental Biology Vol 27*, ed. D. D. Davies, Cambridge University Press, Cambridge, 1973, pp. 65-104.
32. R. Heinrich and T. A. Rapoport, Linear theory of enzymatic chains: its application for the analysis of the crossover theorem and of the glycolysis of human erythrocytes, *Acta Biologica et Medica Germanica*, 1973, **31**, 479-494.
33. R. Heinrich and T. A. Rapoport, A linear steady-state treatment of enzymatic chains. General properties, control and effector strength, *Eur. J. Biochem.*, 1974, **42**, 89-95.
34. D. B. Kell and H. V. Westerhoff, Metabolic control theory: its role in microbiology and biotechnology., *FEMS Microbiol. Rev.*, 1986, **39**, 305-320.
35. D. A. Fell, Metabolic Control Analysis - a survey of its theoretical and experimental development, *Biochem. J.*, 1992, **286**, 313-330.
36. A. Cornish-Bowden, J.-H. S. Hofmeyr and M. L. Cárdenas, Strategies for manipulating metabolic fluxes in biotechnology, *Bioorg Chem*, 1995, **23**, 439-449.
37. R. Heinrich and S. Schuster, *The regulation of cellular systems.*, Chapman & Hall, New York, 1996.
38. D. A. Fell, E. Saavedra and J. Rohwer, 50 years of Metabolic Control Analysis: Its past and current influence in the biological sciences, *Biosystems*, 2024, **235**, 105086.
39. H. Kitano, Biological robustness, *Nat Rev Genet*, 2004, **5**, 826-837.
40. R. Milo, S. Shen-Orr, S. Itzkovitz, N. Kashtan, D. Chklovskii and U. Alon, Network motifs: simple building blocks of complex networks, *Science*, 2002, **298**, 824-827.
41. B. G. Small, B. W. McColl, R. Allmendinger, R. Pahle, G. Lopez-Castejon, N. J. Rothwell, J. Knowles, P. Mendes, D. Brough and D. B. Kell, Efficient discovery of anti-inflammatory small molecule combinations using evolutionary computing *Nature Chem Biol*, 2011, **7**, 902-908.
42. A. E. C. Ihekweba, D. S. Broomhead, R. Grimley, N. Benson, M. R. H. White and D. B. Kell, Synergistic control of oscillations in the NF- κ B signalling pathway, *IEE Systems Biology*, 2005, **152**, 153-160.

43. Y. Yao, X. Zhang, Z. Wang, C. Zheng, P. Li, C. Huang, W. Tao, W. Xiao, Y. Wang, L. Huang and L. Yang, Deciphering the combination principles of Traditional Chinese Medicine from a systems pharmacology perspective based on Ma-huang Decoction, *J Ethnopharmacol*, 2013, **150**, 619-638.
44. X. Zhao, X. Zheng, T.-P. Fan, Z. Li, Y. Zhang and J. Zhang, A novel drug discovery strategy inspired by traditional medicine philosophies, *Science*, 2015, **347**, S38-S40.
45. Y. Zhong, J. Luo, T. Tang, P. Li, T. Liu, H. Cui, Y. Wang and Z. Huang, Exploring Pharmacological Mechanisms of Xuefu Zhuyu Decoction in the Treatment of Traumatic Brain Injury via a Network Pharmacology Approach, *Evid Based Complement Alternat Med*, 2018, **2018**, 8916938.
46. M. Zhao, Y. Chen, C. Wang, W. Xiao, S. Chen, S. Zhang, L. Yang and Y. Li, Systems Pharmacology Dissection of Multi-Scale Mechanisms of Action of Huo-Xiang-Zheng-Qi Formula for the Treatment of Gastrointestinal Diseases, *Front Pharmacol*, 2018, **9**, 1448.
47. Y. Chen, J.-n. Zheng, J. Fang, S.-g. Li, J.-l. Guan and P. Yang, Application of "Monarch, Minister, Assistant and Envoy" Principle to Rheumatoid Arthritis Management, *J Rheum Arth Dis*, 2017, **2**, 1-4.
48. P. D. Dobson and D. B. Kell, Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule?, *Nat Rev Drug Disc*, 2008, **7**, 205-220.
49. D. B. Kell, P. D. Dobson and S. G. Oliver, Pharmaceutical drug transport: the issues and the implications that it is essentially carrier-mediated only., *Drug Disc Today*, 2011, **16**, 704-714.
50. D. B. Kell and S. G. Oliver, How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion, *Front Pharmacol*, 2014, **5**, 231.
51. J. Grixti, S. O'Hagan, P. J. Day and D. B. Kell, Enhancing drug efficacy and therapeutic index through cheminformatics-based selection of small molecule binary weapons that improve transporter-mediated targeting: a cytotoxicity system based on gemcitabine, *Front Pharmacol*, 2017, **8**, 155.
52. D. B. Kell, The transporter-mediated cellular uptake and efflux of pharmaceutical drugs and biotechnology products: how and why phospholipid bilayer transport is negligible in real biomembranes., *Molecules*, 2021, **26**, 5629.
53. S. O'Hagan and D. B. Kell, Consensus rank orderings of molecular fingerprints illustrate the 'most genuine' similarities between marketed drugs and small endogenous human metabolites, but highlight exogenous natural products as the most important 'natural' drug transporter substrates., *ADMET & DMPK*, 2017, **5**, 85-125.
54. J. Mestres, E. Gregori-Puigjané, S. Valverde and R. V. Solé, The topology of drug-target interaction networks: implicit dependence on drug properties and target families, *Mol Biosyst*, 2009, **5**, 1051-1057.
55. S. Li, B. Zhang, D. Jiang, Y. Wei and N. Zhang, Herb network construction and co-module analysis for uncovering the combination rule of traditional Chinese herbal formulae, *BMC Bioinformatics*, 2010, **11 Suppl 11**, S6.
56. X. Su, Z. Yao, S. Li and H. Sun, Synergism of Chinese Herbal Medicine: Illustrated by Danshen Compound, *Evid Based Complement Alternat Med*, 2016, **2016**, 7279361.
57. Y. Yang, Z. Zhang, S. Li, X. Ye, X. Li and K. He, Synergy effects of herb extracts: pharmacokinetics and pharmacodynamic basis, *Fitoterapia*, 2014, **92**, 133-147.
58. X. Zhou, S. W. Seto, D. Chang, H. Kiat, V. Razmovski-Naumovski, K. Chan and A. Bensoussan, Synergistic Effects of Chinese Herbal Medicine: A Comprehensive Review of Methodology and Current Research, *Front Pharmacol*, 2016, **7**, 201.
59. S. P. Rigby, Uses of Molecular Docking Simulations in Elucidating Synergistic, Additive, and/or Multi-Target (SAM) Effects of Herbal Medicines, *Molecules*, 2024, **29**.
60. D.-X. Yan, *Aging and blood stasis: a new TCM approach to geriatrics*, Blue Poppy Press, Boulder, CO, 2015.
61. K. J. Chen, Blood stasis syndrome and its treatment with activating blood circulation to remove blood stasis therapy, *Chin J Integr Med*, 2012, **18**, 891-896.
62. T. Y. Choi, J. H. Jun, J. A. Lee, B. Park, S. You, J. Jung and M. S. Lee, Expert opinions on the concept of blood stasis in China: An interview study, *Chin J Integr Med*, 2016, **22**, 823-831.
63. S. M. Li, H. Xu and K. J. Chen, The diagnostic criteria of blood-stasis syndrome: considerations for standardization of pattern identification, *Chin J Integr Med*, 2014, **20**, 483-489.

64. B. Park, S. You, J. Jung, J. A. Lee, K. J. Yun and M. S. Lee, Korean studies on blood stasis: an overview, *Evid Based Complement Alternat Med*, 2015, **2015**, 316872.
65. Q.-Y. Hao, Z.-X. Jiang, X. Wang, H.-P. Lu, Y. Zhu, Y.-L. Liu, K. Li and Y.-Q. Xie, Studies on blood stasis in the traditional medicine of the Li Culture, *Hist Philos Med*, 2021, **3**, 18.
66. S. You, B. K. Kang, J. Kim, H. Lee, E. H. Shim, M. M. Ko, J. Choi, T. Y. Choi, J. H. Jun, J. Jung, M. Cha, J. A. Lee and M. S. Lee, Four Subgroups of Blood Stasis Syndrome Are Identified by Manifestation Cluster Analysis in Males, *Evid-Based Compl Alt*, 2019, **2019**.
67. T. Y. Choi, J. H. Jun, B. Park, J. A. Lee, S. S. You, J. Y. Jung and M. S. Lee, Concept of blood stasis in Chinese medical textbooks: A systematic review, *Eur J Integr Med*, 2016, **8**, 158-164.
68. L. Liu, Y.-B. Liang, X.-L. Liu, H.-Q. Wang, Y.-F. Qi, M. Wang, B.-X. Chen, Q.-B. Zhou, W.-X. Tong and Y. Zhang, Untargeted metabolomics combined with pseudotargeted lipidomics revealed the metabolite profiles of blood-stasis syndrome in type 2 diabetes mellitus, *Heliyon*, 2024, **10**, e39554.
69. Z. Sun, P. Ping, Y. Li, L. Feng, F. Liu, Y. Zhao, Y. Yao, P. Zhang and S. Fu, Relationships Between Traditional Chinese Medicine Constitution and Age-Related Cognitive Decline in Chinese Centenarians, *Front Aging Neurosci*, 2022, **14**, 870442.
70. X. Luo, J. Xie, L. Huang, W. Gan and M. Chen, Efficacy and safety of activating blood circulation and removing blood stasis of Traditional Chinese Medicine for managing renal fibrosis in patients with chronic kidney disease: a systematic review and Meta-analysis, *J Tradit Chin Med*, 2023, **43**, 429-440.
71. J. Liao, J. Wang, Y. Liu, J. Li, L. Duan, G. Chen and J. Hu, Modern researches on Blood Stasis syndrome 1989-2015: A bibliometric analysis, *Medicine (Baltimore)*, 2016, **95**, e5533.
72. J. Yan, Y. Dong, L. Niu, J. Cai, L. Jiang, C. Wang and J. Xing, Clinical effect of Chinese herbal medicine for removing blood stasis combined with acupuncture on sequelae of cerebral infarction, *Am J Transl Res*, 2021, **13**, 10843-10849.
73. L. Rosenthal, P. Hernandez and D. Vaamonde, Traditional Chinese medicine, Ayurveda, and fertility *Fertility, Pregnancy, and Wellness*, 2022, 209-247.
74. S. Birch, T. Alraek, M. S. Lee, J. A. Lee and T.-H. Kim, Understanding blood stasis in traditional East Asian medicine: a comparison of Asian and Western sources, *Eur J Integr Med*, 2021, **44**, 101341.
75. X. Zhai, X. Wang, L. Wang, L. Xiu, W. Wang and X. Pang, Treating Different Diseases With the Same Method-A Traditional Chinese Medicine Concept Analyzed for Its Biological Basis, *Front Pharmacol*, 2020, **11**, 946.
76. K. Terasawa, H. Shinoda, A. Imadaya, H. Tosa, M. Bandoh and N. Satoh, The presentation of diagnostic criteria for "Yuxie" (stagnated blood) conformation, *Int J Oriental Med*, 1989, **14**, 194-213.
77. C. Matsumoto, T. Kojima, K. Ogawa, S. Kamegai, T. Oyama, Y. Shibagaki, T. Kawasaki, H. Fujinaga, K. Takahashi, H. Hikiami, H. Goto, C. Kiga, K. Koizumi, H. Sakurai, H. Muramoto, Y. Shimada, M. Yamamoto, K. Terasawa, S. Takeda and I. Saiki, A Proteomic Approach for the Diagnosis of 'Oketsu' (blood stasis), a Pathophysiologic Concept of Japanese Traditional (Kampo) Medicine, *Evid Based Complement Alternat Med*, 2008, **5**, 463-474.
78. S. Wang, J. Wang and J. Li, Relationship between the Gensini Score of Blood-Stasis Syndrome in Coronary Heart Disease and VEGF, *World Sci Technol*, 2010, **12**, 355-357.
79. K. H. Cho, K. P. Kim, B. C. Woo, Y. J. Kim, J. Y. Park, S. Y. Cho, S. U. Park, W. S. Jung, J. M. Park and S. K. Moon, Relationship between Blood Stasis Syndrome Score and Cardioankle Vascular Index in Stroke Patients, *Evid Based Complement Alternat Med*, 2012, **2012**, 696983.
80. H. Goto, Blood stasis syndrome in Japan and its molecular biological analysis, *Chin J Integr Med*, 2014, **20**, 490-495.
81. J. Liao, Y. Liu and J. Wang, Identification of more objective biomarkers for Blood-Stasis syndrome diagnosis, *BMC Complement Altern Med*, 2016, **16**, 371.
82. B. K. Kang, T. Y. Park, J. Jung, M. Ko, M. S. Lee and J. A. Lee, The Optimal Cut-Off Value of Blood Stasis Syndrome Score in BSS Diagnosis in Korea, *Evid Based Complement Alternat Med*, 2017, **2017**, 8049481.
83. X. Zhou, X. T. Li, X. Q. Liu, B. Wang and G. Fang, Assessment of Intermingled Phlegm and Blood Stasis Syndrome in Coronary Heart Disease: Development of a Diagnostic Scale, *Evid Based Complement Alternat Med*, 2018, **2018**, 4683431.

84. Y. Zhao, H. Peng, S. Wang and J. Liu, Clinical analysis of acute coronary syndrome patients with Qi-blood syndromes: establishment of a diagnostic prediction model for syndrome differentiation, *Ann Palliat Med*, 2020, **9**, 2096-2110.
85. A. Morita, A. Murakami, K. Noguchi, Y. Watanabe, T. Nakaguchi, S. Ochi, K. Okudaira, Y. Hirasaki and T. Namiki, Combination Image Analysis of Tongue Color and Sublingual Vein Improves the Diagnostic Accuracy of Oketsu (Blood Stasis) in Kampo Medicine, *Front Med (Lausanne)*, 2021, **8**, 790542.
86. K.-j. Chen and H. Xu, International Diagnostic Guidelines for Blood-Stasis Syndrome, *Chinese J Integr Med*, 2022, **28**, 297-303.
87. A. Morita, A. Murakami, Y. Watanabe, Y. Tamura, A. Suganami, Y. Shiko, Y. Kawasaki, T. Nakaguchi, S. Ochi, K. Okudaira, Y. Hirasaki and T. Namik, The association in Kampo medicine between Oketsu (blood stasis) and sublingual vein width of the tongue on a tongue image analyzing system, *Tradit Kampo Med*, 2020, **7**, 108-112.
88. G. Mchedlishvili, Disturbed blood flow structuring as critical factor of hemorheological disorders in microcirculation, *Clin Hemorheol Microcirc*, 1998, **19**, 315-325.
89. J. X. Zhang, Y. Feng, Y. Zhang, Y. Liu, S. D. Li and M. H. Yang, Hemorheology Index Changes in a Rat Acute Blood Stasis Model: A Systematic Review and Meta-Analysis, *Afr J Tradit Complement Altern Med*, 2017, **14**, 96-107.
90. C. F. Dalton, M. I. R. de Oliveira, P. Stafford, N. Peake, B. Kane, A. Higham, D. Singh, N. Jackson, H. Davies, D. Price, R. Duncan, N. Tattersall, A. Barnes and D. P. Smith, Increased fibrinolytic microclot counts in platelet-poor plasma are associated with Long COVID, *medRxiv*, 2024, 2024.2004.2004.24305318.
91. C. N. Bagot and R. Arya, Virchow and his triad: a question of attribution, *Br J Haematol*, 2008, **143**, 180-190.
92. J. L. Mehta, G. Calcaterra and P. P. Bassareo, COVID-19, thromboembolic risk, and Virchow's triad: Lesson from the past, *Clin Cardiol*, 2020, **43**, 1362-1367.
93. S. Ahmed, O. Zimba and A. Y. Gasparyan, Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow's triad, *Clin Rheumatol*, 2020, **39**, 2529-2543.
94. A. S. Wolberg, M. M. Aleman, K. Leiderman and K. R. Machlus, Procoagulant activity in hemostasis and thrombosis: Virchow's triad revisited, *Anesth Analg*, 2012, **114**, 275-285.
95. F. J. Gonzalez-Gonzalez, M. R. Ziccardi and M. D. McCauley, Virchow's Triad and the Role of Thrombosis in COVID-Related Stroke, *Front Physiol*, 2021, **12**, 769254.
96. M. Ząbczyk, A. Stachowicz, J. Natorka, R. Olszanecki, J. R. Wiśniewski and A. Undas, Plasma fibrin clot proteomics in healthy subjects: Relation to clot permeability and lysis time, *J Proteomics*, 2019, **208**, 103487.
97. D. B. Kell and E. Pretorius, Proteomic evidence for amyloidogenic cross-seeding in fibrinolytic microclots, *bioRxiv*, 2024, 2024.2007.2016.603837.
98. A. C. Swanepoel, B. G. Lindeque, P. J. Swart, Z. Abdool and E. Pretorius, Estrogen causes ultrastructural changes of fibrin networks during the menstrual cycle: a qualitative investigation, *Microsc Res Tech*, 2014, **77**, 594-601.
99. A. C. Swanepoel, B. G. Lindeque, P. J. Swart, Z. Abdool and E. Pretorius, Ultrastructural changes of fibrin networks during three phases of pregnancy: a qualitative investigation, *Microsc Res Tech*, 2014, **77**, 602-608.
100. J. Jankun, P. Landeta, E. Pretorius, E. Skrzypczak-Jankun and B. Lipinski, Unusual clotting dynamics of plasma supplemented with iron(III), *Int J Mol Med*, 2014, **33**, 367-372.
101. B. Lipinski, E. Pretorius, H. M. Oberholzer and W. J. Van Der Spuy, Iron enhances generation of fibrin fibers in human blood: Implications for pathogenesis of stroke, *Microsc Res Tech*, 2012, **75**, 1185-1190.
102. B. Lipinski and E. Pretorius, Novel pathway of iron-induced blood coagulation: implications for diabetes mellitus and its complications, *Pol Arch Med Wewn*, 2012, **122**, 115-122.
103. E. Pretorius, N. Vermeulen, J. Bester, B. Lipinski and D. B. Kell, A novel method for assessing the role of iron and its functional chelation in fibrin fibril formation: the use of scanning electron microscopy, *Toxicol Mech Methods*, 2013, **23**, 352-359.
104. E. Pretorius, J. Bester, N. Vermeulen, B. Lipinski, G. S. Gericke and D. B. Kell, Profound morphological changes in the erythrocytes and fibrin networks of patients with hemochromatosis or with hyperferritinemia, and their normalization by iron chelators and other agents, *PLoS One*, 2014, **9**, e85271.

105. E. Pretorius and D. B. Kell, Diagnostic morphology: biophysical indicators for iron-driven inflammatory diseases, *Integrative Biol*, 2014, **6**, 486-510.
106. E. Pretorius, N. Vermeulen, J. Bester and B. Lipinski, Novel use of scanning electron microscopy for detection of iron-induced morphological changes in human blood, *Microsc Res Tech*, 2013, **76**, 268-271.
107. E. Pretorius and B. Lipinski, Differences in morphology of fibrin clots induced with thrombin and ferric ions and its pathophysiological consequences, *Heart Lung Circ*, 2013, **22**, 447-449.
108. A. C. Swanepoel, A. Visagie, Z. de Lange, O. Emmerson, V. G. Nielsen and E. Pretorius, The clinical relevance of altered fibrinogen packaging in the presence of 17beta-estradiol and progesterone, *Thromb Res*, 2016, **146**, 23-34.
109. D. B. Kell and E. Pretorius, Potential roles of fibrinoid microclots in fibromyalgia syndrome, *OSF preprint*, 2024, <https://osf.io/9e2y5/>.
110. M. Biancalana and S. Koide, Molecular mechanism of Thioflavin-T binding to amyloid fibrils, *Biochim Biophys Acta*, 2010, **1804**, 1405-1412.
111. N. Amdursky, Y. Erez and D. Huppert, Molecular rotors: what lies behind the high sensitivity of the thioflavin-T fluorescent marker, *Acc Chem Res*, 2012, **45**, 1548-1557.
112. K. Gade Malmos, L. M. Blancas-Mejia, B. Weber, J. Buchner, M. Ramirez-Alvarado, H. Naiki and D. Otzen, ThT 101: a primer on the use of thioflavin T to investigate amyloid formation, *Amyloid*, 2017, **24**, 1-16.
113. E. Pretorius, S. Mbotwe, J. Bester, C. J. Robinson and D. B. Kell, Acute induction of anomalous and amyloidogenic blood clotting by molecular amplification of highly substoichiometric levels of bacterial lipopolysaccharide, *J R Soc Interface*, 2016, **123**, 20160539.
114. E. Pretorius, S. Mbotwe and D. B. Kell, Lipopolysaccharide-binding protein (LBP) reverses the amyloid state of fibrin seen in plasma of type 2 diabetics with cardiovascular comorbidities, *Sci Rep*, 2017, **7**, 9680.
115. D. B. Kell and E. Pretorius, No effects without causes. The Iron Dysregulation and Dormant Microbes hypothesis for chronic, inflammatory diseases, *Biol Rev*, 2018, **93**, 1518-1557.
116. D. B. Kell and E. Pretorius, Proteins behaving badly. Substoichiometric molecular control and amplification of the initiation and nature of amyloid fibril formation: lessons from and for blood clotting, *Progr Biophys Mol Biol*, 2017, **123**, 16-41.
117. D. B. Kell and E. Pretorius, Are fibrinoid microclots a cause of autoimmunity in Long Covid and other post-infection diseases?, *Biochem J*, 2023, **480**, 1217-1240.
118. E. Pretorius, M. J. Page, L. Hendricks, N. B. Nkosi, S. R. Benson and D. B. Kell, Both lipopolysaccharide and lipoteichoic acids potently induce anomalous fibrin amyloid formation: assessment with novel Amytracker™ stains, *J R Soc Interface*, 2018, **15**, 20170941.
119. H. Huang, J. Hou, M. Li, F. Wei, Y. Liao and B. Xi, Microplastics in the bloodstream can induce cerebral thrombosis by causing cell obstruction and lead to neurobehavioral abnormalities, *Sci Adv*, 2025, **11**, eadr8243.
120. S. Mallapaty, Microplastics block blood flow in the brain, mouse study reveals, *Nature*, 2025, **638**, 20.
121. D. B. Kell, G. J. Laubscher and E. Pretorius, A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications, *Biochem J*, 2022, **479**, 537-559.
122. J. Götz, L. M. Ittner and Y. A. Lim, Common features between diabetes mellitus and Alzheimer's disease, *Cell Mol Life Sci*, 2009, **66**, 1321-1325.
123. J. Janson, T. Laedtke, J. E. Parisi, P. O'Brien, R. C. Petersen and P. C. Butler, Increased risk of type 2 diabetes in Alzheimer disease, *Diabetes*, 2004, **53**, 474-481.
124. L. Li and C. Hölscher, Common pathological processes in Alzheimer disease and type 2 diabetes: A review, *Brain Research Reviews*, 2007, **56**, 384-402.
125. X. Li, D. Song and S. X. Leng, Link between type 2 diabetes and Alzheimer's disease: from epidemiology to mechanism and treatment, *Clin Interv Aging*, 2015, **10**, 549-560.
126. J. A. Luchsinger and D. R. Gustafson, Adiposity, type 2 diabetes, and Alzheimer's disease, *J Alzheimers Dis*, 2009, **16**, 693-704.
127. L. Mascitelli, F. Pezzetta and M. R. Goldstein, Iron, type 2 diabetes mellitus, and Alzheimer's disease, *Cell Mol Life Sci*, 2009, **66**, 2943.

128. J. Miklossy and P. L. McGeer, Common mechanisms involved in Alzheimer's disease and type 2 diabetes: a key role of chronic bacterial infection and inflammation, *Aging (Albany NY)*, 2016, **8**, 575-588.
129. K. Mittal and D. P. Katare, Shared links between type 2 diabetes mellitus and Alzheimer's disease: A review, *Diabetes Metab Syndr*, 2016, **10**, S144-149.
130. N. Moroz, M. Tong, L. Longato, H. Xu and S. M. de la Monte, Limited Alzheimer-type neurodegeneration in experimental obesity and type 2 diabetes mellitus, *J Alzheimers Dis*, 2008, **15**, 29-44.
131. M. E. Oskarsson, J. F. Paulsson, S. W. Schultz, M. Ingelsson, P. Westermark and G. T. Westermark, *In vivo* seeding and cross-seeding of localized amyloidosis: a molecular link between type 2 diabetes and Alzheimer disease, *Am J Pathol*, 2015, **185**, 834-846.
132. A. Taguchi, Vascular factors in diabetes and Alzheimer's disease, *J Alzheimers Dis*, 2009, **16**, 859-864.
133. P. Toro, P. Schonknecht and J. Schroder, Type II diabetes in mild cognitive impairment and Alzheimer's disease: results from a prospective population-based study in Germany, *J Alzheimers Dis*, 2009, **16**, 687-691.
134. A. Vignini, A. Giulietti, L. Nanetti, F. Raffaelli, L. Giusti, L. Mazzanti and L. Provinciali, Alzheimer's disease and diabetes: new insights and unifying therapies, *Current diabetes reviews*, 2013, **9**, 218-227.
135. W. L. Xu, E. von Strauss, C. X. Qiu, B. Winblad and L. Fratiglioni, Uncontrolled diabetes increases the risk of Alzheimer's disease: a population-based cohort study, *Diabetologia*, 2009, **52**, 1031-1039.
136. W. Q. Zhao and M. Townsend, Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease, *Biochim Biophys Acta*, 2009, **1792**, 482-496.
137. C.-j. Zhang, X.-j. Zhang, L.-f. Chen, S.-g. Lai and Q. Wu, The mechanism of different diseases treated by the same way of acupuncture at Chanqianq for cognitive disorder, *World J Acupunc Moxibust*, 2016, **26**, 24-29.
138. X. Zhang, L. Zhou and X. Qian, The Mechanism of "Treating Different Diseases with the Same Treatment" by Qiangji Jianpi Decoction in Ankylosing Spondylitis Combined with Inflammatory Bowel Disease: A Comprehensive Analysis of Multiple Methods, *Gastroenterology Research and Practice*, 2024, **2024**, 9709260.
139. S. F. Fu, W. Yi, J. Q. Ai, A. J. Bah and X. M. Gao, Clinical application of "treating different diseases with the same method" - Xuefu Zhuyu Capsule (a traditional Chinese patent medicine) for blood stasis syndrome, *Journal of the American College of Cardiology*, 2014, **64**, C208-C209.
140. J. Bester, P. Soma, D. B. Kell and E. Pretorius, Viscoelastic and ultrastructural characteristics of whole blood and plasma in Alzheimer-type dementia, and the possible role of bacterial lipopolysaccharides (LPS), *Oncotarget Gerontology*, 2015, **6**, 35284-35303.
141. G. M. de Waal, L. Engelbrecht, T. Davis, W. J. S. de Villiers, D. B. Kell and E. Pretorius, Correlative Light-Electron Microscopy detects lipopolysaccharide and its association with fibrin fibres in Parkinson's Disease, Alzheimer's Disease and Type 2 Diabetes Mellitus, *Sci Rep*, 2018, **8**, 16798.
142. E. Pretorius, J. Bester and D. B. Kell, A bacterial component to Alzheimer-type dementia seen via a systems biology approach that links iron dysregulation and inflammagen shedding to disease *J Alzheimers Dis*, 2016, **53**, 1237-1256.
143. E. Pretorius, J. Bester, M. J. Page and D. B. Kell, The potential of LPS-binding protein to reverse amyloid formation in plasma fibrin of individuals with Alzheimer-type dementia, *Frontiers Aging Neurosci*, 2018, **10**, 257.
144. C. W. Yeh, H. K. Liu, L. C. Lin, K. T. Liou, Y. C. Huang, C. H. Lin, T. T. Tzeng, F. S. Shie, H. J. Tsay and Y. J. Shiao, Xuefu Zhuyu decoction ameliorates obesity, hepatic steatosis, neuroinflammation, amyloid deposition and cognition impairment in metabolically stressed APP^{swe}/PS1^{dE9} mice, *J Ethnopharmacol*, 2017, **209**, 50-61.
145. P. Tao, W. Xu, S. Gu, H. Shi, Q. Wang and Y. Xu, Traditional Chinese medicine promotes the control and treatment of dementia, *Front Pharmacol*, 2022, **13**, 1015966.
146. P. Tao, J. Ji, S. Gu, Q. Wang and Y. Xu, Progress in the Mechanism of Autophagy and Traditional Chinese Medicine Herb Involved in Dementia, *Front Pharmacol*, 2022, **12**, 825330.
147. L. M. Grobbelaar, C. Venter, M. Vlok, M. Ngoepe, G. J. Laubscher, P. J. Lourens, J. Steenkamp, D. B. Kell and E. Pretorius, SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: implications for microclot formation in COVID-19, *Biosci Rep*, 2021, **41**, BSR20210611.
148. L. M. Grobbelaar, A. Kruger, C. Venter, E. M. Burger, G. J. Laubscher, T. G. Maponga, M. J. Kotze, H. C. Kwaan, J. B. Miller, D. Fulkerson, W. Huff, E. Chang, G. Wiarda, C. M. Bunch, M. M. Walsh, S. Raza, M.

- Zamlut, H. B. Moore, E. E. Moore, M. D. Neal, D. B. Kell and E. Pretorius, Relative hypercoagulopathy of the SARS-CoV-2 Beta and Delta variants when compared to the less severe Omicron variants is related to TEG parameters, the extent of fibrin amyloid microclots, and the severity of clinical illness., *Semin Thromb Haemost*, 2022, **48**, 858-868.
149. G. J. Laubscher, P. J. Lourens, C. Venter, D. B. Kell and E. Pretorius, TEG®, Microclot and Platelet Mapping for Guiding Early Management of Severe COVID-19 Coagulopathy, *J Clin Med*, 2021, **10**, 5381.
150. E. Pretorius, C. Venter, G. J. Laubscher, P. J. Lourens, J. Steenkamp and D. B. Kell, Prevalence of amyloid blood clots in COVID-19 plasma, *medRxiv*, 2020, 2020.2007.2028.20163543v20163541.
151. E. Pretorius, C. Venter, G. J. Laubscher, P. J. Lourens, J. Steenkamp and D. B. Kell, Prevalence of readily detected amyloid blood clots in 'unclothed' Type 2 Diabetes Mellitus and COVID-19 plasma: A preliminary report, *Cardiovasc Diabetol*, 2020, **19**, 193.
152. H. Guo, J. Zheng, G. Huang, Y. Xiang, C. Lang, B. Li, D. Huang, Q. Sun, Y. Luo, Y. Zhang, L. Huang, W. Fang, Y. Zheng and S. Wan, Xuebijing injection in the treatment of COVID-19: a retrospective case-control study, *Ann Palliat Med*, 2020, **9**, 3235-3248.
153. D. Y. Wu, X. T. Hou, Z. S. Xia, E. W. Hao, J. L. Xie, J. Y. Liang, Q. M. Liang, Z. C. Du and J. G. Deng, Analysis on oral medication rules of traditional Chinese medicine prescriptions for prevention of COVID-19, *Chin Herb Med*, 2021, **13**, 502-517.
154. L. Ling, X. Wang, Y. Zhang, F. Yin, Z. Zhang and X. Lyu, Efficacy of Qingfei Paidu Granules combined with non-drug traditional Chinese medicine therapy in the treatment of patients with asymptomatic coronavirus disease: A retrospective study, *Medicine (Baltimore)*, 2023, **102**, e34868.
155. J. Ruan, S. Chen, Y. S. Ho, V. T. Wong, M. Y. Lam, H. W. H. Tsang, I. H. Cheng and W. F. Yeung, Chinese medicine practitioners' consensus on traditional Chinese medicine diagnostic patterns, symptoms, and herbal formulas for COVID-19 survivors: A Delphi study, *Eur J Chinese Med*, 2024, **66**, 102339.
156. H. Zhang, Y. Liu, X. Shang, Y. Cao, J. Li, G. Chen, X. Ji, L. Zhang, Y. Fan and Y. Ma, Status and hotspot analysis of Qingfei Paidu Decoction for the prevention and treatment of COVID-19 based on bibliometric analysis, *Front Pharmacol*, 2024, **15**, 1422773.
157. Q. Zhang, Z. Liang, X. Wang, S. Zhang and Z. Yang, Exploring the potential mechanisms of Danshen against COVID-19 via network pharmacology analysis and molecular docking, *Sci Rep*, 2024, **14**, 12780.
158. X. Zhou, Z. Cheng and Y. Hu, COVID-19 and Venous Thromboembolism: From Pathological Mechanisms to Clinical Management, *J Pers Med*, 2021, **11**, 1328.
159. Z. Yang, Y. Liu, L. Wang, S. Lin, X. Dai, H. Yan, Z. Ge, Q. Ren, H. Wang, F. Zhu and S. Wang, Traditional Chinese medicine against COVID-19: Role of the gut microbiota, *Biomed Pharmacother*, 2022, **149**, 112787.
160. E. Pretorius, H. M. Oberholzer, W. J. van der Spuy, A. C. Swanepoel and P. Soma, Qualitative scanning electron microscopy analysis of fibrin networks and platelet abnormalities in diabetes, *Blood Coagul Fibrinol*, 2011, **22**, 463-467.
161. E. Pretorius, J. Bester, N. Vermeulen, S. Alummoottil, P. Soma, A. V. Buys and D. B. Kell, Poorly controlled type 2 diabetes is accompanied by significant morphological and ultrastructural changes in both erythrocytes and in thrombin-generated fibrin: implications for diagnostics, *Cardiovasc Diabetol*, 2015, **134**, 30.
162. E. Pretorius, M. J. Page, L. Engelbrecht, G. C. Ellis and D. B. Kell, Substantial fibrin amyloidogenesis in type 2 diabetes assessed using amyloid-selective fluorescent stains, *Cardiovasc Diabetol*, 2017, **16**, 141.
163. J. Wei, R. Wu and D. Zhao, Analysis on traditional Chinese medicine syndrome elements and relevant factors for senile diabetes, *J Tradit Chin Med*, 2013, **33**, 473-478.
164. J. Xu, L. Bai, E. Ma, Q. Guo, Y. Wang, M. Zhang and Z. Chen, Correlativity between blood measures related to blood stasis blocking collaterals and gene expression of angiotensin-converting enzyme of renal cortex in diabetic rats and effect of stasis removing and collaterals dredging, *J Tradit Chin Med*, 2014, **34**, 597-603.
165. J. Wang, Q. Ma, Y. Li, P. Li, M. Wang, T. Wang, C. Wang, T. Wang and B. Zhao, Research progress on Traditional Chinese Medicine syndromes of diabetes mellitus, *Biomed Pharmacother*, 2020, **121**, 109565.
166. K. Tanaka, K. Chiba and K. Nara, A Review on the Mechanism and Application of Keishibukuryogan, *Front Nutr*, 2021, **8**, 760918.

167. D. B. Kell and E. Pretorius, The potential role of ischaemia-reperfusion injury in chronic, relapsing diseases such as rheumatoid arthritis, long COVID and ME/CFS: evidence, mechanisms, and therapeutic implications, *Biochem J*, 2022, **479**, 1653-1708.
168. A. Kruger, M. Vlok, S. Turner, C. Venter, G. J. Laubscher, D. B. Kell and E. Pretorius, Proteomics of fibrin amyloid microclots in Long COVID/ Post-Acute Sequelae of COVID-19 (PASC) shows many entrapped pro-inflammatory molecules that may also contribute to a failed fibrinolytic system, *Cardiovasc Diabetol*, 2022, **21**, 190.
169. E. Pretorius, M. Vlok, C. Venter, J. A. Bezuidenhout, G. J. Laubscher, J. Steenkamp and D. B. Kell, Persistent clotting protein pathology in Long COVID/ Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin, *Cardiovasc Diabetol*, 2021, **20**, 172.
170. E. Pretorius, C. Venter, G. J. Laubscher, M. J. Kotze, S. Oladejo, L. R. Watson, K. Rajaratnam, B. W. Watson and D. B. Kell, Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/ Post-Acute Sequelae of COVID-19 (PASC) *Cardiovasc Diabetol*, 2022, **21**, 148.
171. S. Turner, M. A. Khan, D. Putrino, A. Woodcock, D. B. Kell and E. Pretorius, Long COVID: pathophysiological factors and abnormal coagulation, *Trends Endocrinol Metab*, 2023, **34**, 321-344.
172. S. Turner, C. A. Naidoo, T. J. Usher, A. Kruger, C. Venter, G. J. Laubscher, M. A. Khan, D. B. Kell and E. Pretorius, Increased Levels of Inflammatory and Endothelial Biomarkers in Blood of Long COVID Patients Point to Thrombotic Endothelialitis, *Semin Thromb Hemost*, 2023.
173. S. Turner, G. J. Laubscher, M. A. Khan, D. B. Kell and E. Pretorius, Accelerating discovery: A novel flow cytometric method for detecting fibrin(ogen) amyloid microclots using long COVID as a model *Heliyon*, 2023, **9**, e19605.
174. R. Ono, R. Arita, S. Takayama, T. Kanno, A. Kikuchi, S. Suzuki, M. Ohsawa, N. Saito, M. Abe, K. Onodera, T. Akaiishi, Y. Tadano and T. Ishii, Progress and treatment of "long COVID" in non-hospitalized patients: A single-center retrospective cohort study, *Trad Kampo Med*, 2023, **10**, 150-158.
175. L. Y. Hu, A. Q. Cai, B. Li, Z. Li, J. P. Liu and H. J. Cao, Chinese herbal medicine for post-viral fatigue: A systematic review of randomized controlled trials, *PLoS One*, 2024, **19**, e0300896.
176. S. de Villiers, J. Bester, D. B. Kell and E. Pretorius, Erythrocyte health and the possible role of amyloidogenic blood clotting in the evolving haemodynamics of female migraine-with-aura pathophysiology: Results from a pilot study, *Frontiers Neurol*, 2019, **10**, 1262.
177. C. S. Shan, Q. Q. Xu, Y. H. Shi, Y. Wang, Z. X. He and G. Q. Zheng, Chuanxiong Formulae for Migraine: A Systematic Review and Meta-Analysis of High-Quality Randomized Controlled Trials, *Front Pharmacol*, 2018, **9**, 589.
178. J. M. Nunes, A. Kruger, A. Proal, D. B. Kell and E. Pretorius, The Occurrence of Hyperactivated Platelets and Fibrinolytic Microclots in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), *Pharmaceuticals (Basel)*, 2022, **15**, 931.
179. J. M. Nunes, D. B. Kell and E. Pretorius, Cardiovascular and haematological pathology in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): a role for Viruses, *Blood Rev*, 2023, **60**, 101075.
180. Y. Li, J. Yang, C. I. Chau, J. Shi, X. Chen, H. Hu and C. O. L. Ung, Is there a role for traditional and complementary medicines in managing chronic fatigue? a systematic review of randomized controlled trials, *Front Pharmacol*, 2023, **14**, 1266803.
181. Y. Zhang, F. Jin, X. Wei, Q. Jin, J. Xie, Y. Pan and W. Shen, Chinese herbal medicine for the treatment of chronic fatigue syndrome: A systematic review and meta-analysis, *Front Pharmacol*, 2022, **13**, 958005.
182. Z. Liu, Z. Lv, X. Zhou, J. Shi, S. Hong, H. Huang and L. Lv, Efficacy of traditional Chinese exercises in patients with post-COVID-19 chronic fatigue syndrome: A protocol for systematic review and meta-analysis, *Medicine (Baltimore)*, 2022, **101**, e31450.
183. T. Liu, W. Sun, S. Guo, T. Chen, M. Zhu, Z. Yuan, B. Li, J. Lu, Y. Shao, Y. Qu, Z. Sun, C. Feng and T. Yang, Research progress on pathogenesis of chronic fatigue syndrome and treatment of traditional Chinese and Western medicine, *Auton Neurosci*, 2024, **255**, 103198.
184. K. J. Wirth and M. Löhn, Microvascular Capillary and Precapillary Cardiovascular Disturbances Strongly Interact to Severely Affect Tissue Perfusion and Mitochondrial Function in Myalgic

- Encephalomyelitis/Chronic Fatigue Syndrome Evolving from the Post COVID-19 Syndrome, *Medicina (Kaunas)*, 2024, **60**, 194.
185. B. Adams, J. M. Nunes, M. J. Page, T. Roberts, J. Carr, T. A. Nell, D. B. Kell and E. Pretorius, Parkinson's disease: a systemic inflammatory disease accompanied by bacterial inflammagens, *Front Ag Neurosci*, 2019, **11**, 210.
 186. E. Pretorius, M. J. Page, S. Mbotwe and D. B. Kell, Lipopolysaccharide-binding protein (LBP) can reverse the amyloid state of fibrin seen or induced in Parkinson's disease, *PlosOne*, 2018, **13**, e0192121.
 187. M. J. van Vuuren, T. A. Nell, J. A. Carr, D. B. Kell and E. Pretorius, Iron dysregulation and inflammagens related to oral and gut health are central to the development of Parkinson's disease, *Biomolecules*, 2021, **11**, 30.
 188. P. Chen, J. Zhang, C. Wang, Y. H. Chai, A. G. Wu, N. Y. Huang and L. Wang, The pathogenesis and treatment mechanism of Parkinson's disease from the perspective of traditional Chinese medicine, *Phytomedicine*, 2022, **100**, 154044.
 189. M. Huo, S. Peng, J. Li, Y. Cao, Z. Chen, Y. Zhang and Y. Qiao, Comparison of the clinical effect features of Han-Ku-Gan and Wen-Xin-Gan based on the efficacy of promoting blood circulation and removing blood stasis, *J Trad Chinese Med Sci*, 2022, **9**, 237-245.
 190. L. Wang, H. An, F. Yu, J. Yang, H. Ding, Y. Bao, H. Xie and D. Huang, The neuroprotective effects of paeoniflorin against MPP(+)-induced damage to dopaminergic neurons via the Akt/Nrf2/GPX4 pathway, *J Chem Neuroanat*, 2022, **122**, 102103.
 191. E. Pretorius, H. M. Oberholzer, W. J. van der Spuy, A. C. Swanepoel and P. Soma, Scanning electron microscopy of fibrin networks in rheumatoid arthritis: a qualitative analysis, *Rheumatol Int*, 2012, **32**, 1611-1615.
 192. E. Pretorius, O.-O. Akeredolu, P. Soma and D. B. Kell, Major involvement of bacterial components in rheumatoid arthritis and its accompanying oxidative stress, systemic inflammation and hypercoagulability, *Exp Biol Med*, 2017, **242**, 355-373.
 193. K. Nozaki, H. Hikiami, H. Goto, T. Nakagawa, N. Shibahara and Y. Shimada, Keishibukuryogan (gui-zhi-fu-ling-wan), a Kampo formula, decreases disease activity and soluble vascular adhesion molecule-1 in patients with rheumatoid arthritis, *Evid Based Complement Alternat Med*, 2006, **3**, 359-364.
 194. W. Hou, G. Xu and H. Wang, Overview of Chinese Medicine and Autoimmune Diseases, and the Role of Yin Deficiency, in *Treating Autoimmune Disease with Chinese Medicine*, ed. W. Hou, G. Xu and H. Wang, Elsevier, Amsterdam, 2011, pp. 13-52.
 195. J. Schofield, S. T. Abrams, R. Jenkins, S. Lane, G. Wang and C. H. Toh, Microclots, as defined by amyloid-fibrinogen aggregates, predict risks of disseminated intravascular coagulation and mortality, *Blood Adv*, 2024, **8**, 2499-2508.
 196. F. Meng, H. Lai, Z. Luo, Y. Liu, X. Huang, J. Chen, B. Liu, Y. Guo, Y. Cai and Q. Huang, Effect of Xuefu Zhuyu Decoction Pretreatment on Myocardium in Sepsis Rats, *Evid Based Complement Alternat Med*, 2018, **2018**, 2939307.
 197. C. F. Bi, J. Liu, S. W. Hao, Z. X. Xu, X. Ma, X. F. Kang, L. S. Yang and J. F. Zhang, Xuebijing injection protects against sepsis-induced myocardial injury by regulating apoptosis and autophagy via mediation of PI3K/AKT/mTOR signaling pathway in rats, *Aging (Albany NY)*, 2023, **15**, 4374-4390.
 198. J. Sun, Q. Xue, L. Guo, L. Cui and J. Wang, Xuebijing protects against lipopolysaccharide-induced lung injury in rabbits, *Exp Lung Res*, 2010, **36**, 211-218.
 199. J. Wang, J. Zhu, J. Guo and Q. Wang, Could Xuebijing Injection Reduce the Mortality of Severe Pneumonia Patients? A Systematic Review and Meta-Analysis, *Evid Based Complement Alternat Med*, 2020, **2020**, 9605793.
 200. G. Chen, Y. Gao, Y. Jiang, F. Yang, S. Li, D. Tan and Q. Ma, Efficacy and Safety of Xuebijing Injection Combined With Ulinastatin as Adjunctive Therapy on Sepsis: A Systematic Review and Meta-Analysis, *Front Pharmacol*, 2018, **9**, 743.
 201. X. D. He, Y. Wang, Q. Wu, H. X. Wang, Z. D. Chen, R. S. Zheng, Z. S. Wang, J. B. Wang and Y. Yang, Xuebijing Protects Rats from Sepsis Challenged with *Acinetobacter baumannii* by Promoting Annexin A1 Expression and Inhibiting Proinflammatory Cytokines Secretion, *Evid Based Complement Alternat Med*, 2013, **2013**, 804940.

202. S. Y. Hou, X. H. Feng, C. L. Lin and Y. F. Tan, Efficacy of Xuebijing for coagulopathy in patients with sepsis, *Saudi Med J*, 2015, **36**, 164-169.
203. C. Li, P. Wang, L. Zhang, M. Li, X. Lei, S. Liu, Z. Feng, Y. Yao, B. Chang, B. Liu and H. Shang, Efficacy and safety of Xuebijing injection (a Chinese patent) for sepsis: A meta-analysis of randomized controlled trials, *J Ethnopharmacol*, 2018, **224**, 512-521.
204. S. H. Xiao, L. Luo, X. H. Liu, Y. M. Zhou, H. M. Liu and Z. F. Huang, Curative efficacy and safety of traditional Chinese medicine xuebijing injections combined with ulinastatin for treating sepsis in the Chinese population: A meta-analysis, *Medicine (Baltimore)*, 2018, **97**, e10971.
205. J. Zheng, X. Xiang, B. Xiao, H. Li, X. Gong, S. Yao and T. Yuan, Xuebijing combined with ulinastatin benefits patients with sepsis: A meta-analysis, *Am J Emerg Med*, 2018, **36**, 480-487.
206. Y. Song, C. Yao, Y. Yao, H. Han, X. Zhao, K. Yu, L. Liu, Y. Xu, Z. Liu, Q. Zhou, Y. Wang, Z. Ma, Y. Zheng, D. Wu, Z. Tang, M. Zhang, S. Pan, Y. Chai, Y. Song, J. Zhang, L. Pan, Y. Liu, H. Yu, X. Yu, H. Zhang, X. Wang, Z. Du, X. Wan, Y. Tang, Y. Tian, Y. Zhu, H. Wang, X. Yan, Z. Liu, B. Zhang, N. Zhong, H. Shang and C. Bai, XueBijing Injection Versus Placebo for Critically Ill Patients With Severe Community-Acquired Pneumonia: A Randomized Controlled Trial, *Crit Care Med*, 2019, **47**, e735-e743.
207. C. Cheng and X. Yu, Research Progress in Chinese Herbal Medicines for Treatment of Sepsis: Pharmacological Action, Phytochemistry, and Pharmacokinetics, *Int J Mol Sci*, 2021, **22**.
208. C. Li, P. Wang, M. Li, R. Zheng, S. Chen, S. Liu, Z. Feng, Y. Yao and H. Shang, The current evidence for the treatment of sepsis with Xuebijing injection: Bioactive constituents, findings of clinical studies and potential mechanisms, *J Ethnopharmacol*, 2021, **265**, 113301.
209. Q. Wu, C. H. Yin, Y. Li, J. Q. Cai, H. Y. Yang, Y. Y. Huang, Y. X. Zheng, K. Xiong, H. L. Yu, A. P. Lu, K. X. Wang, D. G. Guan and Y. P. Chen, Detecting Critical Functional Ingredients Group and Mechanism of Xuebijing Injection in Treating Sepsis, *Front Pharmacol*, 2021, **12**, 769190.
210. J. Lv, X. Guo, H. Zhao, G. Zhou and Y. An, Xuebijing Administration Alleviates Pulmonary Endothelial Inflammation and Coagulation Dysregulation in the Early Phase of Sepsis in Rats, *J Clin Med*, 2022, **11**, 6696.
211. T. Shang, Z. S. Zhang, X. T. Wang, J. Chang, M. E. Zhou, M. Lyu, S. He, J. Yang, Y. X. Chang, Y. Wang, M. C. Li, X. Gao, Y. Zhu and Y. Feng, Xuebijing injection inhibited neutrophil extracellular traps to reverse lung injury in sepsis mice via reducing Gasdermin D, *Front Pharmacol*, 2022, **13**, 1054176.
212. X. Yu, W. Niu, Y. Y. Wang, O. E. Olaleye, J. N. Wang, M. Y. Duan, J. L. Yang, R. R. He, Z. X. Chu, K. Dong, G. P. Zhang, C. X. Liu, C. Cheng and C. Li, Novel assays for quality evaluation of XueBijing: Quality variability of a Chinese herbal injection for sepsis management, *J Pharm Anal*, 2022, **12**, 664-682.
213. F. Chen, S. Yan, J. Xu, Y. Jiang, J. Wang, H. Deng, J. Wang, L. Zou, Y. Liu and Y. Zhu, Exploring the potential mechanism of Xuebijing injection against sepsis based on metabolomics and network pharmacology, *Anal Biochem*, 2023, **682**, 115332.
214. X. Liao and J. Rello, Efficacy of Xuebijing Injection for Sepsis (EXIT-SEP): Lost in Translation, *Anaesth Crit Care Pain Med*, 2023, **42**, 101257.
215. S. Liu, C. Yao, J. Xie, H. Liu, H. Wang, Z. Lin, B. Qin, D. Wang, W. Lu, X. Ma, Y. Liu, L. Liu, C. Zhang, L. Xu, R. Zheng, F. Zhou, Z. Liu, G. Zhang, L. Zhou, J. Liu, A. Fei, G. Zhang, Y. Zhu, K. Qian, R. Wang, Y. Liang, M. Duan, D. Wu, R. Sun, Y. Wang, X. Zhang, Q. Cao, M. Yang, M. Jin, Y. Song, L. Huang, F. Zhou, D. Chen, Q. Liang, C. Qian, Z. Tang, Z. Zhang, Q. Feng, Z. Peng, R. Sun, Z. Song, Y. Sun, Y. Chai, L. Zhou, C. Cheng, L. Li, X. Yan, J. Zhang, Y. Huang, F. Guo, C. Li, Y. Yang, H. Shang, H. Qiu and E.-S. Investigators, Effect of an Herbal-Based Injection on 28-Day Mortality in Patients With Sepsis: The EXIT-SEP Randomized Clinical Trial, *JAMA Intern Med*, 2023, **183**, 647-655.
216. M. Zhang, R. Zheng, W. J. Liu, J. L. Hou, Y. L. Yang and H. C. Shang, Xuebijing injection, a Chinese patent medicine, against severe pneumonia: Current research progress and future perspectives, *J Integr Med*, 2023, **21**, 413-422.
217. X. F. Kang, X. L. Lu, C. F. Bi, X. D. Hu, Y. Li, J. K. Li, L. S. Yang, J. Liu, L. Ma and J. F. Zhang, Xuebijing injection protects sepsis induced myocardial injury by mediating TLR4/NF-kappaB/IKKalpha and JAK2/STAT3 signaling pathways, *Aging (Albany NY)*, 2023, **15**, 8501-8517.

218. C. Zhang, X. Chen, T. Wei, J. Song, X. Tang, J. Bi, C. Chen, J. Zhou, X. Su and Y. Song, Xuebijing alleviates LPS-induced acute lung injury by downregulating pro-inflammatory cytokine production and inhibiting gasdermin-E-mediated pyroptosis of alveolar epithelial cells, *Chin J Nat Med*, 2023, **21**, 576-588.
219. C. Cheng, C. Ren, M. Z. Li, Y. H. Liu, R. Q. Yao, Y. Yu, X. Yu, J. L. Wang, L. X. Wang, Y. C. Leng, H. Zhang, F. F. Du, N. Dong, F. Q. Wang, Y. Wu, F. Xu, X. M. Zhu, G. P. Zhang, K. Dong, S. Liu, X. Q. Yao, C. Li and Y. M. Yao, Pharmacologically significant constituents collectively responsible for anti-sepsis action of XueBiJing, a Chinese herb-based intravenous formulation, *Acta Pharmacol Sin*, 2024, **45**, 1077-1092.
220. J. Wang, C. Luo, M. Luo, S. Zhou and G. Kuang, Targets and Mechanisms of Xuebijing in the Treatment of Acute Kidney Injury Associated with Sepsis: A Network Pharmacology-based Study, *Curr Comput Aided Drug Des*, 2024, **20**, 752-763.
221. X. Zhou, M. Zhong, X. Xi, J. Li. and G. Tang, Efficacy and safety of Chinese herbal medicine as adjunctive therapy in sepsis patients with bloodstream infection: a propensity-matched analysis, *J Tradit Chin Med*, 2024, **44**, 197-204.
222. F. Zou, J. Zou, Q. Du, L. Liu, D. Li, L. Zhao, M. Tang, L. Zuo and Z. Sun, XueBiJing injection improves the symptoms of sepsis-induced acute lung injury by mitigating oxidative stress and ferroptosis, *J Ethnopharmacol*, 2025, **337**, 118732.
223. W. Wu, R. L. Jiang, L. C. Wang, S. Lei, X. Xing, Y. H. Zhi, J. N. Wu, Y. C. Wu, M. F. Zhu and L. Q. Huang, Effect of Shenfu injection on intestinal mucosal barrier in a rat model of sepsis, *Am J Emerg Med*, 2015, **33**, 1237-1243.
224. N. Zhang, J. Liu, Z. Qiu, Y. Ye, J. Zhang and T. Lou, Shenfu injection for improving cellular immunity and clinical outcome in patients with sepsis or septic shock, *Am J Emerg Med*, 2017, **35**, 1-6.
225. S. Jin, R. Jiang, S. Lei, L. Jin, C. Zhu, W. Feng and Y. Shen, Shenfu injection prolongs survival and protects the intestinal mucosa in rats with sepsis by modulating immune response, *Turk J Gastroenterol*, 2019, **30**, 364-371.
226. J. Liu, F. Liu, T. Liang, P. Cao, J. Li, Y. Zhang and Y. Liu, Efficacy of Shenfu decoction on sepsis in rats with condition induced by cecal ligation and puncture, *J Tradit Chin Med*, 2020, **40**, 621-628.
227. P. Xu, W. Q. Zhang, J. Xie, Y. S. Wen, G. X. Zhang and S. Q. Lu, Shenfu injection prevents sepsis-induced myocardial injury by inhibiting mitochondrial apoptosis, *J Ethnopharmacol*, 2020, **261**, 113068.
228. S. Luo, L. Gou, S. Liu and X. Cao, Efficacy and safety of Shenfu injection in the treatment of sepsis: A protocol for systematic review and meta-analysis, *Medicine (Baltimore)*, 2021, **100**, e27196.
229. C. Xu, Y. Xia, Z. Jia, S. Wang, T. Zhao and L. Wu, The curative effect of Shenfu-injection in the treatment of burn sepsis and its effect on the patient's immune function, HMGB, and vWF, *Am J Transl Res*, 2022, **14**, 2428-2435.
230. P. Huang, Y. Guo, X. Hu, X. Fang, X. Xu and Q. Liu, Mechanism of Shenfu injection in suppressing inflammation and preventing sepsis-induced apoptosis in murine cardiomyocytes based on network pharmacology and experimental validation, *J Ethnopharmacol*, 2024, **322**, 117599.
231. J. Liao, C. Qin, Z. Wang, L. Gao, S. Zhang, Y. Feng, J. Liu and L. Tao, Effect of shenfu injection in patients with septic shock: A systemic review and meta-analysis for randomized clinical trials, *J Ethnopharmacol*, 2024, **320**, 117431.
232. D. Liu, T. Pan, X. Li, D. Zhu, Y. Li, H. He, F. Wu, L. Jiang, Y. Chen, X. Wang, J. Liu, R. Tan and H. Qu, Effectiveness and safety of Shenfu injection in septic patients with hypoperfusion: A multi-center, open-label, randomized, controlled trial, *J Intensive Med*, 2024, **4**, 484-490.
233. L. Xiao, L. Niu, X. Xu, Y. Zhao, L. Yue, X. Liu and G. Li, Comparative Efficacy of Tonic Chinese Herbal Injections for Treating Sepsis or Septic Shock: A Systematic Review and Bayesian Network Meta-Analysis of Randomized Controlled Trials, *Front Pharmacol*, 2022, **13**, 830030.
234. H. Yuan, Y. Liu, K. Huang, H. Hao and Y. T. Xue, Therapeutic Mechanism and Key Active Ingredients of Shenfu Injection in Sepsis: A Network Pharmacology and Molecular Docking Approach, *Evid Based Complement Alternat Med*, 2022, **2022**, 9686149.
235. H. J. Yuan, G. H. Xiang, Y. Liu, Y. Li, W. L. Liu, J. X. Wei, Y. T. Xue and H. Hao, Exploration and verification of the therapeutic mechanism of shenfu injection in sepsis-induced myocardial injury, *PLoS One*, 2025, **20**, e0317738.

236. J. M. Grixti, A. Chandran, J.-H. Pretorius, M. Walker, A. Sekhar, E. Pretorius and D. B. Kell, The clots removed from ischaemic stroke patients by mechanical thrombectomy are amyloid in nature, *medRxiv*, 2024, 10.1101/2024.1111.1101.24316555v24316551.
237. M. Xu, R. X. Wu, X. L. Li, Y. S. Zeng, J. Y. Liang, K. Fu, Y. Liang and Z. Wang, Traditional medicine in China for ischemic stroke: bioactive components, pharmacology, and mechanisms, *J Integr Neurosci*, 2022, **21**, 26.
238. L. W. Hsu, W. C. Shiao, N. C. Chang, M. C. Yu, T. L. Yen, P. A. Thomas, T. Jayakumar and J. R. Sheu, The neuroprotective effects of Tao-Ren-Cheng-Qi Tang against embolic stroke in rats, *Chin Med*, 2017, **12**, 7.
239. H. Zhang, H. Ouyang, J. Zhang, L. Lin, M. Wei, B. Lu and L. Ji, Exploring the efficacy and mechanism of *Glycyrrhizae Radix et Rhizoma* in improving collagen-induced arthritis in mice, *J Ethnopharmacol*, 2024, **322**, 117554.
240. L. H. Shaw, W. M. Chen and T. H. Tsai, Identification of multiple ingredients for a Traditional Chinese Medicine preparation (bu-yang-huan-wu-tang) by liquid chromatography coupled with tandem mass spectrometry, *Molecules*, 2013, **18**, 11281-11298.
241. H. W. Wang, K. T. Liou, Y. H. Wang, C. K. Lu, Y. L. Lin, I. J. Lee, S. T. Huang, Y. H. Tsai, Y. C. Cheng, H. J. Lin and Y. C. Shen, Deciphering the neuroprotective mechanisms of Bu-yang Huan-wu decoction by an integrative neurofunctional and genomic approach in ischemic stroke mice, *J Ethnopharmacol*, 2011, **138**, 22-33.
242. Z. Z. Chen, X. Gong, Q. Guo, H. Zhao and L. Wang, Bu Yang Huan Wu decoction prevents reperfusion injury following ischemic stroke in rats via inhibition of HIF-1 alpha, VEGF and promotion beta-ENaC expression, *J Ethnopharmacol*, 2019, **228**, 70-81.
243. K. Y. Chen, K. C. Wu, D. Y. Hueng, K. F. Huang and C. Y. Pang, Anti-inflammatory effects of powdered product of Bu Yang Huan Wu decoction: Possible role in protecting against Transient Focal Cerebral Ischemia, *Int J Med Sci*, 2020, **17**, 1854-1863.
244. J. W. Peng, Y. Liu, G. Meng, J. Y. Zhang and L. F. Yu, Effects of salvianolic acid on cerebral perfusion in patients after acute stroke: A single-center randomized controlled trial, *Exp Ther Med*, 2018, **16**, 2600-2614.
245. J. Lyu, Y. Xie, Z. Wang and L. Wang, Salvianolic Acids for Injection Combined with Conventional Treatment for Patients with Acute Cerebral Infarction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, *Med Sci Monit*, 2019, **25**, 7914-7927.
246. C. D. Liu, N. N. Liu, S. Zhang, G. D. Ma, H. G. Yang, L. L. Kong and G. H. Du, Salvianolic acid A prevented cerebrovascular endothelial injury caused by acute ischemic stroke through inhibiting the Src signaling pathway, *Acta Pharmacol Sin*, 2021, **42**, 370-381.
247. Y. Yang, Y. He, X. Wei, H. Wan, Z. Ding, J. Yang and H. Zhou, Network Pharmacology and Molecular Docking-Based Mechanism Study to Reveal the Protective Effect of Salvianolic Acid C in a Rat Model of Ischemic Stroke, *Front Pharmacol*, 2021, **12**, 799448.
248. Q. Zhang, L. Zhang, Y. Liu, X. Tian, X. Li, B. Han, Y. Zhang, Z. Wu, H. Yu, H. Zhao, S. Wang, K. Ma and Y. Wang, Research progress on the pharmacological effect and clinical application of Tongqiao Huoxue Decoction in the treatment of ischaemic stroke, *Biomed Pharmacother*, 2021, **138**, 111460.
249. H. G. Lee, S. Kwon, S. K. Moon, S. Y. Cho, S. U. Park, W. S. Jung, J. M. Park, C. N. Ko and K. H. Cho, Neuroprotective Effects of Geopung-Chunghyuldan Based on Its Salvianolic Acid B Content Using an In Vivo Stroke Model, *Curr Issues Mol Biol*, 2023, **45**, 1613-1626.
250. L. Wang, Y. Liu, J. Wei, X. Liang and Y. Zhang, Effects of intravenous thrombolysis with and without salvianolic acids for injection on the functional recovery of patients with acute ischemic stroke: A systematic review, meta-analysis, and trial sequential analysis, *Phytother Res*, 2023, **37**, 2513-2530.
251. H. Ren, A. H. Yang, Y. S. Cai, Y. Qin and T. Y. Luo, Study on correlation between Chinese medicine syndromes in stroke and neurological deficits during recovery phase: Perspective, *Medicine (Baltimore)*, 2024, **103**, e39600.
252. J. Wang, P. Su, C. Wan, Y. Xu, J. Huang, J. Niu and Z. Jin, Role of salvianolic acid B in the treatment of acute ischemic stroke: a systematic review and meta-analysis of animal models, *Front Pharmacol*, 2024, **15**, 1479765.

253. H. Yang, M. M. Ibrahim, S. Zhang, Y. Sun, J. Chang, H. Qi and S. Yang, Targeting post-stroke neuroinflammation with Salvianolic acid A: molecular mechanisms and preclinical evidence, *Front Immunol*, 2024, **15**, 1433590.
254. M. Y. Yang, Y. Liu, Y. W. Yu, B. F. Gong, J. Ruan and H. Y. Fan, Application of targeted liposomes-based salvianolic acid A for the treatment of ischemic stroke, *Neurotherapeutics*, 2024, **21**, e00342.
255. R. Yang, N. Hu, T. Y. Liu, Y. Qu, J. Liu, J. H. Wang, B. F. Yang and C. L. Li, Salvianolic acid A provides neuroprotective effects on cerebral ischemia-reperfusion injury in rats via PKA/CREB/c-Fos signaling pathway, *Phytomedicine*, 2024, **124**, 155326.
256. D. Y. Zhong, H. Y. Li, L. Li, R. M. Ma, C. T. Jiang, D. X. Li and Y. H. Deng, Effect of Tongqiao Huoxue Decoction Combined with Western Medicine on Ischemic Stroke: A Systematic Review, *Evid Based Complement Alternat Med*, 2020, **2020**, 8877998.
257. F. Hou, H. Liu, Q. Gong and H. Xu, Network pharmacology of Huatan Tongluo decoction and clinical effects of its combination with acupuncture in the treatment of stroke, *Am J Transl Res*, 2022, **14**, 8215-8224.
258. D. B. Kell and E. Pretorius, Proteomic evidence for amyloidogenic cross-seeding in fibrinolytic microclots, *Int J Mol Sci*, 2024, **25**, 10809.
259. D. B. Kell and E. Pretorius, The proteome content of blood clots observed under different conditions: successful role in predicting clot amyloidogenicity, *Molecules*, 2025, **30**, 668.
260. S. A. Bondarev, K. S. Antonets, A. V. Kajava, A. A. Nizhnikov and G. A. Zhouravleva, Protein Co-Aggregation Related to Amyloids: Methods of Investigation, Diversity, and Classification, *Int J Mol Sci*, 2018, **19**, 2292.
261. W. Cao, S. Liao, Y. Zhang, L. Zhou, G. Li, W. Ouyang and Z. Wen, Effectiveness and safety of Xuefu Zhuyu oral liquid on -stagnation and blood-stasis pattern in patients with stable angina, tension-type headache and primary dysmenorrhea: rationale and design of a master protocol, *J Tradit Chin Med*, 2023, **43**, 815-823.
262. J. Chen, P. Lu, X. Zuo, Q. Shi, H. Zhao, L. Luo, J. Yi, C. Zheng, Y. Yang and W. Wang, Clinical data mining of phenotypic network in angina pectoris of coronary heart disease, *Evid Based Complement Alternat Med*, 2012, **2012**, 546230.
263. F. Y. Chu, J. Wang, K. W. Yao and Z. Z. Li, Effect of Xuefu Zhuyu Capsule (血府逐瘀胶囊) on the symptoms and signs and health-related quality of life in the unstable angina patients with blood-stasis syndrome after percutaneous coronary intervention: A Randomized controlled trial, *Chin J Integr Med*, 2010, **16**, 399-405.
264. P. Huang, Z. Li, L. Chen, J. Zeng, S. Zhao, Y. Tang, B. Huang, H. Guan, Y. Chen, Y. Feng, S. Lei, Q. Wu, H. Zhang, X. Huang, L. Zeng, Y. Liu, Z. Zeng and B. Chen, The comparative effects of oral Chinese patent medicines combined with western medicine in stable angina: A systematic review and network meta-analysis of 179 trials, *Front Pharmacol*, 2022, **13**, 918689.
265. J. Li, P. Zhang, Y. Zhang, H. Wang, L. Wu, J. Zhao, Y. Liu, W. Zeng, R. Guo, J. Mei and F. Xu, A Randomized Controlled Trial on the Efficacy of Xinnaoning Capsule in the Treatment of CSAP Complicated With Qi Stagnation and Blood Stasis Syndrome, *Front Cardiovasc Med*, 2022, **9**, 859956.
266. Y. Li, H. Zhao, J. Du, Z. Jiao, D. Shen, S. Gao, Y. Zheng, Z. Li, L. Li, Y. Wang and C. Yu, Clinical metabolomic analysis of Danlou tablets with antioxidant effects for treating stable angina pectoris, *J Pharm Biomed Anal*, 2022, **219**, 114922.
267. W. Liu, L. Zhou, L. Feng, D. Zhang, C. Zhang, Y. Gao and B. G. behalf of the, BuqiTongluo Granule for Ischemic Stroke, Stable Angina Pectoris, Diabetic Peripheral Neuropathy with Qi Deficiency and Blood Stasis Syndrome: Rationale and Novel Basket Design, *Front Pharmacol*, 2021, **12**, 764669.
268. J. Wang, X. Yang, F. Chu, J. Chen, Q. He, K. Yao, F. Teng, Y. Gao, Y. Xing, A. Wu and Y. Xing, The effects of xuefu zhuyu and shengmai on the evolution of syndromes and inflammatory markers in patients with unstable angina pectoris after percutaneous coronary intervention: a randomised controlled clinical trial, *Evid Based Complement Alternat Med*, 2013, **2013**, 896467.
269. J. Wang and G. Yu, A Systems Biology Approach to Characterize Biomarkers for Blood Stasis Syndrome of Unstable Angina Patients by Integrating MicroRNA and Messenger RNA Expression Profiling, *Evid Based Complement Alternat Med*, 2013, **2013**, 510208.

270. X. R. Wang, D. D. Song, T. Q. Tao, T. He, X. D. Wu, X. M. Li and X. H. Liu, Qi-Regulating and Blood Circulation-Promoting Therapy Improves Health Status of Stable Angina Pectoris Patients with Depressive Symptoms, *Evid Based Complement Alternat Med*, 2021, **2021**, 7319417.
271. X. Wang, X. Xing, P. Huang, Z. Zhang, Z. Zhou, L. Liang, R. Yao, X. Wu and L. Yang, A Chinese classical prescription Xuefu Zhuyu decoction in the treatment of coronary heart disease: An overview, *Heliyon*, 2024, **10**, e28919.
272. J. H. Weng, F. G. Hou, X. Wang, Z. Y. Wang and M. P. Wu, A Clinical Study on the Efficacy of the Yangxin Huoxue Formula in Treating Stable Angina Pectoris (Qi Deficiency and Blood Stasis Syndrome) with Concurrent Anxiety and Depression Disorders, *J Multidiscip Healthc*, 2024, **17**, 5317-5327.
273. R. Yang, Z. Bai, C. Liang and F. Qi, Treatment of microvascular angina pectoris by activating blood circulation to remove blood stasis: A systematic review and meta-analysis, *Medicine (Baltimore)*, 2024, **103**, e40012.
274. K. W. Yao, J. Wang, C. L. Zhu, J. T. Wu and J. Z. Fang, Results of different quantitative diagnosis analysis on the symptoms and signs of blood stasis syndrome in coronary heart disease, *World Sci Technol*, 2009, **11**, 684-688.
275. K. W. Yao, Q. Y. He, F. Teng and J. Wang, Logistic regression analysis of syndrome essential factors in patients with unstable angina pectoris, *J Tradit Chin Med*, 2011, **31**, 273-276.
276. Z. Sun, D. Zhong, J. Zhang, Q. Wang, C. Li, T. Yuan, X. Dai, J. Duan and K. Yao, Tongxinshu capsules in the treatment of stable angina pectoris due to qi deficiency and blood stasis in coronary heart disease: A multicenter, randomized, double-blind, placebo-controlled trial, *J Ethnopharmacol*, 2025, **343**, 119437.
277. G. P. Qi, A. J. Zhang, Z. Xu, Z. H. Li, W. B. Zeng, X. Liu, J. M. Ma, X. S. Zheng and Z. J. Li, Application of a Complex Network Modeling Approach to Explore the Material Basis and Mechanisms of Traditional Chinese Medicine: A Case Study of Xuefu Zhuyu Decoction for the Treatment of Two Types of Angina Pectoris, *Ieee Access*, 2022, **10**, 114103-114117.
278. D. Bai and J. Song, Plasma metabolic biomarkers for syndrome of phlegm and blood stasis in hyperlipidemia and atherosclerosis, *J Tradit Chin Med*, 2012, **32**, 578-583.
279. Z. Liu, H. Yang, M. Zhang, J. Cai and Z. Huang, The Interaction Effect between Blood Stasis Constitution and Atherosclerotic Factors on Cognitive Impairment in Elderly People, *Evid Based Complement Alternat Med*, 2018, **2018**, 8914090.
280. A. Morita, T. Namiki, T. Nakaguchi, K. Murai, Y. Watanabe, M. Nakamura, Y. Kawasaki, Y. Shiko, Y. Tamura, A. Suganami, A. Murakami, A. Yagi, H. Okamoto and Y. Hirasaki, Role of Blood Stasis Syndrome of Kampo Medicine in the Early Pathogenic Stage of Atherosclerosis: A Retrospective Cross-Sectional Study, *Evid Based Complement Alternat Med*, 2021, **2021**, 5557392.
281. H. L. Zuo, K. G. Linghu, Y. L. Wang, K. M. Liu, Y. Gao, H. Yu, F. Q. Yang and Y. J. Hu, Interactions of antithrombotic herbal medicines with Western cardiovascular drugs, *Pharmacol Res*, 2020, **159**, 104963.
282. X. Wei, M. Gao, N. Sheng, W. Yao, B. Bao, F. Cheng, Y. Cao, H. Yan, L. Zhang, M. Shan and P. Chen, Mechanism investigation of Shi-Xiao-San in treating blood stasis syndrome based on network pharmacology, molecular docking and in vitro/vivo pharmacological validation, *J Ethnopharmacol*, 2023, **301**, 115746.
283. W. Zhi, Y. Liu, X. Wang and H. Zhang, Recent advances of traditional Chinese medicine for the prevention and treatment of atherosclerosis, *J Ethnopharmacol*, 2023, **301**, 115749.
284. F. Maione and N. Mascolo, Danshen and the Cardiovascular System: New Advances for an Old Remedy, *Semin Thromb Hemost*, 2016, **42**, 321-322.
285. N. Ammash, E. A. Konik, R. D. McBane, D. Chen, J. I. Tange, D. E. Grill, R. M. Herges, T. G. McLeod, P. A. Friedman and W. E. Wysokinski, Left atrial blood stasis and Von Willebrand factor-ADAMTS13 homeostasis in atrial fibrillation, *Arterioscler Thromb Vasc Biol*, 2011, **31**, 2760-2766.
286. S. Bäck, I. Skoda, J. Lantz, L. Henriksson, L. O. Karlsson, A. Persson, C. J. Carlhäll and T. Ebbers, Elevated atrial blood stasis in paroxysmal atrial fibrillation during sinus rhythm: a patient-specific computational fluid dynamics study, *Front Cardiovasc Med*, 2023, **10**, 1219021.
287. D. B. Kell, G. Y. H. Lip and E. Pretorius, Fibrinolytic Microclots and Atrial Fibrillation, *Biomedicines*, 2024, **12**, 891.

288. X. Ni, Y. Zhang-James, X. Han, S. Lei, J. Sun and R. Zhou, Traditional Chinese medicine in the treatment of ADHD: a review, *Child Adolesc Psychiatr Clin N Am*, 2014, **23**, 853-881.
289. S. Zhao, Y. Deng, Z. Chen and S. Wang, How does traditional chinese medicine treat attention deficit hyperactivity disorder - A different understanding and treatment strategy, *Open J Orthop Rheumatol*, 2023, **8**, 013-017.
290. Y. Y. Zhang and Y. P. Li, Progress of traditional Chinese Medicine on ADHD Treatment Based on Syndrome Differentiation, *Drug Combin Therapy*, 2021, **3**, 11.
291. R. Sun, H. Yuan, J. Wang, K. Zhu, Y. Xiong, Y. Zheng, X. Ni and M. Huang, *Rehmanniae Radix Preparata* ameliorates behavioral deficits and hippocampal neurodevelopmental abnormalities in ADHD rat model, *Front Neurosci*, 2024, **18**, 1402056.
292. H. S. Shen, C. Y. Hsu, H. T. Yip and I. H. Lin, Lower risk of ischemic stroke among patients with chronic kidney disease using chinese herbal medicine as add-on therapy: A real-world nationwide cohort study, *Front Pharmacol*, 2022, **13**, 883148.
293. C. Q. Song, Z. Y. Zhu, M. Liu, W. B. Yang, X. T. Bai and Z. Nan, Clinical efficacy and safety of Xuefu Zhuyu decoction in the treatment of diabetic kidney disease: A protocol for systematic review and meta-analysis, *Medicine*, 2022, **101**.
294. W. Liu, S. Yang, M. Fu, J. Li, Y. Song, B. Wei, E. Liu and Z. Sun, Chinese patent medicine for chronic obstructive pulmonary disease based on principles of tonifying Qi, promoting blood circulation by removing blood stasis, and resolving phlegm: a systematic review of randomized controlled trials, *J Tradit Chin Med*, 2015, **35**, 1-10.
295. Y. Hu, Y. Lan, Q. Ran, Q. Gan and W. Huang, Analysis of the Clinical Efficacy and Molecular Mechanism of Xuefu Zhuyu Decoction in the Treatment of COPD Based on Meta-Analysis and Network Pharmacology, *Comput Math Methods Med*, 2022, **2022**, 2615580.
296. S. Qin, P. Tan, J. Xie, Y. Zhou and J. Zhao, A systematic review of the research progress of traditional Chinese medicine against pulmonary fibrosis: from a pharmacological perspective, *Chin Med*, 2023, **18**, 96.
297. Q. Yang, D. Yin, H. Wang, Y. Gao, X. Wang, D. Wu, J. Tong, C. Wang and Z. Li, Uncovering the action mechanism of Shenqi Tiaoshen formula in the treatment of chronic obstructive pulmonary disease through network pharmacology, molecular docking, and experimental verification, *J Tradit Chin Med*, 2024, **44**, 770-783.
298. X. Yu, W. Qin, H. Cai, C. Ren, S. Huang, X. Lin, L. Tang, Z. Shan, W. H. A. Al-Ameer, L. Wang, H. Yan and M. Chen, Analyzing the molecular mechanism of xuefuzhuyu decoction in the treatment of pulmonary hypertension with network pharmacology and bioinformatics and verifying molecular docking, *Comput Biol Med*, 2024, **169**, 107863.
299. W. Zhou and Y. Wang, A network-based analysis of the types of coronary artery disease from traditional Chinese medicine perspective: potential for therapeutics and drug discovery, *J Ethnopharmacol*, 2014, **151**, 66-77.
300. K. J. Chen, D. Z. Shi, C. G. Fu, Z. Y. Gao, H. Xu, S. Z. Lv, S. J. You and L. Huang, Diagnostic criterion of blood stasis syndrome for coronary heart disease : Activating Blood Circulation Committee of Chinese Association of Integrative Medicine, *Chin J Integr Med*, 2016, **22**, 803-804.
301. S. Zhang, Z. L. Chen, Y. P. Tang, J. L. Duan and K. W. Yao, Efficacy and Safety of Xue-Fu-Zhu-Yu Decoction for Patients with Coronary Heart Disease: A Systematic Review and Meta-Analysis, *Evid Based Complement Alternat Med*, 2021, **2021**, 9931826.
302. Q. Q. Xin, X. Chen, R. Yuan, Y. H. Yuan, J. Q. Hui, Y. Miao, W. H. Cong and K. J. Chen, Correlation of Platelet and Coagulation Function with Blood Stasis Syndrome in Coronary Heart Disease: A Systematic Review and Meta-Analysis, *Chin J Integr Med*, 2021, **27**, 858-866.
303. H. Shi, Z. Tang, T. Liu, X. Zhang, Y. Wang, J. Li, C. Dong, W. Chen, R. Hou, G. Si and Y. Liu, The Effect and Safety of Xuefu Zhuoyue Prescription for Coronary Heart Disease: An Overview of Systematic Reviews and Meta-Analyses, *Evid Based Complement Alternat Med*, 2022, **2022**, 9096940.
304. G. Yang, S. Zhou, H. He, Z. Shen, Y. Liu, J. Hu and J. Wang, Exploring the "gene-protein-metabolite" network of coronary heart disease with phlegm and blood stasis syndrome by integrated multi-omics strategy, *Front Pharmacol*, 2022, **13**, 1022627.

305. G. Yu and J. Wang, Susceptible gene polymorphisms for blood stasis syndrome of coronary heart disease, *Chin J Integr Med*, 2016.
306. M. Lyu, C. L. Yan, H. X. Liu, T. Y. Wang, X. H. Shi, J. P. Liu, J. Orgah, G. W. Fan, J. H. Han, X. Y. Wang and Y. Zhu, Network pharmacology exploration reveals endothelial inflammation as a common mechanism for stroke and coronary artery disease treatment of Danhong injection, *Sci Rep*, 2017, **7**, 15427.
307. F. Kui, W. Gu, F. Gao, Y. Niu, W. Li, Y. Zhang, L. Guo, J. Wang, Z. Guo, S. Cen and G. Du, Research on Effect and Mechanism of Xuefu Zhuyu Decoction on CHD Based on Meta-Analysis and Network Pharmacology, *Evid Based Complement Alternat Med*, 2021, **2021**, 9473531.
308. T. Q. Tao, T. He, X. R. Wang and X. H. Liu, Metabolic Profiling Analysis of Patients With Coronary Heart Disease Undergoing Xuefu Zhuyu Decoction Treatment, *Frontiers in Pharmacology*, 2019, **10**.
309. H. Qian, B. B. Chen, M. Zhang, S. J. Zeng, Z. Z. Jia, S. Wang, S. Gao, A. H. Shi and J. Xie, Network pharmacology and molecular docking approach to explore the potential mechanisms of Xuefu Zhuyu Capsule in coronary heart disease, *Medicine*, 2025, **104**.
310. Y. Wang, J. Wang, W. Lv, H. Chen, Q. Yang, Y. Zhang, R. Guo, X. L. Ma and Q. Y. Zhang, Clinical intervention effect of Xuefu Zhuyu decoction on chronic heart failure complicated with depression, *World J Psychiatr*, 2024, **14**.
311. X. Y. Lu, H. Xu, T. Zhao and G. Li, Study of Serum Metabonomics and Formula-Pattern Correspondence in Coronary Heart Disease Patients Diagnosed as Phlegm or Blood Stasis Pattern Based on Ultra Performance Liquid Chromatography Mass Spectrometry, *Chin J Integr Med*, 2018, **24**, 905-911.
312. B. Liang, Y. Xiang, X. Zhang, C. Wang, B. Jin, Y. Zhao and F. Zheng, Systematic Pharmacology and GEO Database Mining Revealed the Therapeutic Mechanism of Xuefu Zhuyu Decoration for Atherosclerosis Cardiovascular Disease, *Front Cardiovasc Med*, 2020, **7**, 592201.
313. J. Han, Y. Miao, L. Song, X. Zhou, Y. Liu, L. Wang, K. Zhu, H. Ma, Y. Ma, Q. Li and D. Han, Xuefu Zhuyu Decoction improves hyperlipidemia through the MAPK/NF-kappaB and MAPK/PPARalpha/CPT-1A signaling pathway, *FASEB J*, 2025, **39**, e70363.
314. S. Zhu, Y. Song, X. Chen and W. Qian, Traditional Chinese and western medicine for the prevention of deep venous thrombosis after lower extremity orthopedic surgery: a meta-analysis of randomized controlled trials, *J Orthop Surg Res*, 2018, **13**, 79.
315. S. T. Yan, F. Gao, T. W. Dong, H. Fan, M. M. Xi, F. Miao and P. F. Wei, Meta-Analysis of Randomized Controlled Trials of Xueshuantong Injection in Prevention of Deep Venous Thrombosis of Lower Extremity after Orthopedic Surgery, *Evid Based Complement Alternat Med*, 2020, **2020**, 8877791.
316. B. Huang, P. Tang, Y. Liu, F. Liu, Y. Zheng, X. Yang, X. Zhang, H. Xie, L. Lin, B. Lin and B. Lin, Xuefu Zhuyu decoction alleviates deep vein thrombosis through inhibiting the activation of platelets and neutrophils via sirtuin 1/nuclear factor kappa-B pathway, *J Ethnopharmacol*, 2024, **333**, 118485.
317. J. Jo, J. Leem, J. M. Lee and K. S. Park, Herbal medicine (Hyeolbuchukeo-tang or Xuefu Zhuyu decoction) for treating primary dysmenorrhoea: protocol for a systematic review of randomised controlled trials, *BMJ Open*, 2017, **7**, e015056.
318. J. Jung, M. M. Ko, M. S. Lee, S. M. Lee and J. A. Lee, Diagnostic Indicators for Blood Stasis Syndrome Patients with Gynaecological Diseases, *Chin J Integr Med*, 2018, **24**, 752-757.
319. J. Leem, J. Jo, C. Y. Kwon, H. Lee, K. S. Park and J. M. Lee, Herbal medicine (Hyeolbuchukeo-tang or Xuefu Zhuyu decoction) for treating primary dysmenorrhea: A systematic review and meta-analysis of randomized controlled trials, *Medicine (Baltimore)*, 2019, **98**, e14170.
320. G. Li, Z. Zhang, L. Zhou, S. Liao, J. Sun, Y. Liu, X. Wang and Z. Wen, Chinese herbal formula Xuefu Zhuyu for primary dysmenorrhea patients (CheruPDYS): a study protocol for a randomized placebo-controlled trial, *Trials*, 2021, **22**, 95.
321. M. N. Tran, H. J. Jun and S. Lee, Identifying the molecular mechanism of blood stasis syndrome through the symptom phenotype-genotype association approach, *Medicine (Baltimore)*, 2024, **103**, e40717.
322. X. L. Li, Y. Jin, R. Gao, Q. X. Zhou, F. Huang and L. Liu, Wenjing decoction: Mechanism in the treatment of dysmenorrhea with blood stasis syndrome through network pharmacology and experimental verification, *J Ethnopharmacol*, 2025, **337**, 118818.

323. R. Chen, J. Moriya, J. Yamakawa, T. Takahashi and T. Kanda, Traditional chinese medicine for chronic fatigue syndrome, *Evid Based Complement Alternat Med*, 2010, **7**, 3-10.
324. Q. Shi, H. Zhao, J. Chen, Y. Li, Z. Li, J. Wang and W. Wang, Study on qi deficiency syndrome identification modes of coronary heart disease based on metabolomic biomarkers, *Evid Based Complement Alternat Med*, 2014, **2014**, 281829.
325. L. Luo, J. Chen, S. Guo, J. Wang, K. Gao, P. Zhang, C. Chen, H. Zhao and W. Wang, Chinese Herbal Medicine in the Treatment of Chronic Heart Failure: Three-Stage Study Protocol for a Randomized Controlled Trial, *Evid Based Complement Alternat Med*, 2015, **2015**, 927160.
326. K. Gao, H. Zhao, J. Gao, B. Wen, C. Jia, Z. Wang, F. Zhang, J. Wang, H. Xie, J. Wang, W. Wang and J. Chen, Mechanism of Chinese Medicine Herbs Effects on Chronic Heart Failure Based on Metabolic Profiling, *Front Pharmacol*, 2017, **8**, 864.
327. Y. Lin, Y. Han and Y. Wang, Traditional Chinese medicine for cardiovascular disease: efficacy and safety, *Front Cardiovasc Med*, 2024, **11**, 1419169.
328. B. K. Kang, S. Jang, M. M. Ko and J. Jung, A Study on the Development of a Korean Metabolic Syndrome Questionnaire Using Blood Stasis Clinical Data, *Evid Based Complement Alternat Med*, 2019, **2019**, 8761417.
329. M. M. Ko, S. Jang and J. Jung, An observational study on diagnosis index of metabolic disease with blood-stasis, *Medicine (Baltimore)*, 2020, **99**, e21140.
330. J. C. Bae, No More NAFLD: The Term Is Now MASLD, *Endocrinol Metab (Seoul)*, 2024, **39**, 92-94.
331. J. Liu, B. Dong, L. Yang, W. Huang and S. Tang, Xuefu Zhuyu decoction for nonalcoholic fatty liver disease: A protocol for systematic review and meta-analysis, *Medicine (Baltimore)*, 2021, **100**, e25358.
332. S. Zheng, C. Xue, S. Li, X. Zao, X. Li, Q. Liu, X. Cao, W. Wang, W. Qi, P. Zhang and Y. Ye, Chinese medicine in the treatment of non-alcoholic fatty liver disease based on network pharmacology: a review, *Front Pharmacol*, 2024, **15**, 1381712.
333. M. T. El Hussein and A. Hewko, Management of Postural Orthostatic Tachycardia Syndrome: A Canadian Approach, *J Nurs Pract*, 2025, **21**, 105258.
334. D. B. Kell, M. A. Khan, B. Kane, G. Y. H. Lip and E. Pretorius, Possible Role of Fibrinoid Microclots in Postural Orthostatic Tachycardia Syndrome (POTS): Focus on Long COVID, *J Pers Med*, 2024, **14**, 170.
335. K. J. Wirth and M. Löhn, Orthostatic Intolerance after COVID-19 Infection: Is Disturbed Microcirculation of the Vasa Vasorum of Capacitance Vessels the Primary Defect?, *Medicina (Kaunas)*, 2022, **58**, 1807.
336. X. Wang, W. Wei, Y. Qi, L. Dong and Y. Zhang, Clinical Effects of Integrated Traditional Chinese and Western Medicine in Treating Severe Preeclampsia and Its Influence on Maternal and Infant Outcomes after Cesarean Section under Combined Lumbar and Epidural Anesthesia, *Evid Based Complement Alternat Med*, 2021, **2021**, 6366914.
337. H. Dong, J. Song, Y. Jia, H. Cui and X. Chen, Research on the Improvement of Endothelial Cell Function and Trophoblast Apoptosis in Rats with Preeclampsia by Tanshinone IIA, *Pharmacognosy Mag*, 2025, **21**, 116-123.
338. X. Zhang, J. Li, P. Zhou, Q. Luo, Z. Xiang and H. Wu, Effect of *Salvia Miltiorrhiza* Injection on Blood Pressure and Cardiac Function in Rats with Gestational Hypertension and Preeclampsia, *J Biosci Med*, 2023, **11**, 152-160.
339. Y. Chen, Y. Liu, M. Liang, Y. Wang, H. Zhang, L. Huang and J. Ye, Effects of magnesium sulfate combined with compound Danshen injection on pregnancy outcome, vascular endothelia function, liver and kidney function in patients with EOSPE, *Int J Clin Med*, 2020, **13**, 3703-3709.
340. D. B. Kell and L. C. Kenny, A dormant microbial component in the development of pre-eclampsia., *Front Med Obs Gynecol*, 2016, **3**, 60.
341. L. C. Kenny and D. B. Kell, Immunological tolerance, pregnancy and pre-eclampsia: the roles of semen microbes and the father, *Front Med Obs Gynecol*, 2018, **4**, 239.
342. L. Han, X. Liu, H. Li, J. Zou, Z. Yang, J. Han, W. Huang, L. Yu, Y. Zheng and L. Li, Blood coagulation parameters and platelet indices: changes in normal and preeclamptic pregnancies and predictive values for preeclampsia, *PLoS One*, 2014, **9**, e114488.
343. C. R. Glazier and F. A. Baciewicz, Jr., Epidemiology, Etiology, and Pathophysiology of Pulmonary Embolism, *Int J Angiol*, 2024, **33**, 76-81.

344. W. Li, R. Wang, W. Huang, Y. Shen, J. Du and Y. Tian, BuyangHuanwu Decoction attenuates cerebral vasospasm caused by subarachnoid hemorrhage in rats via PI3K/AKT/eNOS axis, *Open Life Sci*, 2022, **17**, 735-743.
345. J. Zhou, P. Guo, Z. Guo, X. Sun, Y. Chen and H. Feng, Fluid metabolic pathways after subarachnoid hemorrhage, *J Neurochem*, 2022, **160**, 13-33.
346. C. J. McMahon, S. Hopkins, A. Vail, A. T. King, D. Smith, K. J. Illingworth, S. Clark, N. J. Rothwell and P. J. Tyrrell, Inflammation as a predictor for delayed cerebral ischemia after aneurysmal subarachnoid haemorrhage, *J Neurointerv Surg*, 2013, **5**, 512-517.
347. X. Tang, X. Liu, M. S. M. H. Zhao and Y. Zhang, Traditional Chinese medicine in the treatment of high incidence diseases in cold areas: the thrombotic diseases, *Frigid Zone Med*, 2021, 23-44.
348. Q. Yin, X. Zhang, S. Liao, X. Huang, C. C. Wan and Y. Wang, Potential anticoagulant of traditional chinese medicine and novel targets for anticoagulant drugs, *Phytomedicine*, 2023, **116**, 154880.
349. H. Yu, X. Chai, W. C. Geng, L. Zhang, F. Ding, D. S. Guo and Y. Wang, Facile and label-free fluorescence strategy for evaluating the influence of bioactive ingredients on FMO3 activity via supramolecular host-guest reporter pair, *Biosens Bioelectron*, 2021, **192**, 113488.
350. R. N. Sha, L. Tang, Y. W. Du, S. X. Wu, H. W. Shi, H. X. Zou, X. R. Zhang, X. L. Dong and L. Zhou, Effectiveness and safety of Ginkgo biloba extract (GBE50) in the treatment of dizziness caused by cerebral arteriosclerosis: a multi-center, double-blind, randomized controlled trial, *J Tradit Chin Med*, 2022, **42**, 83-89.
351. S. H. Ahmed, S. Waseem, T. G. Shaikh, N. A. Qadir, S. A. Siddiqui, I. Ullah, A. Waris and Z. Yousaf, SARS-CoV-2 vaccine-associated-tinnitus: A review, *Ann Med Surg (Lond)*, 2022, **75**, 103293.
352. R. R. Figueiredo, N. de O. Penido, A. A. de Azevedo, P. M. de Oliveira, A. G. de Siqueira, G. M. R. Figueiredo, W. Schlee and B. Langguth, Tinnitus emerging in the context of a COVID-19 infection seems not to differ in its characteristics from tinnitus unrelated to COVID-19, *Front Neurol*, 2022, **13**, 974179.
353. W. Wang, A. Yellamsetty, R. M. Edmonds, S. R. Barcavage and S. Bao, COVID-19 vaccination-related tinnitus is associated with pre-vaccination metabolic disorders, *Front Pharmacol*, 2024, **15**, 1374320.
354. Q. Yao, L. Zhang, J. Zhou, M. Li, W. Jing, X. Li, J. Han, L. He and Y. Zhang, Imaging Diagnosis of Transient Ischemic Attack in Clinic and Traditional Chinese Medicine, *Biomed Res Int*, 2019, **2019**, 5094842.
355. Y. Kang, Z. Yang, K. Zhou and Y. Zhou, Treating transient ischemic attack from the evil of Phlegm and blood stasis based on abnormal lipid metabolism, *Acad J Med Health Sci*, 2023, **4**, 51-55.
356. D. O. Kleindorfer, A. Towfighi, S. Chaturvedi, K. M. Cockroft, J. Gutierrez, D. Lombardi-Hill, H. Kamel, W. N. Kernan, S. J. Kittner, E. C. Leira, O. Lennon, J. F. Meschia, T. N. Nguyen, P. M. Pollak, P. Santangeli, A. Z. Sharrief, S. C. Smith, Jr., T. N. Turan and L. S. Williams, 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association, *Stroke*, 2021, **52**, e364-e467.
357. X. Jin, G. Shen, F. Gao, X. Zheng, X. Xu, F. Shen, G. Li, J. Gong, L. Wen, X. Yang and X. Bie, Traditional Chinese drug ShuXueTong facilitates angiogenesis during wound healing following traumatic brain injury, *J Ethnopharmacol*, 2008, **117**, 473-477.
358. Z. K. Liu, C. F. Ng, H. T. Shiu, H. L. Wong, W. C. Chin, J. F. Zhang, P. K. Lam, W. S. Poon, C. B. Lau, P. C. Leung and C. H. Ko, Neuroprotective effect of Da Chuanxiong Formula against cognitive and motor deficits in a rat controlled cortical impact model of traumatic brain injury, *J Ethnopharmacol*, 2018, **217**, 11-22.
359. C. Y. Kwon, B. Lee, J. Leem, S. Y. Chung and J. W. Kim, Korean medicine treatments including blood stasis-removing therapy and auriculotherapy for persistent headache after traumatic brain injury: A case report, *Explore (NY)*, 2019, **15**, 419-424.
360. B. Lee, J. Leem, H. Kim, H. G. Jo, S. H. Yoon, A. Shin, J. U. Sul, Y. Y. Choi, Y. Yun and C. Y. Kwon, Herbal medicine for acute management and rehabilitation of traumatic brain injury: A protocol for a systematic review, *Medicine (Baltimore)*, 2019, **98**, e14145.
361. T. Li, E. Hu, P. Li, Z. Yang, Y. Wu, R. Ding, X. Zhu, T. Tang and Y. Wang, Metabolomics Deciphers Potential Targets of Xuefu Zhuyu Decoction Against Traumatic Brain Injury in Rat, *Front Pharmacol*, 2020, **11**, 559618.

362. Z. Y. Yang, T. Tang, P. F. Li, X. X. Li, Y. Wu, D. D. Feng, M. R. Hu, F. Dai, F. Zheng, W. Zhang and Y. Wang, Systematic analysis of tRNA-derived small RNAs reveals therapeutic targets of Xuefu Zhuyu decoction in the cortexes of experimental traumatic brain injury, *Phytomedicine*, 2022, **102**, 154168.
363. C. Wei, J. Wang, J. Yu, Q. Tang, X. Liu, Y. Zhang, D. Cui, Y. Zhu, Y. Mei, Y. Wang and W. Wang, Therapy of traumatic brain injury by modern agents and traditional Chinese medicine, *Chin Med*, 2023, **18**, 25.
364. M. Maegele, H. Schöchl, T. Menovsky, H. Maréchal, N. Marklund, A. Buki and S. Stanworth, Coagulopathy and haemorrhagic progression in traumatic brain injury: advances in mechanisms, diagnosis, and management, *Lancet Neurol*, 2017, **16**, 630-647.
365. J. Jung, M. M. Ko, J. A. Lee and M. S. Lee, Recognition of Association Between Blood Stasis Syndrome and Traumatic Injury among Doctors of Korean Medicine: A Cross-Sectional Observation Study, *Chin J Integr Med*, 2018, **24**, 254-259.
366. S. Law and J. D. Gillmore, When to Suspect and How to Approach a Diagnosis of Amyloidosis, *Am J Med*, 2022, **135 Suppl 1**, S2-S8.
367. E. Mughtar, A. Dispenzieri, H. Magen, M. Grogan, M. Mauermann, E. D. McPhail, P. J. Kurtin, N. Leung, F. K. Buadi, D. Dingli, S. K. Kumar and M. A. Gertz, Systemic amyloidosis from A (AA) to T (ATTR): a review, *J Intern Med*, 2021, **289**, 268-292.
368. J. Jung, M. H. Cha, H. Lee, M. M. Ko, J. A. Lee, S. Lee and M. S. Lee, The association of C-reactive protein and serum amyloid P with blood stasis syndrome in Traditional Korean Medicine for general disease conditions: A cross-sectional, observational study, *Eur J Integr Med*, 2016, **8**, 432-437.
369. S. Noble and J. Pasi, Epidemiology and pathophysiology of cancer-associated thrombosis, *Br J Cancer*, 2010, **102 Suppl 1**, S2-9.
370. O. Leiva, R. Newcomb, J. M. Connors and H. Al-Samkari, Cancer and thrombosis: new insights to an old problem, *J Med Vasc*, 2020, **45**, 6S8-6S16.
371. O. Leiva, D. AbdelHameid, J. M. Connors, C. P. Cannon and D. L. Bhatt, Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis: JACC: CardioOncology State-of-the-Art Review, *JACC CardioOncol*, 2021, **3**, 619-634.
372. A. A. Khorana and R. L. Fine, Pancreatic cancer and thromboembolic disease, *Lancet Oncol*, 2004, **5**, 655-663.
373. A. S. Epstein, G. A. Soff, M. Capanu, C. Crosbie, M. A. Shah, D. P. Kelsen, B. Denton, S. Gardos and E. M. O'Reilly, Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer, *Cancer*, 2012, **118**, 3053-3061.
374. J. F. Timp, S. K. Braekkan, H. H. Versteeg and S. C. Cannegieter, Epidemiology of cancer-associated venous thrombosis, *Blood*, 2013, **122**, 1712-1723.
375. D. Ansari, D. Ansari, R. Andersson and A. Andren-Sandberg, Pancreatic cancer and thromboembolic disease, 150 years after Trousseau, *Hepatobiliary Surg Nutr*, 2015, **4**, 325-335.
376. M. Ouaiissi, C. Frascioni, D. Mege, L. Panicot-Dubois, L. Boiron, L. Dahan, P. Debourdeau, C. Dubois, D. Farge and I. Sielezneff, Impact of venous thromboembolism on the natural history of pancreatic adenocarcinoma, *Hepatobiliary Pancreat Dis Int*, 2015, **14**, 436-442.
377. A. K. Berger, H. M. Singh, W. Werft, A. Muckenhuber, M. R. Sprick, A. Trumpp, W. Weichert, D. Jager and C. Springfield, High prevalence of incidental and symptomatic venous thromboembolic events in patients with advanced pancreatic cancer under palliative chemotherapy: A retrospective cohort study, *Pancreatology*, 2017, **17**, 629-634.
378. K. Ishigaki, Y. Nakai, H. Isayama, K. Saito, T. Hamada, N. Takahara, S. Mizuno, D. Mohri, H. Kogure, S. Matsubara, N. Yamamoto, M. Tada and K. Koike, Thromboembolisms in Advanced Pancreatic Cancer: A Retrospective Analysis of 475 Patients, *Pancreas*, 2017, **46**, 1069-1075.
379. D. Mege, L. Crescence, M. Ouaiissi, I. Sielezneff, R. Guieu, F. Dignat-George, C. Dubois and L. Panicot-Dubois, Fibrin-bearing microparticles: marker of thrombo-embolic events in pancreatic and colorectal cancers, *Oncotarget*, 2017, **8**, 97394-97406.
380. F. T. M. Bosch, F. I. Mulder, P. W. Kamphuisen, S. Middeldorp, P. M. Bossuyt, H. R. Buller and N. van Es, Primary thromboprophylaxis in ambulatory cancer patients with a high Khorana score: a systematic review and meta-analysis, *Blood Adv*, 2020, **4**, 5215-5225.

381. H. E. Fuentes, D. M. Oramas, L. H. Paz, Y. Wang, X. A. Andrade and A. J. Tafur, Venous Thromboembolism Is an Independent Predictor of Mortality Among Patients with Gastric Cancer, *J Gastrointest Cancer*, 2018, **49**, 415-421.
382. L. A. Diaz Quintero, H. E. Fuentes, A. J. Tafur, K. Majmudar, J. P. Salazar Adum, I. Golemi, L. H. Paz, S. Stocker and M. Talamonti, Pancreatic cancer thromboembolic outcomes: rate of thrombosis after adenocarcinoma and non-adenocarcinoma pancreatic cancer surgery, *Int Angiol*, 2019, **38**, 194-200.
383. J. Godinho, M. Casa-Nova, J. Moreira-Pinto, P. Simoes, F. Paralta Branco, L. Leal-Costa, A. Faria, F. Lopes, J. A. Teixeira and J. L. Passos-Coelho, ONKOTEV Score as a Predictive Tool for Thromboembolic Events in Pancreatic Cancer-A Retrospective Analysis, *Oncologist*, 2020, **25**, e284-e290.
384. R. G. Hanna-Sawires, J. V. Groen, A. Hamming, R. A. E. M. Tollenaar, W. E. Mesker, S. A. C. Luelmo, A. L. Vahrmeijer, B. A. Bonsing, H. H. Versteeg, F. A. Klok and J. S. D. Mieog, Incidence, timing and risk factors of venous thromboembolic events in patients with pancreatic cancer, *Thromb Res*, 2021, **207**, 134-139.
385. J. Heffley, E. Ganguly, B. J. Tompkins, S. Ades, C. E. Holmes and R. Zubarik, Venous thromboembolism in patients with pancreatic adenocarcinoma: Disease burden and initiation of ambulatory thromboprophylaxis, *Pancreatology*, 2024, **24**, 894-898.
386. A. Falanga, F. Schieppati and D. Russo, Cancer Tissue Procoagulant Mechanisms and the Hypercoagulable State of Patients with Cancer, *Semin Thromb Hemost*, 2015, **41**, 756-764.
387. J. E. Bower, Cancer-related fatigue--mechanisms, risk factors, and treatments, *Nat Rev Clin Oncol*, 2014, **11**, 597-609.
388. Z. Butt, S. K. Rosenbloom, A. P. Abernethy, J. L. Beaumont, D. Paul, D. Hampton, P. B. Jacobsen, K. L. Syrjala, J. H. Von Roenn and D. Cella, Fatigue is the most important symptom for advanced cancer patients who have had chemotherapy, *J Natl Compr Canc Netw*, 2008, **6**, 448-455.
389. V. Narayanan and C. Koshy, Fatigue in cancer: a review of literature, *Indian J Palliat Care*, 2009, **15**, 19-25.
390. Y. Song, X. Sun, L. Shen, Z. Qu, J. Yin, Z. Wang and H. Zhang, Genes of cancer-related fatigue: a scoping review, *Front Oncol*, 2024, **14**, 1446321.
391. M. S. Y. Thong, C. J. F. van Noorden, K. Steindorf and V. Arndt, Cancer-Related Fatigue: Causes and Current Treatment Options, *Curr Treat Options Oncol*, 2020, **21**, 17.
392. S. Yang, S. Chu, Y. Gao, Q. Ai, Y. Liu, X. Li and N. Chen, A Narrative Review of Cancer-Related Fatigue (CRF) and Its Possible Pathogenesis, *Cells*, 2019, **8**.
393. J. Yang, Y. Li, C. I. Chau, J. Shi, X. Chen, H. Hu and C. O. L. Ung, Efficacy and safety of traditional Chinese medicine for cancer-related fatigue: a systematic literature review of randomized controlled trials, *Chin Med*, 2023, **18**, 142.
394. J. Zeng, Q. Wu, X. D. Meng and J. Wang, Systematic review of Buzhong Yiqi method in alleviating cancer-related fatigue: a meta-analysis and exploratory network pharmacology approach, *Front Pharmacol*, 2024, **15**, 1451773.
395. F. Liang, J. Sun, Q. Li, C. H. Li and Z.-z. Fan, Analysis of clinical syndromes in 47 patients with pancreatic cancer at late stage, *J Tradit Chin Med*, 2011, **31**, 182-184.
396. Z. Liu, Z. Yu, X. Ouyang, J. Du, X. Lan and M. Zhao, Applied research on serum protein fingerprints for prediction of Qi deficiency syndrome and phlegm and blood stasis in patients with non-small cell lung cancer, *J Tradit Chin Med*, 2012, **32**, 350-354.
397. Z. Guo, Y. Lou, M. Kong, Q. Luo, Z. Liu and J. Wu, A Systematic Review of Phytochemistry, Pharmacology and Pharmacokinetics on Astragali Radix: Implications for Astragali Radix as a Personalized Medicine, *Int J Mol Sci*, 2019, **20**, 1463.
398. Y. X. Huang, D. Q. Xu, S. J. Yue, Y. Y. Chen, H. J. Tao, R. J. Fu, L. M. Xing, T. Wang, Y. L. Ma, B. A. Wang, Y. P. Tang and J. A. Duan, Deciphering the Active Compounds and Mechanisms of Qixuehe Capsule on Qi Stagnation and Blood Stasis Syndrome: A Network Pharmacology Study, *Evid Based Complement Alternat Med*, 2020, **2020**, 5053914.
399. B. S. Kim, S. Jin, J. Y. Park and S. Y. Kim, Scoping review of the medicinal effects of *Eupolyphaga sinensis* Walker and the underlying mechanisms, *J Ethnopharmacol*, 2022, **296**, 115454.
400. F. Zhang, K. Ganesan, Q. Liu and J. Chen, A Review of the Pharmacological Potential of *Spatholobus suberectus* Dunn on Cancer, *Cells*, 2022, **11**, 2885.

401. Y. Zhang, H. Xu, Y. Li, Y. Sun and X. Peng, Advances in the treatment of pancreatic cancer with traditional Chinese medicine, *Front Pharmacol*, 2023, **14**, 1089245.
402. L. Jin, B. Tang, X. Liu, W. Mao, L. Xia, Y. Du, B. Ji, Q. Shou and H. Fu, Blood Stasis Syndrome Accelerates the Growth and Metastasis of Breast Cancer by Promoting Hypoxia and Immunosuppressive Microenvironment in Mice, *J Immunol Res*, 2022, **2022**, 7222638.
403. D. B. Kell and E. Pretorius, The proteome content of blood clots observed under different conditions: successful role in predicting clot amyloid(ogenicity), *bioRxiv*, 2024, 2024.2011.2029.626062.
404. A. Aguzzi and A. K. K. Lakkaraju, Cell Biology of Prions and Prionoids: A Status Report, *Trends Cell Biol*, 2016, **26**, 40-51.
405. K. H. Ashe and A. Aguzzi, Prions, prionoids and pathogenic proteins in Alzheimer disease, *Prion*, 2013, **7**, 55-59.
406. I. Hafner Bratkovič, Prions, prionoid complexes and amyloids: the bad, the good and something in between, *Swiss Med Wkly*, 2017, **147**, w14424.
407. P. P. Liberski, Prion, prionoids and infectious amyloid, *Parkinsonism Relat Disord*, 2014, **20 Suppl 1**, S80-84.
408. C. Scheckel and A. Aguzzi, Prions, prionoids and protein misfolding disorders, *Nat Rev Genet*, 2018, **19**, 405-418.
409. A. Verma, Prions, prion-like prionoids, and neurodegenerative disorders, *Ann Indian Acad Neurol*, 2016, **19**, 169-174.
410. C. Wells, S. E. Brennan, M. Keon and N. K. Saksena, Prionoid Proteins in the Pathogenesis of Neurodegenerative Diseases, *Front Mol Neurosci*, 2019, **12**, 271.
411. D. B. Kell, Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases, *BMC Med Genom*, 2009, **2**, 2
412. M. Yi, Q. Li, Y. Zhao, S. Nie, N. Wu and D. Wang, Metabolomics study on the therapeutic effect of traditional Chinese medicine Xue-Fu-Zhu-Yu decoction in coronary heart disease based on LC-Q-TOF/MS and GC-MS analysis, *Drug Metab Pharmacokinet*, 2019, **34**, 340-349.
413. Y. Zhao, S. Nie, M. Yi, N. Wu, W. Wang, Z. Zhang, Y. Yao and D. Wang, UPLC-QTOF/MS-based metabolomics analysis of plasma reveals an effect of Xue-Fu-Zhu-Yu capsules on blood-stasis syndrome in CHD rats, *J Ethnopharmacol*, 2019, **241**, 111908.
414. H. He, G. Chen, J. Gao, Y. Liu, C. Zhang, C. Liu, H. Li, Q. He, J. Li and J. Wang, Xue-Fu-Zhu-Yu capsule in the treatment of qi stagnation and blood stasis syndrome: a study protocol for a randomised controlled pilot and feasibility trial, *Trials*, 2018, **19**, 515.
415. S. Chen, X. Wu, T. Li, W. Cheng, X. Han, Y. Li, B. Wang, Y. Teng, M. Zhao and Y. Wang, The Improvement of Cardiac and Endothelial Functions of Xue-Fu-Zhu-Yu Decoction for Patients with Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials, *Evid Based Complement Alternat Med*, 2022, **2022**, 2671343.
416. D. J. Xue, Z. Zhen, K. X. Wang, J. L. Zhao, Y. Gao, Y. P. Chen, Y. B. Shen, Z. Z. Peng, D. G. Guan and T. Huang, Uncovering the potential mechanism of Xue Fu Zhu Yu Decoction in the treatment of intracerebral hemorrhage, *BMC Complement Med Ther*, 2022, **22**, 103.
417. C. E. Kuo, S. F. Hsu, C. C. Chen, S. Y. Wu, Y. C. Hung, C. Y. Hsu, I. J. Tsai and W. L. Hu, Prescription characteristics of Xue-Fu-Zhu-Yu-Tang in pain management: a population-based study using the National Health Insurance Research Database in Taiwan, *Front Pharmacol*, 2023, **14**, 1233156.
418. D. Wang, P. Wang, R. Zhang and X. Xi, Efficacy and safety of Xuefu Zhuyu decoction combined with Western medicine for angina pectoris in coronary heart disease: A protocol for systematic review and meta-analysis, *Medicine (Baltimore)*, 2020, **99**, e23195.
419. S. Liao, Z. Zhang, G. Li, L. Zhou, J. Jiang, N. Zhang, Y. Wang, Y. Du and Z. Wen, Chinese Herbal Formula Xuefu Zhuyu for Stable Angina (CheruSA): Study Protocol for a Multicenter Randomized Controlled Trial, *Evid Based Complement Alternat Med*, 2020, **2020**, 7612721.
420. Q. Huang, X. Qiao and X. Xu, Potential synergism and inhibitors to multiple target enzymes of Xuefu Zhuyu Decoction in cardiac disease therapeutics: a computational approach, *Bioorg Med Chem Lett*, 2007, **17**, 1779-1783.

421. G. Zhang, G. Yang, Y. Deng, X. Zhao, Y. Yang, J. Rao, W. Wang, X. Liu, J. He and L. Lv, Ameliorative effects of Xue-Fu-Zhu-Yu decoction, Tian-Ma-Gou-Teng-Yin and Wen-Dan decoction on myocardial fibrosis in a hypertensive rat mode, *BMC Complement Altern Med*, 2016, **16**, 56.
422. G. Chen, H. He, K. Hu, J. Gao, J. Li, M. Han and J. Wang, Sensitive Biomarker Analysis of Xue-Fu-Zhu-Yu Capsule for Patients with Qi Stagnation and Blood Stasis Pattern: A Nested Case-Control Study, *Evid Based Complement Alternat Med*, 2019, **2019**, 7182865.
423. L. Zhao, X. Qiu, R. Wang and D. Wang, (1)H NMR-based metabolomics study of the dynamic effect of Xue-Fu-Zhu-Yu capsules on coronary heart disease rats induced by high-fat diet, coronary artery ligation, *J Pharm Biomed Anal*, 2021, **195**, 113869.
424. G. Z. Yi, Y. Q. Qiu, Y. Xiao and L. X. Yuan, The usefulness of xuefu zhuyu tang for patients with angina pectoris: a meta-analysis and systematic review, *Evid Based Complement Alternat Med*, 2014, **2014**, 521602.
425. X. Yang, X. Xiong, G. Yang and J. Wang, Chinese patent medicine Xuefu Zhuyu capsule for the treatment of unstable angina pectoris: A systematic review of randomized controlled trials, *Complement Ther Med*, 2014, **22**, 391-399.
426. T. Yang, X. Li, Z. Lu, X. Han and M. Zhao, Effectiveness and safety of Xuefu Zhuyu decoction for treating coronary heart disease angina: A systematic review and meta-analysis, *Medicine (Baltimore)*, 2019, **98**, e14708.
427. G. Qi, K. Jiang, J. Qu, A. Zhang, Z. Xu, Z. Li, X. Zheng and Z. Li, The Material Basis and Mechanism of Xuefu Zhuyu Decoction in Treating Stable Angina Pectoris and Unstable Angina Pectoris, *Evid Based Complement Alternat Med*, 2022, **2022**, 3741027.
428. Y. Li, B. Liu, L. Liu, Q. Xu, Q. Shen, W. Li and J. Zhao, Potential active compounds and molecular mechanism of Xuefu Zhuyu decoction for atherosclerosis, based on network pharmacology and molecular docking, *Medicine (Baltimore)*, 2022, **101**, e29654.
429. D. Liu, Y. Zeng, P. Liang, Y. Jiang, S. An and P. Ren, Efficacy and safety of Xuefu Zhuyu Granules combined with western medicine in the treatment of angina pectoris of coronary heart disease: A study protocol of a randomized, double-blind, placebo-controlled clinical trial, *Medicine (Baltimore)*, 2022, **101**, e31235.
430. J. Yuan, F. Yan, W. Li and G. Yuan, Network pharmacological analysis of Xuefu Zhuyu decoction in the treatment of atherosclerosis, *Front Pharmacol*, 2022, **13**, 1069704.
431. T. Yi, P. Gao, M. Hou, H. Lv, M. Huang, S. Gao, J. He, D. Yang, W. Chen, T. Zhu, C. Yu, F. Liu, H. Yin and S. Jin, The mechanisms underlying the actions of Xuefu Zhuyu decoction pretreatment against neurological deficits after ischemic stroke in mice: The mediation of glymphatic function by aquaporin-4 and its anchoring proteins, *Front Pharmacol*, 2022, **13**, 1053253.
432. J. Duan, J. Lin, N. Zhang, Q. Wang, N. Li and K. Yao, Effect of Xuefu Zhuyu Capsule on Myocardial Infarction: Network Pharmacology and Experimental Verification, *Evid Based Complement Alternat Med*, 2023, **2023**, 5652276.
433. Y. Yang, C. Su, X. Z. Zhang, J. Li, S. C. Huang, H. F. Kuang and Q. Y. Zhang, Mechanisms of Xuefu Zhuyu Decoction in the treatment of coronary heart disease based on integrated metabolomics and network pharmacology approach, *J Chromatogr B Analyt Technol Biomed Life Sci*, 2023, **1223**, 123712.
434. D. Jia, M. Zhao, X. Zhang, X. Cheng, Q. Wei, L. Lou, Y. Zhao, Q. Jin, M. Chen and D. Zhang, Transcriptomic analysis reveals the critical role of chemokine signaling in the anti-atherosclerosis effect of Xuefu Zhuyu decoction, *J Ethnopharmacol*, 2024, **332**, 118245.
435. I. L. Hung, C. J. Chung, W. L. Hu, Y. N. Liao, C. Y. Hsu, J. H. Chiang and Y. C. Hung, Chinese Herbal Medicine as an Adjunctive Therapy Improves the Survival Rate of Patients with Ischemic Heart Disease: A Nationwide Population-Based Cohort Study, *Evid Based Complement Alternat Med*, 2022, **2022**, 5596829.
436. Z. Xing, Z. Xia, W. Peng, J. Li, C. Zhang, C. Fu, T. Tang, J. Luo, Y. Zou, R. Fan, W. Liu, X. Xiong, W. Huang, C. Sheng, P. Gan and Y. Wang, Xuefu Zhuyu decoction, a traditional Chinese medicine, provides neuroprotection in a rat model of traumatic brain injury via an anti-inflammatory pathway, *Sci Rep*, 2016, **6**, 20040.
437. J. Zhou, T. Liu, H. Cui, R. Fan, C. Zhang, W. Peng, A. Yang, L. Zhu, Y. Wang and T. Tang, Xuefu zhuyu decoction improves cognitive impairment in experimental traumatic brain injury via synaptic regulation, *Oncotarget*, 2017, **8**, 72069-72081.

438. D. Feng, Z. Xia, J. Zhou, H. Lu, C. Zhang, R. Fan, X. Xiong, H. Cui, P. Gan, W. Huang, W. Peng, F. He, Z. Wang, Y. Wang and T. Tang, Metabolomics reveals the effect of Xuefu Zhuyu Decoction on plasma metabolism in rats with acute traumatic brain injury, *Oncotarget*, 2017, **8**, 94692-94710.
439. L. Zhu, T. Tang, R. Fan, J. K. Luo, H. J. Cui, C. H. Zhang, W. J. Peng, P. Sun, X. G. Xiong and Y. Wang, Xuefu Zhuyu decoction improves neurological dysfunction by increasing synapsin expression after traumatic brain injury, *Neural Regen Res*, 2018, **13**, 1417-1424.
440. Z. Y. Yang, Y. Wu, X. Li, T. Tang, Y. Wang, Z. B. Huang and R. Fan, Bioinformatics Analysis of miRNAs and mRNAs Network-Xuefu Zhuyu Decoction Exerts Neuroprotection of Traumatic Brain Injury Mice in the Subacute Phase, *Front Pharmacol*, 2022, **13**, 772680.
441. F. Dai, T. Tang, R. Lu, P. Li, D. Feng, M. Hu, Y. Wang and P. Gan, Systematic Analysis of tRNA-Derived Small RNAs Reveals the Effects of Xuefu-Zhuyu Decoction on the Hippocampi of Rats after Traumatic Brain Injury, *Evid Based Complement Alternat Med*, 2022, **2022**, 5748719.
442. E. Hu, T. Tang, Y. M. Li, T. Li, L. Zhu, R. Q. Ding, Y. Wu, Q. Huang, W. Zhang, Q. Wu and Y. Wang, Spatial amine metabolomics and histopathology reveal localized brain alterations in subacute traumatic brain injury and the underlying mechanism of herbal treatment, *CNS Neurosci Ther*, 2024, **30**, e14231.
443. D. Feng, P. Li, W. Xiao, Z. Pei, P. Chen, M. Hu, Z. Yang, T. Li, Z. Xia, H. Cui, H. Li, Q. Huang, W. Zhang, T. Tang and Y. Wang, N(6)-methyladenosine profiling reveals that Xuefu Zhuyu decoction upregulates METTL14 and BDNF in a rat model of traumatic brain injury, *J Ethnopharmacol*, 2023, **317**, 116823.
444. Y. Wang, Q. J. Yan, E. Hu, Y. Wu, R. Q. Ding, Q. Chen, M. H. Cheng, X. Y. Yang, T. Tang and T. Li, Xuefu Zhuyu Decoction Improves Blood-Brain Barrier Integrity in Acute Traumatic Brain Injury Rats via Regulating Adenosine, *Chin J Integr Med*, 2025.
445. T. Li, L. Zhang, M. Cheng, E. Hu, Q. Yan, Y. Wu, W. Luo, H. Su, Z. Yu, X. Guo, Q. Chen, F. Zheng, H. Li, W. Zhang, T. Tang, J. Luo and Y. Wang, Metabolomics integrated with network pharmacology of blood-entry constituents reveals the bioactive component of Xuefu Zhuyu decoction and its angiogenic effects in treating traumatic brain injury, *Chin Med*, 2024, **19**, 131.
446. Z. Pei, X. Guo, F. Zheng, Z. Yang, T. Li, Z. Yu, X. Li, X. Guo, Q. Chen, C. Fu, T. Tang, D. Feng and Y. Wang, Xuefu Zhuyu decoction promotes synaptic plasticity by targeting miR-191a-5p/BDNF-TrkB axis in severe traumatic brain injury, *Phytomedicine*, 2024, **129**, 155566.
447. C. Fu, Q. Wu, Z. Zhang, Z. Xia, H. Ji, H. Lu and Y. Wang, UPLC-ESI-IT-TOF-MS metabolomic study of the therapeutic effect of Xuefu Zhuyu decoction on rats with traumatic brain injury, *J Ethnopharmacol*, 2019, **245**, 112149.
448. H. Tang, J. Wang, Y. Fang, Y. Yin, W. Liu, Y. Hu and J. Peng, Hepatic transcriptome discloses the potential targets of Xuefu Zhuyu Decoction ameliorating non-alcoholic fatty liver disease induced by high-fat diet, *J Tradit Complement Med*, 2024, **14**, 135-147.
449. H. Zhang, H. Hua, J. Liu, C. Wang, C. Zhu, Q. Xia, W. Jiang, X. Cheng, X. Hu and Y. Zhang, Integrative analysis of the efficacy and pharmacological mechanism of Xuefu Zhuyu decoction in idiopathic pulmonary fibrosis via evidence-based medicine, bioinformatics, and experimental verification, *Heliyon*, 2024, **10**, e38122.
450. A. Xu, Z. H. Wen, S. X. Su, Y. P. Chen, W. C. Liu, S. Q. Guo, X. F. Li, X. Zhang, R. Li, N. B. Xu, K. X. Wang, W. X. Li, D. G. Guan and C. Z. Duan, Elucidating the Synergistic Effect of Multiple Chinese Herbal Prescriptions in the Treatment of Post-stroke Neurological Damage, *Front Pharmacol*, 2022, **13**, 784242.
451. B. Ning, X. Zhu, X. Wu, W. Zhu, R. Wang, C. Qi and M. Li, Efficacy of different traditional Chinese medicine decoctions in the treatment of ischemic stroke: a network meta-analysis, *Front Pharmacol*, 2024, **15**, 1486458.
452. P. Wang, X. Xiong and S. Li, Efficacy and Safety of a Traditional Chinese Herbal Formula Xuefu Zhuyu Decoction for Hypertension: A Systematic Review and Meta-Analysis, *Medicine (Baltimore)*, 2015, **94**, e1850.
453. S. Wang, C. Wu, Y. Li, B. Ye, S. Wang, G. Li, J. Wu, S. Liu, M. Zhang, Y. Jia, H. Cao, C. Jiang and F. Wu, Analysis of the Anti-Tumour Effect of Xuefu Zhuyu Decoction Based on Network Pharmacology and Experimental Verification in *Drosophila*, *Front Pharmacol*, 2022, **13**, 922457.
454. X. Wang, D. Y. Zhang, S. J. Yin, H. Jiang, M. Lu, F. Q. Yang and Y. J. Hu, Screening of Potential Thrombin and Factor Xa Inhibitors from the Danshen-Chuanxiong Herbal Pair through a Spectrum-Effect Relationship Analysis, *Molecules*, 2021, **26**, 7293.

455. H. Q. Pang, J. X. Guo, Y. Yang, L. Xu, J. Wang, F. Yang, Z. B. Xu, Y. F. Huang, W. Shi, X. Lu, M. E. H. Ibrahim, W. C. Hu, B. C. Yan and L. Liu, Elucidating the chemical interaction effects of herb pair Danshen-Chuanxiong and its anti-ischemic stroke activities evaluation, *J Ethnopharmacol*, 2024, **318**, 117058.
456. C. Zhao, X. Bai, Y. Ding, A. Wen and Q. Fu, Combining systems pharmacology, metabolomics, and transcriptomics to reveal the mechanism of *Salvia miltiorrhiza*-Cortex moutan herb pair for the treatment of ischemic stroke, *Front Pharmacol*, 2024, **15**, 1431692.
457. Y. Liu, H. J. Yin, D. Z. Shi and K. J. Chen, Chinese herb and formulas for promoting blood circulation and removing blood stasis and antiplatelet therapies, *Evid Based Complement Alternat Med*, 2012, **2012**, 184503.
458. J. Li, X. Zhou, C. Zheng, L. Lai and L. Li, Comparison of mechanisms and efficacies of five formulas for improving blood circulation and removing blood stasis., *Digital Chinese Med*, 2021, **4**, 144-158.
459. J. J. Lee, W. H. Hsu, T. L. Yen, N. C. Chang, Y. J. Luo, G. Hsiao and J. R. Sheu, Traditional Chinese medicine, Xue-Fu-Zhu-Yu decoction, potentiates tissue plasminogen activator against thromboembolic stroke in rats, *J Ethnopharmacol*, 2011, **134**, 824-830.
460. L. Zhang, L. Zhu, Y. Wang, Z. Jiang, X. Chai, Y. Zhu, X. Gao and A. Qi, Characterization and quantification of major constituents of Xue Fu Zhu Yu by UPLC-DAD-MS/MS, *J Pharm Biomed Anal*, 2012, **62**, 203-209.
461. C. Fu, Z. Xia, Y. Liu, H. Lu, Z. Zhang, Y. Wang and X. Fan, Qualitative analysis of major constituents from Xue Fu Zhu Yu Decoction using ultra high performance liquid chromatography with hybrid ion trap time-of-flight mass spectrometry, *J Sep Sci*, 2016, **39**, 3457-3468.
462. Y. Sun, R. Guo, Y. Geng, H. Shang, X. Guo, Y. Wu, Y. Wang, L. Li, X. Li, S. Zhang, N. Xu and X. Li, Longitudinal Distribution Map of the Active Components and Endophytic Fungi in *Angelica sinensis* (Oliv.) Diels Root and Their Potential Correlations, *Metabolites*, 2024, **14**, 48.
463. C. Yang, X. Li and J. Rong, Amygdalin isolated from *Semen Persicae* (Tao Ren) extracts induces the expression of follistatin in HepG2 and C2C12 cell lines, *Chin Med*, 2014, **9**, 23.
464. C. Yang, J. Zhao, Y. Cheng, X. Li and J. Rong, Bioactivity-guided fractionation identifies amygdalin as a potent neurotrophic agent from herbal medicine *Semen Persicae* extract, *Biomed Res Int*, 2014, **2014**, 306857.
465. X. Zhou, L. Tang, Y. Xu, G. Zhou and Z. Wang, Towards a better understanding of medicinal uses of *Carthamus tinctorius* L. in traditional Chinese medicine: a phytochemical and pharmacological review, *J Ethnopharmacol*, 2014, **151**, 27-43.
466. Y. Zhang, L. Song, R. Pan, J. Gao, B. X. Zang and M. Jin, Hydroxysafflor Yellow A Alleviates Lipopolysaccharide-Induced Acute Respiratory Distress Syndrome in Mice, *Biol Pharm Bull*, 2017, **40**, 135-144.
467. X. Bai, W. X. Wang, R. J. Fu, S. J. Yue, H. Gao, Y. Y. Chen and Y. P. Tang, Therapeutic Potential of Hydroxysafflor Yellow A on Cardio-Cerebrovascular Diseases, *Front Pharmacol*, 2020, **11**, 01265.
468. L. Yu, Z. Jin, M. Li, H. Liu, J. Tao, C. Xu, L. Wang and Q. Zhang, Protective potential of hydroxysafflor yellow A in cerebral ischemia and reperfusion injury: An overview of evidence from experimental studies, *Front Pharmacol*, 2022, **13**, 1063035.
469. X. Xue, Y. Deng, J. Wang, M. Zhou, L. Liao, C. Wang, C. Peng and Y. Li, Hydroxysafflor yellow A, a natural compound from *Carthamus tinctorius* L with good effect of alleviating atherosclerosis, *Phytomedicine*, 2021, **91**, 153694.
470. X. Zhang, D. Shen, Y. Feng, Y. Li and H. Liao, Pharmacological Actions, Molecular Mechanisms, Pharmacokinetic Progressions, and Clinical Applications of Hydroxysafflor Yellow A in Antidiabetic Research, *J Immunol Res*, 2021, **2021**, 4560012.
471. J. Asgarpanah and N. Kazemivash, Phytochemistry, pharmacology and medicinal properties of *Carthamus tinctorius* L, *Chin J Integr Med*, 2013, **19**, 153-159.
472. G. Yu, Z. Luo, Y. Zhou, L. Zhang, Y. Wu, L. Ding and Y. Shi, Uncovering the pharmacological mechanism of *Carthamus tinctorius* L. on cardiovascular disease by a systems pharmacology approach, *Biomed Pharmacother*, 2019, **117**, 109094.
473. Y. Liang and L. Wang, *Carthamus tinctorius* L.: A natural neuroprotective source for anti-Alzheimer's disease drugs, *J Ethnopharmacol*, 2022, **298**, 115656.
474. H. Ao, W. Feng and C. Peng, Hydroxysafflor Yellow A: A Promising Therapeutic Agent for a Broad Spectrum of Diseases, *Evid Based Complement Alternat Med*, 2018, **2018**, 8259280.

475. C. Ge, D. Meng, Y. Peng, P. Huang, N. Wang, X. Zhou and D. Chang, The activation of the HIF-1 α -VEGFA-Notch1 signaling pathway by Hydroxysafflor yellow A promotes angiogenesis and reduces myocardial ischemia-reperfusion injury, *Int Immunopharmacol*, 2024, **142**, 113097.
476. J. Ruan, L. Wang, N. Wang, P. Huang, D. Chang, X. Zhou, S. Seto, D. Li and J. Hou, Hydroxysafflor Yellow A promotes angiogenesis of brain microvascular endothelial cells from ischemia/reperfusion injury via glycolysis pathway *in vitro*, *J Stroke Cerebrovasc Dis*, 2025, **34**, 108107.
477. Y. Q. Tan, H. W. Chen, J. Li and Q. J. Wu, Efficacy, Chemical Constituents, and Pharmacological Actions of Radix Paeoniae Rubra and Radix Paeoniae Alba, *Front Pharmacol*, 2020, **11**, 1054.
478. Q. Xin, R. Yuan, W. Shi, Z. Zhu, Y. Wang and W. Cong, A review for the anti-inflammatory effects of paeoniflorin in inflammatory disorders, *Life Sci*, 2019, **237**, 116925.
479. Y. X. Zhou, X. H. Gong, H. Zhang and C. Peng, A review on the pharmacokinetics of paeoniflorin and its anti-inflammatory and immunomodulatory effects, *Biomed Pharmacother*, 2020, **130**, 110505.
480. Y. Lu, L. Yin, W. Yang, Z. Wu and J. Niu, Antioxidant effects of Paeoniflorin and relevant molecular mechanisms as related to a variety of diseases: A review, *Biomed Pharmacother*, 2024, **176**, 116772.
481. X. Ma, W. Zhang, Y. Jiang, J. Wen, S. Wei and Y. Zhao, Paeoniflorin, a Natural Product With Multiple Targets in Liver Diseases-A Mini Review, *Front Pharmacol*, 2020, **11**, 531.
482. X. E. Zhang, Y. B. Pang, Q. Bo, S. Y. Hu, J. Y. Xiang, Z. R. Yang, X. M. Zhang, A. J. Chen, J. H. Zeng, X. Ma and J. Guo, Protective effect of paeoniflorin in diabetic nephropathy: A preclinical systematic review revealing the mechanism of action, *PLoS One*, 2023, **18**, e0282275.
483. J. Yang, Y. Ren, Z. G. Lou, X. Wan, G. B. Weng and D. Cen, Paeoniflorin inhibits the growth of bladder carcinoma via deactivation of STAT3, *Acta Pharm*, 2018, **68**, 211-222.
484. S. Vellasamy, D. Murugan, R. Abas, A. Alias, W. Y. Seng and C. K. Woon, Biological Activities of Paeonol in Cardiovascular Diseases: A Review, *Molecules*, 2021, **26**, 4976.
485. W. Yu, I. Ilyas, N. Aktar and S. Xu, A review on therapeutical potential of paeonol in atherosclerosis, *Front Pharmacol*, 2022, **13**, 950337.
486. C. Yang, J. Cheng, Q. Zhu, Q. Pan, K. Ji and J. Li, Review of the Protective Mechanism of Paeonol on Cardiovascular Disease, *Drug Des Devel Ther*, 2023, **17**, 2193-2208.
487. Z. Chen, C. Zhang, F. Gao, Q. Fu, C. Fu, Y. He and J. Zhang, A systematic review on the rhizome of *Ligusticum chuanxiong* Hort. (Chuanxiong), *Food Chem Toxicol*, 2018, **119**, 309-325.
488. Y. Qin, F. Chen, Z. Tang, H. Ren, Q. Wang, N. Shen, W. Lin, Y. Xiao, M. Yuan, H. Chen, T. Bu, Q. Li and L. Huang, *Ligusticum chuanxiong* Hort as a medicinal and edible plant foods: Antioxidant, anti-aging and neuroprotective properties in *Caenorhabditis elegans*, *Front Pharmacol*, 2022, **13**, 1049890.
489. Y. Hu, A. Wang, J. Chen and H. Chen, Ligustrazine: A Review of Its Role and Mechanism in the Treatment of Obstetrical and Gynecological Diseases, *Clin Exp ObsGynecol*, 2023, **50**, 164.
490. S. Huang, J. Chen, X. Liu, C. Xing, L. Zhao, K. Chan and G. Lu, Evaluation of the Pharmaceutical Activities of Chuanxiong, a Key Medicinal Material in Traditional Chinese Medicine, *Pharmaceuticals (Basel)*, 2024, **17**.
491. X. Yuan, B. Han, Z. M. Feng, J. S. Jiang, Y. N. Yang and P. C. Zhang, Chemical constituents of *Ligusticum chuanxiong* and their anti-inflammation and hepatoprotective activities, *Bioorg Chem*, 2020, **101**, 104016.
492. J.-S. Li, H.-F. Wang, Y.-P. Bai, S.-Y. Li, X.-Q. Yu and Y. Li, Ligustrazine injection for chronic pulmonary heart disease: a systematic review and meta-analysis, *Evid Based Complement Alternat Med*, 2012, **2012**, 792726.
493. H. Shao, L. Zhao, F. Chen, S. Zeng, S. Liu and J. Li, Efficacy of Ligustrazine Injection as Adjunctive Therapy for Angina Pectoris: A Systematic Review and Meta-Analysis, *Med Sci Monit*, 2015, **21**, 3704-3715.
494. Z. Zhuang, Z. H. Wang, Y. Y. Huang, Q. Zheng and X. D. Pan, Protective effect and possible mechanisms of ligustrazine isolated from *Ligusticum wallichii* on nephropathy in rats with diabetes: A preclinical systematic review and meta-analysis, *J Ethnopharmacol*, 2020, **252**, 112568.
495. Q. Xie, L. Zhang, L. Xie, Y. Zheng, K. Liu, H. Tang, Y. Liao and X. Li, Z-ligustilide: A review of its pharmacokinetics and pharmacology, *Phytother Res*, 2020, **34**, 1966-1991.
496. L. Shen, Q. Tian, Q. Ran, Q. Gan, Y. Hu, D. Du, Z. Qin, X. Duan, X. Zhu and W. Huang, Z-Ligustilide: A Potential Therapeutic Agent for Atherosclerosis Complicating Cerebrovascular Disease, *Biomolecules*, 2024, **14**, 1624.

497. H. Qi, S. O. Siu, Y. Chen, Y. Han, I. K. Chu, Y. Tong, A. S. Lau and J. Rong, Senkyunolides reduce hydrogen peroxide-induced oxidative damage in human liver HepG2 cells via induction of heme oxygenase-1, *Chem Biol Interact*, 2010, **183**, 380-389.
498. M. Wang, H. Hayashi, I. Horinokita, M. Asada, Y. Iwatani, J. X. Liu and N. Takagi, Neuroprotective effects of Senkyunolide I against glutamate-induced cells death by attenuating JNK/caspase-3 activation and apoptosis, *Biomed Pharmacother*, 2021, **140**, 111696.
499. Y. Huang, Y. Wu, H. Yin, L. Du and C. Chen, Senkyunolide I: A Review of Its Phytochemistry, Pharmacology, Pharmacokinetics, and Drug-Likeness, *Molecules*, 2023, **28**.
500. P. Li, W. Tang, H. Wen, S. Zhou and H. Cao, Senkyunolide I prevent chondrocytes from oxidative stress through Nrf2/HO-1 signaling pathway, *Naunyn Schmiedebergs Arch Pharmacol*, 2025.
501. Q. Li, J. Sheng, M. Baruscotti, Z. Liu, Y. Wang and L. Zhao, Identification of Senkyunolide I as a novel modulator of hepatic steatosis and PPAR α signaling in zebrafish and hamster models, *J Ethnopharmacol*, 2025, **336**, 118743.
502. Q. Wei, F. He, J. Rao, X. Xiang, L. Li and H. Qi, Targeting non-classical autophagy-dependent ferroptosis and the subsequent HMGB1/TfR1 feedback loop accounts for alleviating solar dermatitis by senkyunolide I, *Free Radic Biol Med*, 2024, **223**, 263-280.
503. Y. F. Zha, J. Xie, P. Ding, C. L. Zhu, P. Li, Z. Z. Zhao, Y. H. Li and J. F. Wang, Senkyunolide I protect against lung injury via inhibiting formation of neutrophil extracellular trap in a murine model of cecal ligation and puncture, *Int Immunopharmacol*, 2021, **99**, 107922.
504. Y. Hu, M. Duan, S. Liang, Y. Wang and Y. Feng, Senkyunolide I protects rat brain against focal cerebral ischemia-reperfusion injury by up-regulating p-Erk1/2, Nrf2/HO-1 and inhibiting caspase 3, *Brain Res*, 2015, **1605**, 39-48.
505. Y. Y. Hu, Y. Wang, S. Liang, X. L. Yu, L. Zhang, L. Y. Feng and Y. Feng, Senkyunolide I attenuates oxygen-glucose deprivation/reoxygenation-induced inflammation in microglial cells, *Brain Res*, 2016, **1649**, 123-131.
506. Y. L. Zhu, J. Huang, X. Y. Chen, J. Xie, Q. Yang, J. F. Wang and X. M. Deng, Senkyunolide I alleviates renal Ischemia-Reperfusion injury by inhibiting oxidative stress, endoplasmic reticulum stress and apoptosis, *Int Immunopharmacol*, 2022, **102**, 108393.
507. Q. Yang, Z. Z. Zhao, J. Xie, Y. P. Wang, K. Yang, Y. Guo, J. F. Wang and X. M. Deng, Senkyunolide I attenuates hepatic ischemia/reperfusion injury in mice via anti-oxidative, anti-inflammatory and anti-apoptotic pathways, *Int Immunopharmacol*, 2021, **97**, 107717.
508. T. Yi, J. Y. Fang, L. Zhu, Y. N. Tang, H. Ji, Y. Z. Zhang, J. C. Yu, X. J. Zhang, Z. L. Yu, Z. Z. Zhao and H. B. Chen, The variation in the major constituents of the dried rhizome of *Ligusticum chuanxiong* (Chuanxiong) after herbal processing, *Chin Med*, 2016, **11**, 26.
509. J. Q. Li, J. F. Wang, J. Li, S. H. Zhang, D. He, R. S. Tong and S. Y. She, A validated LC-MS/MS method for the determination of senkyunolide I in dog plasma and its application to a pharmacokinetic and bioavailability studies, *Biomed Chromatogr*, 2018, **32**, e4182.
510. X. P. Chen, W. Li, X. F. Xiao, L. L. Zhang and C. X. Liu, Phytochemical and pharmacological studies on *Radix Angelica sinensis*, *Chin J Nat Med*, 2013, **11**, 577-587.
511. C. Huang, Y. Zhao, S. Huang, L. Li, Z. Yuan and G. Xu, Screening of anti-thrombin active components from *Ligusticum chuanxiong* by affinity-ultrafiltration coupled with HPLC-Q-Orbitrap-MS(n), *Phytochem Anal*, 2023, **34**, 443-452.
512. S. Q. Tang, Y. H. Chen, X. P. Chen, X. D. Zhang and W. Huang, *In Vivo* Effect of Guiding-Herb *Radix Platycodonis* and *Radix Cyathulae* on Paeoniflorin Pharmacokinetics of Xuefu Zhuyu Tang in Rats, *Afr J Tradit Complement Altern Med*, 2017, **14**, 289-296.
513. Y. Huang, S. Wang, L. Liu, W. Peng, J. Wang, Y. Song, Q. Yuan, X. Yuan and C. Wu, Review of traditional uses, botany, chemistry, pharmacology, pharmacokinetics, and toxicology of *Radix Cyathulae*, *Chin Med*, 2019, **14**, 17.
514. X. Zhang, Z. Sun, W. Sun, Y. Li, F. Gao, F. Teng, Z. Han, Y. Lu, S. Zhang and L. Li, Bioinformatics Analysis and Experimental Findings Reveal the Therapeutic Actions and Targets of *Cyathulae Radix* Against Type 2 Diabetes Mellitus, *J Diabetes Res*, 2024, **2024**, 5521114.

515. S. H. Kim, T. H. Yook and J. U. Kim, *Rehmanniae Radix*, an Effective Treatment for Patients with Various Inflammatory and Metabolic Diseases: Results from a Review of Korean Publications, *J Pharmacopuncture*, 2017, **20**, 81-88.
516. C. Liu, R. Ma, L. Wang, R. Zhu, H. Liu, Y. Guo, B. Zhao, S. Zhao, J. Tang, Y. Li, J. Niu, M. Fu, D. Zhang and S. Gao, *Rehmanniae Radix* in osteoporosis: A review of traditional Chinese medicinal uses, phytochemistry, pharmacokinetics and pharmacology, *J Ethnopharmacol*, 2017, **198**, 351-362.
517. J. Jia, J. Chen, G. Wang, M. Li, Q. Zheng and D. Li, Progress of research into the pharmacological effect and clinical application of the traditional Chinese medicine *Rehmanniae Radix*, *Biomed Pharmacother*, 2023, **168**, 115809.
518. Y. Matsumoto and K. Sekimizu, A hyperglycemic silkworm model for evaluating hypoglycemic activity of *Rehmanniae Radix*, an herbal medicine, *Drug Discov Ther*, 2016, **10**, 14-18.
519. Y. Li, Q. Chen, H. J. Sun, J. H. Zhang and X. Liu, The Active Ingredient Catalpol in *Rehmannia glutinosa* Reduces Blood Glucose in Diabetic Rats via the AMPK Pathway, *Diabetes Metab Syndr Obes*, 2024, **17**, 1761-1767.
520. M. F. Zhang, J. H. Wang, S. Sun, Y. T. Xu, D. Wan, S. Feng, Z. Tian and H. F. Zhu, Catalpol attenuates ischemic stroke by promoting neurogenesis and angiogenesis via the SDF-1alpha/CXCR4 pathway, *Phytomedicine*, 2024, **128**, 155362.
521. C. Wu, Z. Shi, Q. Ge, H. Xu, Z. Wu, P. Tong and H. Jin, Catalpol promotes articular cartilage repair by enhancing the recruitment of endogenous mesenchymal stem cells, *J Cell Mol Med*, 2024, **28**, e18242.
522. X. Lang, L. Xu, L. Li and X. Feng, The Mechanism of Catalpol to Improve Oxidative Damage of Dermal Fibroblasts Based on Nrf2/HO-1 Signaling Pathway, *Drug Des Devel Ther*, 2024, **18**, 2287-2297.
523. Z. H. Liu, Q. Y. Xu, Y. Wang, H. X. Gao, Y. H. Min, X. W. Jiang and W. H. Yu, Catalpol from *Rehmannia glutinosa* Targets Nrf2/NF-kappaB Signaling Pathway to Improve Renal Anemia and Fibrosis, *Am J Chin Med*, 2024, **52**, 1451-1485.
524. Z. Zhang, Y. Dai, Y. Xiao and Q. Liu, Protective effects of catalpol on cardio-cerebrovascular diseases: A comprehensive review, *J Pharm Anal*, 2023, **13**, 1089-1101.
525. Z. Fu, X. Su, Q. Zhou, H. Feng, R. Ding and H. Ye, Protective effects and possible mechanisms of catalpol against diabetic nephropathy in animal models: a systematic review and meta-analysis, *Front Pharmacol*, 2023, **14**, 1192694.
526. Y. Bai, R. Zhu, Y. Tian, R. Li, B. Chen, H. Zhang, B. Xia, D. Zhao, F. Mo, D. Zhang and S. Gao, Catalpol in Diabetes and its Complications: A Review of Pharmacology, Pharmacokinetics, and Safety, *Molecules*, 2019, **24**.
527. C. Mei, X. Wang, F. Meng, X. Zhang, L. Chen, S. Yan, J. Xue, X. Sun and Y. Wang, Aucuboside Inhibits the Generation of Th17 Cells in Mice Colitis, *Front Pharmacol*, 2021, **12**, 696599.
528. L. Gao, D. Wang, J. Ren, X. Tan, J. Chen, Z. Kong, Y. Nie and M. Yan, Acteoside ameliorates learning and memory impairment in APP/PS1 transgenic mice by increasing A β degradation and inhibiting tau hyperphosphorylation, *Phytother Res*, 2024, **38**, 1735-1744.
529. K. Jia, Y. Zhang, R. Luo, R. Liu, Y. Li, J. Wu, K. Xie, J. Liu, S. Li, F. Zhou and X. Li, Acteoside ameliorates hepatic ischemia-reperfusion injury via reversing the senescent fate of liver sinusoidal endothelial cells and restoring compromised sinusoidal networks, *Int J Biol Sci*, 2023, **19**, 4967-4988.
530. Y. Xiao, Q. Ren and L. Wu, The pharmacokinetic property and pharmacological activity of acteoside: A review, *Biomed Pharmacother*, 2022, **153**, 113296.
531. R. A. Khan, R. Hossain, P. Roy, D. Jain, A. S. Mohammad Saikat, A. P. Roy Shuvo, M. Akram, W. F. Elbossaty, I. N. Khan, S. Painuli, P. Semwal, A. Rauf, M. T. Islam and H. Khan, Anticancer effects of acteoside: Mechanistic insights and therapeutic status, *Eur J Pharmacol*, 2022, **916**, 174699.
532. H. Wu, Q. Huang, S. Chao, J. Yu, S. Xu, F. Wang, X. Shang and Y. Zhu, Determination of Ferulic Acid in *Angelica sinensis* by Temperature-Controlled Hydrophobic Ionic Liquids-Based Ultrasound/Heating-Assisted Extraction Coupled with High Performance Liquid Chromatography, *Molecules*, 2020, **25**, 3356.
533. V. Bunel, M. H. Antoine, J. Nortier, P. Duez and C. Stévigny, Nephroprotective effects of ferulic acid, Z-ligustilide and E-ligustilide isolated from *Angelica sinensis* against cisplatin toxicity *in vitro*, *Toxicol In Vitro*, 2015, **29**, 458-467.

534. J. Lu and C. Wang, Ferulic acid from *Angelica sinensis* (Oliv.) Diels ameliorates lipid metabolism in alcoholic liver disease via AMPK/ACC and PI3K/AKT pathways, *J Ethnopharmacol*, 2025, **338**, 119118.
535. L. L. Zhang, M. Y. Huang, Y. Yang, M. Q. Huang, J. J. Shi, L. Zou and J. J. Lu, Bioactive platycodins from *Platycodonis Radix*: Phytochemistry, pharmacological activities, toxicology and pharmacokinetics, *Food Chem*, 2020, **327**, 127029.
536. L. Zhang, X. Wang, J. Zhang, D. Liu and G. Bai, Ethnopharmacology, phytochemistry, pharmacology and product application of *Platycodon grandiflorum*: A review, *Chin Herb Med*, 2024, **16**, 327-343.
537. M. Khan, A. Maryam, H. Zhang, T. Mehmood and T. Ma, Killing cancer with platycodin D through multiple mechanisms, *J Cell Mol Med*, 2016, **20**, 389-402.
538. L. Xie, Y. X. Zhao, Y. Zheng and X. F. Li, The pharmacology and mechanisms of platycodin D, an active triterpenoid saponin from *Platycodon grandiflorus*, *Front Pharmacol*, 2023, **14**, 1148853.
539. R. Ji, S. Wang, X. Chen, Z. Yang, Z. Zhang, S. Bao, Z. Xiao, Y. Zhang, T. Yin and J. Yang, Platycodin D ameliorates polycystic ovary syndrome-induced ovarian damage by upregulating CD44 to attenuate ferroptosis, *Free Radic Biol Med*, 2024, **224**, 707-722.
540. O. G. Kwon, S. K. Ku, H. D. An and Y. J. Lee, The Effects of Platycodin D, a Saponin Purified from *Platycodi Radix*, on Collagen-Induced DBA/1J Mouse Rheumatoid Arthritis, *Evid Based Complement Alternat Med*, 2014, **2014**, 954508.
541. H. Kato, S. Suzuki, K. Nakao, E. B. Lee and K. Takagi, Vasodilating effect of crude platycodin in anesthetized dogs, *Jpn J Pharmacol*, 1973, **23**, 709-716.
542. T. Y. Kim, S. Jeon, Y. Jang, L. Gotina, J. Won, Y. H. Ju, S. Kim, M. W. Jang, W. Won, M. G. Park, A. N. Pae, S. Han, S. Kim and C. J. Lee, Platycodin D, a natural component of *Platycodon grandiflorum*, prevents both lysosome- and TMPRSS2-driven SARS-CoV-2 infection by hindering membrane fusion, *Exp Mol Med*, 2021, **53**, 956-972.
543. J. Wu, G. Huang, Y. Li and X. Li, Flavonoids from *Aurantii Fructus Immaturus* and *Aurantii Fructus*: promising phytomedicines for the treatment of liver diseases, *Chin Med*, 2020, **15**, 89.
544. J. Zhu, Y. Luo, H. Tong, L. Zhong, Q. Gong, Y. Wang, M. Yang and Q. Song, "Drying effect" of fructus aurantii components and the mechanism of action based on network pharmacology and *in vitro* pharmacodynamic validation, *Front Pharmacol*, 2023, **14**, 1114010.
545. E. M. Suolinna, D. R. Lang and E. Racker, Quercetin, an artificial regulator of the high aerobic glycolysis of tumor cells, *J Natl Cancer Inst*, 1974, **53**, 1515-1519.
546. E. Racker, Effect of quercetin on ATP-driven pumps and glycolysis, *Prog Clin Biol Res*, 1986, **213**, 257-271.
547. F. Yang, X. Dong, X. Yin, W. Wang, L. You and J. Ni, *Radix Bupleuri*: A Review of Traditional Uses, Botany, Phytochemistry, Pharmacology, and Toxicology, *Biomed Res Int*, 2017, **2017**, 7597596.
548. B. Yuan, R. Yang, Y. Ma, S. Zhou, X. Zhang and Y. Liu, A systematic review of the active saikosaponins and extracts isolated from *Radix Bupleuri* and their applications, *Pharm Biol*, 2017, **55**, 620-635.
549. H. Jiang, L. Yang, A. Hou, J. Zhang, S. Wang, W. Man, S. Zheng, H. Yu, X. Wang, B. Yang, Q. Wang and H. Kuang, Botany, traditional uses, phytochemistry, analytical methods, processing, pharmacology and pharmacokinetics of *Bupleuri Radix*: A systematic review, *Biomed Pharmacother*, 2020, **131**, 110679.
550. Y. Zhong, J. Li, X. Zhu, N. Huang, R. Liu and R. Sun, A comprehensive review of bupleuri radix and its bioactive components : with a major focus on treating chronic liver diseases, *J Ethnopharmacol*, 2024, **330**, 118244.
551. O. Hong Liang, C. Ee Meng, C. Mohamad, N. F. Mohd Nasir, T. Xiao Jian, B. Chong You, E. Ziezie Mohd Tarmizi, L. Kim Yee, Y. Kok Yeow, K. Shing Fhan, L. Kim Fey, T. Kian Keong, M. R. Mohd Roslan and S. A. Baharuddin, Frequency-dependent dielectric spectroscopic analysis on phytochemical and antioxidant activities in *Radix Glycyrrhizae* extract, *Heliyon*, 2024, **10**, e37077.
552. M. Ramalingam, H. Kim, Y. Lee and Y. I. Lee, Phytochemical and Pharmacological Role of Liquiritigenin and Isoliquiritigenin From *Radix Glycyrrhizae* in Human Health and Disease Models, *Front Aging Neurosci*, 2018, **10**, 348.
553. Y. Zhang, J. Lu, T. Chang, X. Tang, Q. Wang, D. Pan, J. Wang, H. Nan, W. Zhang, L. Liu and B. Qi, A bibliometric review of *Glycyrrhizae Radix et Rhizoma* (licorice) research: Insights and future directions, *J Ethnopharmacol*, 2024, **321**, 117409.

554. F. Li, B. Liu, T. Li, Q. Wu, Z. Xu, Y. Gu, W. Li, P. Wang, T. Ma and H. Lei, Review of Constituents and Biological Activities of Triterpene Saponins from *Glycyrrhizae Radix et Rhizoma* and Its Solubilization Characteristics, *Molecules*, 2020, **25**, 3904.
555. M. N. Asl and H. Hosseinzadeh, Review of pharmacological effects of *Glycyrrhiza* sp. and its bioactive compounds, *Phytother Res*, 2008, **22**, 709-724.
556. C. Bailly and G. Vergoten, Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome?, *Pharmacol Ther*, 2020, **214**, 107618.
557. J. Chrzanowski, A. Chrzanowska and W. Grabon, Glycyrrhizin: An old weapon against a novel coronavirus, *Phytother Res*, 2021, **35**, 629-636.
558. S. Banerjee, S. K. Baidya, N. Adhikari, B. Ghosh and T. Jha, Glycyrrhizin as a promising kryptonite against SARS-CoV-2: Clinical, experimental, and theoretical evidences, *J Mol Struct*, 2023, **1275**, 134642.
559. Y. Yi, W. Li, K. Liu, H. Xue, R. Yu, M. Zhang, Y. O. Bao, X. Lai, J. Fan, Y. Huang, J. Wang, X. Shi, J. Li, H. Wei, K. Xiang, L. Li, R. Zhang, X. Zhao, X. Qiao, H. Yang and M. Ye, Licorice-saponin A3 is a broad-spectrum inhibitor for COVID-19 by targeting viral spike and anti-inflammation, *J Pharm Anal*, 2023, **14**, 115-127.
560. S. W. Fatima, S. Alam and S. K. Khare, Molecular and structural insights of beta-boswellic acid and glycyrrhizic acid as potent SARS-CoV-2 Envelope protein inhibitors, *Phytomed Plus*, 2022, **2**, 100241.
561. J. Zuo, T. Meng, Y. Wang and W. Tang, A Review of the Antiviral Activities of Glycyrrhizic Acid, Glycyrrhetic Acid and Glycyrrhetic Acid Monoglucuronide, *Pharmaceuticals (Basel)*, 2023, **16**, 641.
562. H. Hosseinzadeh and M. Nassiri-Asl, Pharmacological Effects of *Glycyrrhiza* spp. and Its Bioactive Constituents: Update and Review, *Phytother Res*, 2015, **29**, 1868-1886.
563. S. Xiao, Z. Tian, Y. Wang, L. Si, L. Zhang and D. Zhou, Recent progress in the antiviral activity and mechanism study of pentacyclic triterpenoids and their derivatives, *Med Res Rev*, 2018, **38**, 951-976.
564. C. Huan, Y. Xu, W. Zhang, T. Guo, H. Pan and S. Gao, Research Progress on the Antiviral Activity of Glycyrrhizin and its Derivatives in Licorice, *Front Pharmacol*, 2021, **12**, 680674.
565. Y. Liu, L. Yang, H. Wang and Y. Xiong, Recent Advances in Antiviral Activities of Triterpenoids, *Pharmaceuticals (Basel)*, 2022, **15**.
566. D. B. Kell, Scientific discovery as a combinatorial optimisation problem: how best to navigate the landscape of possible experiments?, *Bioessays*, 2012, **34**, 236-244.
567. R. Breinbauer, I. R. Vetter and H. Waldmann, From protein domains to drug candidates-natural products as guiding principles in the design and synthesis of compound libraries, *Angew Chem Int Ed Engl*, 2002, **41**, 2879-2890.
568. R. J. Young, S. L. Flitsch, M. Grigalunas, P. D. Leeson, R. J. Quinn, N. J. Turner and H. Waldmann, The Time and Place for Nature in Drug Discovery, *JACS Au*, 2022, **2**, 2400-2416.
569. D. Domingo-Fernández, Y. Gadiya, A. J. Preto, C. A. Kretzler, S. Mubeen, A. Allen, D. Healey and V. Colluru, Natural Products Have Increased Rates of Clinical Trial Success throughout the Drug Development Process, *J Nat Prod*, 2024, **87**, 1844-1851.
570. K. Singh, J. K. Gupta, D. K. Chanchal, M. G. Shinde, S. Kumar, D. Jain, Z. M. Almarhoon, A. M. Alshahrani, D. Calina, J. Sharifi-Rad and A. Tripathi, Natural products as drug leads: exploring their potential in drug discovery and development, *Naunyn Schmiedebergs Arch Pharmacol*, 2024.
571. Y. Wang, F. Wang, W. Liu, Y. Geng, Y. Shi, Y. Tian, B. Zhang, Y. Luo and X. Sun, New drug discovery and development from natural products: Advances and strategies, *Pharmacol Ther*, 2024, **264**, 108752.
572. Z. R. Goddard, M. Searcey and A. Osbourn, Advances in triterpene drug discovery, *Trends Pharmacol Sci*, 2024, **45**, 964-968.
573. A. Alqahtani, K. Hamid, A. Kam, K. H. Wong, Z. Abdelhak, V. Razmovski-Naumovski, K. Chan, K. M. Li, P. W. Groundwater and G. Q. Li, The pentacyclic triterpenoids in herbal medicines and their pharmacological activities in diabetes and diabetic complications, *Curr Med Chem*, 2013, **20**, 908-931.
574. K. Hamid, A. Alqahtani, M. S. Kim, J. L. Cho, P. H. Cui, C. G. Li, P. W. Groundwater and G. Q. Li, Tetracyclic triterpenoids in herbal medicines and their activities in diabetes and its complications, *Curr Top Med Chem*, 2015, **15**, 2406-2430.
575. T. Akihisa, J. Zhang and H. Tokuda, Potentially Chemopreventive Triterpenoids and Other Secondary Metabolites From Plants and Fungi, *Stud Nat Prod Chem*, 2016, **21**, 1-50.

576. R. Thimmappa, K. Geisler, T. Louveau, P. O'Maille and A. Osbourn, Triterpene biosynthesis in plants, *Annu Rev Plant Biol*, 2014, **65**, 225-257.
577. M. J. Stephenson, R. A. Field and A. Osbourn, The protosteryl and dammarenyl cation dichotomy in polycyclic triterpene biosynthesis revisited: has this 'rule' finally been broken?, *Nat Prod Rep*, 2019, **36**, 1044-1052.
578. X. J. Yan, L. H. Gong, F. Y. Zheng, K. J. Cheng, Z. S. Chen and Z. Shi, Triterpenoids as reversal agents for anticancer drug resistance treatment, *Drug Discov Today*, 2014, **19**, 482-488.
579. M. C. A. Galappaththi, N. M. Patabendige, B. M. Premarathne, K. K. Hapuarachchi, S. Tibpromma, D. Q. Dai, N. Suwannarach, S. Rapior and S. C. Karunarathna, A Review of Ganoderma Triterpenoids and Their Bioactivities, *Biomolecules*, 2022, **13**, 24.
580. R. Rodriguez-Rodriguez, Oleonic acid and related triterpenoids from olives on vascular function: molecular mechanisms and therapeutic perspectives, *Curr Med Chem*, 2015, **22**, 1414-1425.
581. N. A. J. C. Furtado, L. Pirson, H. Edelberg, M. M. L. C. Loira-Pastoriza, V. Preat, Y. Larondelle and C. M. André, Pentacyclic Triterpene Bioavailability: An Overview of *In Vitro* and *In Vivo* Studies, *Molecules*, 2017, **22**, 400.
582. Z. Luo, W. Zhou, T. Xie, W. Xu, C. Shi, Z. Xiao, Y. Si, Y. Ma, Q. Ren, L. Di and J. Shan, The role of botanical triterpenoids and steroids in bile acid metabolism, transport, and signaling: Pharmacological and toxicological implications, *Acta Pharm Sin B*, 2024, **14**, 3385-3415.
583. T. H. Won, M. Arifuzzaman, C. N. Parkhurst, I. C. Miranda, B. Zhang, E. Hu, S. Kashyap, J. Letourneau, W. B. Jin, Y. Fu, D. V. Guzior, J. R. I. L. C. Bank, R. A. Quinn, C. J. Guo, L. A. David, D. Artis and F. C. Schroeder, Host metabolism balances microbial regulation of bile acid signalling, *Nature*, 2025, **638**, 216-224.
584. T. Claro da Silva, J. E. Polli and P. W. Swaan, The solute carrier family 10 (SLC10): Beyond bile acid transport, *Mol Aspects Med*, 2013, **34**, 252-269.
585. F. Chen, E. A. Eckman and C. B. Eckman, Reductions in levels of the Alzheimer's amyloid beta peptide after oral administration of ginsenosides, *FASEB J*, 2006, **20**, 1269-1271.
586. D. Paris, N. J. Ganey, V. Laporte, N. S. Patel, D. Beaulieu-Abdelahad, C. Bachmeier, A. March, G. Ait-Ghezala and M. J. Mullan, Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease, *J Neuroinflammation*, 2010, **7**, 17.
587. S. P. Patil, S. Maki, S. A. Khedkar, A. C. Rigby and C. Chan, Withanolide A and asiatic acid modulate multiple targets associated with amyloid-beta precursor protein processing and amyloid-beta protein clearance, *J Nat Prod*, 2010, **73**, 1196-1202.
588. P. Ruzskowski and T. Bobkiewicz-Kozłowska, Natural Triterpenoids and their Derivatives with Pharmacological Activity Against Neurodegenerative Disorders, *Mini Rev Org Chem*, 2014, **11**, 307-315.
589. F. Chen, Y. Wang, M. Yang, J. Yin, Q. Meng, F. Bu, D. Sun and J. Liu, Interaction of the ginsenosides with kappa-casein and their effects on amyloid fibril formation by the protein: Multi-spectroscopic approaches, *J Photochem Photobiol B*, 2016, **160**, 306-317.
590. K. Fujihara, S. Koike, Y. Ogasawara, K. Takahashi, K. Koyama and K. Kinoshita, Inhibition of amyloid beta aggregation and protective effect on SH-SY5Y cells by triterpenoid saponins from the cactus *Polaskia chichipe*, *Bioorg Med Chem*, 2017, **25**, 3377-3383.
591. S. Dubey, M. Kallubai and R. Subramanyam, Improving the inhibition of beta-amyloid aggregation by withanolide and withanoside derivatives, *Int J Biol Macromol*, 2021, **173**, 56-65.
592. K. Fujihara, T. Shimoyama, R. Kawazu, H. Sasaki, K. Koyama, K. Takahashi and K. Kinoshita, Amyloid beta aggregation inhibitory activity of triterpene saponins from the cactus *Stenocereus pruinosus*, *J Nat Med*, 2021, **75**, 284-298.
593. T. Zheng, Y. Wang, C. Zhao, J. Xu, X. Huang and W. Du, Triterpenoids impede the fibrillation and cytotoxicity of human islet amyloid polypeptide, *Int J Biol Macromol*, 2022, **199**, 189-200.
594. A. A. Bankar, V. P. Nagulwar, N. R. Kotagale and N. N. Inamdar, Neuroprotective perspectives of triterpenoids, *Expl Neurosci*, 2024, **3**, 231-254.
595. J. Qiu, W. Li, S. H. Feng, M. Wang and Z. Y. He, Ginsenoside Rh2 promotes nonamyloidogenic cleavage of amyloid precursor protein via a cholesterol-dependent pathway, *Genet Mol Res*, 2014, **13**, 3586-3598.

596. H. J. Kim, S. W. Jung, S. Y. Kim, I. H. Cho, H. C. Kim, H. Rhim, M. Kim and S. Y. Nah, *Panax ginseng* as an adjuvant treatment for Alzheimer's disease, *J Ginseng Res*, 2018, **42**, 401-411.
597. M. P. Razgonova, V. V. Veselov, A. M. Zakharenko, K. S. Golokhvast, A. E. Nosyrev, G. Cravotto, A. Tsatsakis and D. A. Spandidos, *Panax ginseng* components and the pathogenesis of Alzheimer's disease (Review), *Mol Med Rep*, 2019, **19**, 2975-2998.
598. L. Wang, G. Jin, H. Yu, Q. Li and H. Yang, Protective effect of Tenuifolin against Alzheimer's disease, *Neurosci Lett*, 2019, **705**, 195-201.
599. M. S. Planchard, M. A. Samel, A. Kumar and V. Rangachari, The natural product betulinic acid rapidly promotes amyloid-beta fibril formation at the expense of soluble oligomers, *ACS Chem Neurosci*, 2012, **3**, 900-908.
600. S. E. B. Tyler and L. D. K. Tyler, Therapeutic roles of plants for 15 hypothesised causal bases of Alzheimer's disease, *Nat Prod Bioprospect*, 2022, **12**, 34.
601. E. Lima and J. Medeiros, Terpenes as Potential Anti-Alzheimer's Disease Agents, *Appl Sci*, 2024, **14**, 3898.
602. C. Wei, J. Fan, X. Sun, J. Yao, Y. Guo, B. Zhou and Y. Shang, Acetyl-11-keto-beta-boswellic acid ameliorates cognitive deficits and reduces amyloid-beta levels in APP^{swe}/PS1^{dE9} mice through antioxidant and anti-inflammatory pathways, *Free Radic Biol Med*, 2020, **150**, 96-108.
603. Z. Bednarikova, M. Gancar, R. Wang, L. Zheng, Y. Tang, Y. Luo, Y. Huang, B. Spodniakova, L. Ma and Z. Gazova, Extracts from Chinese herbs with anti-amyloid and neuroprotective activities, *Int J Biol Macromol*, 2021, **179**, 475-484.
604. N. H. Mustafa, M. Sekar, S. Fuloria, M. Y. Begum, S. H. Gan, N. Rani, S. Ravi, K. Chidambaram, V. Subramaniyan, K. V. Sathasivam, S. Jeyabalan, S. Uthirapathy, S. Ponnusankar, P. T. Lum, V. Bhalla and N. K. Fuloria, Chemistry, Biosynthesis and Pharmacology of Sarsasapogenin: A Potential Natural Steroid Molecule for New Drug Design, Development and Therapy, *Molecules*, 2022, **27**, 2032.
605. Y. Du, M. Fu, Y. T. Wang and Z. Dong, Neuroprotective Effects of Ginsenoside Rf on Amyloid-beta-Induced Neurotoxicity in vitro and in vivo, *J Alzheimers Dis*, 2018, **64**, 309-322.
606. N. Wang, E. Wang, R. Wang, F. Muhammad, T. Li, J. Yue, Y. Zhou, D. Zhi and H. Li, Ursolic acid ameliorates amyloid beta-induced pathological symptoms in *Caenorhabditis elegans* by activating the proteasome, *Neurotoxicology*, 2022, **88**, 231-240.
607. K. Iwasa, S. Yagishita, N. Yagishita-Kyo, A. Yamagishi, S. Yamamoto, K. Yamashina, C. Haruta, M. Asai, K. Maruyama, K. Shimizu and K. Yoshikawa, Long term administration of loquat leaves and their major component, ursolic acid, attenuated endogenous amyloid-beta burden and memory impairment, *Sci Rep*, 2023, **13**, 16770.
608. Y. Zhang, H. Chen, R. Li, K. Sterling and W. Song, Amyloid beta-based therapy for Alzheimer's disease: challenges, successes and future, *Signal Transduct Target Ther*, 2023, **8**, 248.
609. J. Zhao, J. Yang, L. Ding, F. Wang and L. Lin, A Review of the Pathogenesis and Chinese Medicine Intervention of Alzheimer's Disease, *J Integr Neurosci*, 2022, **22**, 2.
610. M. F. Nagoor Meeran, S. N. Goyal, K. Suchal, C. Sharma, C. R. Patil and S. K. Ojha, Pharmacological Properties, Molecular Mechanisms, and Pharmaceutical Development of Asiatic Acid: A Pentacyclic Triterpenoid of Therapeutic Promise, *Front Pharmacol*, 2018, **9**, 892.
611. I. Mook-Jung, J. E. Shin, S. H. Yun, K. Huh, J. Y. Koh, H. K. Park, S. S. Jew and M. W. Jung, Protective effects of asiaticoside derivatives against beta-amyloid neurotoxicity, *J Neurosci Res*, 1999, **58**, 417-425.
612. S. S. Jew, C. H. Yoo, D. Y. Lim, H. Kim, I. Mook-Jung, M. W. Jung, H. Choi, Y. H. Jung, H. Kim and H. G. Park, Structure-activity relationship study of asiatic acid derivatives against beta amyloid (A beta)-induced neurotoxicity, *Bioorg Med Chem Lett*, 2000, **10**, 119-121.
613. S. Hossain, M. Hashimoto, M. Katakura, A. Al Mamun and O. Shido, Medicinal value of asiaticoside for Alzheimer's disease as assessed using single-molecule-detection fluorescence correlation spectroscopy, laser-scanning microscopy, transmission electron microscopy, and in silico docking, *BMC Complement Altern Med*, 2015, **15**, 118.
614. C. L. Chen, W. H. Tsai, C. J. Chen and T. M. Pan, *Centella asiatica* extract protects against amyloid beta(1-40)-induced neurotoxicity in neuronal cells by activating the antioxidative defence system, *J Tradit Complement Med*, 2016, **6**, 362-369.

615. N. E. Gray, J. A. Zweig, M. Caruso, J. Y. Zhu, K. M. Wright, J. F. Quinn and A. Soumyanath, *Centella asiatica* attenuates hippocampal mitochondrial dysfunction and improves memory and executive function in beta-amyloid overexpressing mice, *Mol Cell Neurosci*, 2018, **93**, 1-9.
616. N. E. Gray, A. Alcazar Magana, P. Lak, K. M. Wright, J. Quinn, J. F. Stevens, C. S. Maier and A. Soumyanath, *Centella asiatica* - Phytochemistry and mechanisms of neuroprotection and cognitive enhancement, *Phytochem Rev*, 2018, **17**, 161-194.
617. M. Wang, M. Chen, Y. Ding, Z. Zhu, Y. Zhang, P. Wei, J. Wang, Y. Qiao, L. Li, Y. Li and A. Wen, Pretreatment with beta-Boswellic Acid Improves Blood Stasis Induced Endothelial Dysfunction: Role of eNOS Activation, *Sci Rep*, 2015, **5**, 15357.
618. L. Huang, R. Xu, X. Huang, Y. Wang, J. Wang, Y. Liu and Z. Liu, Traditional Chinese medicine injection for promoting blood circulation and removing blood stasis in treating angina pectoris of coronary heart disease: A protocol for systematic review and network meta-analysis, *Medicine (Baltimore)*, 2021, **100**, e25608.
619. J. Chen, D. Cao, S. Jiang, X. Liu, W. Pan, H. Cui, W. Yang, Z. Liu, J. Jin and Z. Zhao, Triterpenoid saponins from *Ilex pubescens* promote blood circulation in blood stasis syndrome by regulating sphingolipid metabolism and the PI3K/AKT/eNOS signaling pathway, *Phytomedicine*, 2022, **104**, 154242.
620. B. Wei, C. Sun, H. Wan, Q. Shou, B. Han, M. Sheng, L. Li and G. Kai, Bioactive components and molecular mechanisms of *Salvia miltiorrhiza* Bunge in promoting blood circulation to remove blood stasis, *J Ethnopharmacol*, 2023, **317**, 116697.
621. H. Oku, E. Iwaoka, M. Shinga, E. Yamamoto, M. Iinuma and K. Ishigur, Effect of the Dried Flowers of *Campsis grandiflora* on Stagnant Blood Syndrome, *Nat Prod Commun*, 2019, **14**, 9.
622. P. D. Dobson, Y. Patel and D. B. Kell, "Metabolite-likeness" as a criterion in the design and selection of pharmaceutical drug libraries, *Drug Disc Today*, 2009, **14**, 31-40.
623. S. O'Hagan and D. B. Kell, Analysing and navigating natural products space for generating small, diverse, but representative chemical libraries, *Biotechnol J*, 2018, **13**, 1700503.
624. S. O'Hagan and D. B. Kell, Generation of a small library of natural products designed to cover chemical space inexpensively, *Pharm Front*, 2019, **1**, e190005.
625. S. O'Hagan and D. B. Kell, Structural similarities between some common fluorophores used in biology, marketed drugs, endogenous metabolites, and natural products, *Marine Drugs*, 2020, **18**, 582.
626. A. Capecchi and J. L. Reymond, Classifying natural products from plants, fungi or bacteria using the COCONUT database and machine learning, *J Cheminform*, 2021, **13**, 82.
627. P. Ertl and A. Schuffenhauer, Cheminformatics analysis of natural products: lessons from nature inspiring the design of new drugs, *Prog Drug Res*, 2008, **66**, 217, 219-235.
628. J. L. Medina-Franco and F. I. Saldívar-González, Cheminformatics to Characterize Pharmacologically Active Natural Products, *Biomolecules*, 2020, **10**, 1566.
629. F. D. Prieto-Martínez, U. Norinder and J. L. Medina-Franco, Cheminformatics Explorations of Natural Products, *Prog Chem Org Nat Prod*, 2019, **110**, 1-35.
630. M. Sorokina and C. Steinbeck, Review on natural products databases: where to find data in 2020, *J Cheminform*, 2020, **12**, 20.
631. S. Wetzel, A. Schuffenhauer, S. Roggo, P. Ertl and H. Waldmann, Cheminformatic analysis of natural products and their chemical space, *Chimia*, 2007, **61**, 355-360.

632. X. He, X. Duan, J. Liu, X. Sha, Y. Gong, W. Lu, Z. Li, X. Chen, Y. Li and Z. Shen, The antiinflammatory effects of Xuefu Zhuyu decoction on C3H/HeJ mice with alopecia areata, *Phytomedicine*, 2021, **81**, 153423.
633. L. Gao, L. Zhong, T. Feng, J. Yue, Q. Lu, L. Li, A. Wu, G. Lin, Q. He, K. Liu, G. Cao, Z. Meng, L. Nie and H. Zang, An AI-driven strategy for active compounds discovery and non-destructive quality control in traditional Chinese medicine: A case of Xuefu Zhuyu Oral Liquid, *Talanta*, 2025, **287**, 127627.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.